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Abstract
Toll-like receptor (TLR)-4 is a pattern recognition receptor (PRR) that recognises the
pathogen-associated molecular pattern (PAMP) lipopolysaccharide (LPS) produced by Gram-
negative bacteria. LPS binds to Myeloid differentiation 2 (MD-2)/TLR-4 heterodimers,
driving their dimerisation and inducing a conformational change of the intracellular TLR-4
toll/interleukin-1 receptor (TIR) domains. The adaptor protein Myeloid differentiation pri-
mary response gene 88 (MyD88)-adaptor-like (Mal)/TIR domain-containing adaptor protein
(TIRAP) then binds to the TIR domains of TLR-4 and acts as a bridge for MyD88 which goes
on to form the myddosome, a large protein complex of six to eight MyD88 molecules and
four Interleukin-1 receptor-associated kinase (IRAK) 4 and four IRAK1/2 molecules. This
triggers a signalling cascade which results in nuclear factor (NF)-κB transcription factor acti-
vation and production of pro-inflammatory effector molecules such as the cytokine Tumour
Necrosis Factor (TNF)-α . Upon activation TLR-4 is also endocytosed where it interacts with
a second set of adaptor proteins TIR-domain-containing adaptor-inducing interferon (IFN)-β
(TRIF)-related adaptor molecule (TRAM) and TRIF to initiate the type I IFN response.
How TLR-4 dimerisation results in the formation of the oligomeric myddosome is not fully
understood, but it is possible that the stoichiometry of Mal/TIRAP may be important in the
formation of this protein complex. The aim of my thesis was to determine the stoichiometry
of Mal/TIRAP at the plasma membrane of immortalised bone marrow derived macrophages
(iBMDMs) and whether this stoichiometry changes upon stimulation with different TLR-4
ligands.
To investigate Mal stoichiometry I first developed a viral transduction experimental cell
model to visualise fluorescently labelled Mal. Mal-/- iBMDMs were lentivirally transduced
with a MalHALO construct. The halotag was fluorescently labelled then the cells were
stimulated with TLR-4 ligands, such as LPS, fixed at different time points, then imaged.
Total internal reflection fluorescence (TIRF) microscopy was used to image the plasma
membrane and photobleaching experiments performed to determine Mal stoichiometry. I
developed a computer-based analysis pipeline to analyse the resulting photobleaching data.
viii
Under resting conditions, Mal is present at the plasma membrane in clusters of approximately
ten Mal molecules per cluster. After five minutes of stimulation with 10 ng/ml LPS Mal
redistributes into cluster sizes of approximately six, twelve and much larger. After ten
and fifteen minutes stimulation with 10 ng/ml LPS the clusters return to the resting size
of approximately ten Mal molecules per cluster with a few much larger clusters remaining
present. This confirms the rapid time frame within which TLR-4 signaling occurs at the
plasma membrane and is consistent with myddosome stoichiometry of six MyD88 molecules
or proposed super myddosomes of twelve MyD88 molecules. The computer-based analysis
pipeline developed can be used to analyse any protein of interest at the plasma membrane.
Protein ligands have also been found to activate TLR-4; for example allergens, such as Fel
d 1 and Der p 2, as well as endogenous damage associated molecular patterns (DAMPs), such
as extracellular matrix (ECM) proteins, for example fragments of fibronectin and tenascin-
C. The mechanism by which these proteins interact with TLR-4 and induce signaling is
unclear. Proteins from the ECM (fragments FNIII1c, FNIII13-14, FNIII9-E and FNIII9-E-14
from fibronectin and the fibrinogen-like globe (FBG) domain of tenascin-C) were tested
using a transient transfection assay in HEK293 cells and shown to activate TLR-4.
In conclusion, I have developed new tools and methodology to investigate how TLR-4
signals in response to LPS and DAMPs in living cells. Whether DAMP-activated TLR-4
forms similar signalling complexes to those induced by LPS will form part of a future study.
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Chapter 1
Introduction
1.1 The TLR-4 signalling pathway
1.1.1 Toll Like Receptor signalling pathways
Pattern recognition receptors (PRRs) represent a diverse array of proteins that play a pivotal
role in the host innate immune response. These include Toll-like receptors (TLRs), NOD-
like receptors (NLRs), C-type lectin receptors (CLRs) and many more [1–3]. PRRs are
widely expressed on immune cell subsets such as macrophages and dendritic cells. Other
cell types, however, including epithelial cells and stromal cells also express PRRs and
contribute to cytokine production [4–6]. PRRs are germline encoded and recognise pathogen-
associated molecular patterns (PAMPs) such as Lipopolysaccharide (LPS), the ligand for
TLR-4 (Poltorak et al., 1998) and flagellin, the ligand for TLR-5 and NLRC4 [2].
Humans have 10 TLRs that are expressed either at the plasma membrane (e.g. TLR-1,
-2, -5, -6 and -10) or in endosomes (e.g. TLR-3, -7, -8 and -9) [7]. A non-exhaustive
list of microbial TLR ligands can be found in Table 1.1. Unlike the other TLRs that
activate inflammatory signalling, TLR-10 is a proposed anti-inflammatory global suppressor
of TLR signalling whose ligand is unknown; although when intracellular, TLR-10 may
plan an inflammatory role [8]. When a TLR binds its ligand it undergoes a process of
dimerisation inducing a conformational change of its intracellular toll/interleukin-1 receptor
(TIR) homology domain. Adaptor proteins are then recruited to this domain, producing a
signalling cascade that ultimately results in the induction of inflammatory cytokine gene
expression generating the acute phase response, enabling the initiation of an adaptive immune
response [9]. TLR-4 is unique amongst the TLRs in that it signals via two distinct pathways.
Membrane bound TLR-4/Myeloid differentiation (MD)-2 recognises LPS and signals via the
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adaptor proteins Myeloid Differentiation Primary Response Protein 88 (MyD88)-Adaptor-
like (Mal) [10, 11] and MyD88 [12, 13]. Homodimerised TLR-4 is then endocytosed
to initiate signalling from the endosome via TIR Domain-containing Adaptor Inducing
Interferon-β (TRIF)-related Adaptor Molecule (TRAM) and TRIF [14]. A fifth adaptor
protein, Sterile α- and armadillo-motif-containing protein (SARM), is a negative regulator
of TLR induced signalling via TRIF [15] and possibly MyD88 [16].
Table 1.1 Toll-like receptor microbial ligands
TLR Microbial ligand
1/2 Triacyl-lipopeptide [17]
2/6 Diacyl-lipopeptide [18]
2 Peptidoglycan and lipoteichoic acid [19]
3 Double-stranded RNA [20]
4 LPS [21]
5 Flagellin [22]
7 Single-stranded RNA [23]
8 Single-stranded RNA [24]
9 CpG rich microbial DNA [25]
1.1.2 Toll-like Receptor-4
TLR-4 structure
TLR-4 was first identified in humans in 1997 [1] shortly before LPS was reported as its
principal ligand [21]. Since then, TLR-4 has been the focus of intense research and its
structure bound with MD-2 and LPS was elucidated in 2009 [26].
TLR-4 is a type-1 membrane protein consisting of a solenoid ectodomain comprised of a
Leucine Rich Repeat (LRR) region followed by a single transmembrane domain and a TIR
domain. Upon ligand binding, two TLR-4/MD-2 complexes dimerise to form an m-shaped
multimer [26]. Five LPS acyl chains are buried into the hydrophobic pocket of MD-2 whilst
the sixth acyl chain forms a hydrophobic interaction with conserved phenylalanine residues
(F440 and F463) at the core of a hydrophobic patch on the TLR-4 surface. LRR 15-17 form
the main dimerisation interface in TLR-4, whilst in MD-2 the phenylalanine residue F126 is
at the core of the dimerisation interface and induces localised structural changes in MD-2
creating hydrophilic interactions with TLR-4. These dimerisation interactions are supported
by a number of secondary interactions such as hydrogen bonds and ionic bonds between
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MD-2 and TLR-4, and charge interactions between the phosphates in LPS with both TLR-4
and MD-2 [26].
TLR-4 clustering
Once bound to LPS the mobility of TLR-4 decreases and it has been proposed that TLR-4
locates into lipid rafts forming clusters [27, 28]. Interestingly, immunostimulatory hexaacy-
lated LPS from Escherichia coli induced greater colocalisation with TLR-4 and the formation
of larger TLR-4 clusters compared to tetraacylated LPS from Yersinia pestis [29]. It has
been suggested that confinement of TLR-4 into microdomains promotes the formation of
clusters that trigger signalling [28]. However, it has also been suggested that TLR-4 dimerises
and does not cluster with other dimers, but that dimers may congregate together into the
confinements of a microdomain (Unpublished data, Bryant group). It has been hypothesised
that a number of different proteins, for example C-X-C chemokine receptor type 4, growth
differentiation factor 5 [30], the integrin CD11b/CD18 [31] and CD55 [32], may also be
recruited in to lipid rafts with TLR-4 depending on the ligand detected, resulting in a ligand
specific signalling output [33].
TLR-4 proximal membrane signalling
Aggregates of bacterial LPS bind to Lipid Binding Protein (LBP) that subsequently delivers
monomeric LPS to multiple CD14 molecules [34–37]. CD14, a GPI anchored protein,
transfers LPS to the MD-2/TLR-4 complex [38]. As well as transferring LPS to TLR-4, CD14
clustering also induces local production of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2)
[39]. PI(4,5)P2 is primarily found on the cytosolic side of the plasma membrane, and is
mainly produced by phosphorylation of PI(4)P by phosphatidylinositol 4-phosphate 5-kinase
(PI5K) Iα , Iβ and Iγ [40]. Clustering of CD14 induces local production of PI(4,5)P2 by PI5K
isoforms Iα and Iγ in a biphasic manner at 5-10 minutes and 60 minutes post stimulation.
TLR-4/MD-2 ligand engagement induces homodimerisation, producing a conformational
change in the TLR-4 TIR domains. This conformational change may allow Mal (located at the
plasma membrane by its PI(4,5)P2 binding domain) to be recruited via TIR-TIR interactions,
recruiting the C-terminally bound MyD88 to the activated TLR-4 complex [11, 10, 41–
43]. MyD88 then homo-oligomerises via its death domains (DD) to form a large oligomeric
signalling platform - the myddosome. The myddosome is composed of 6-8 MyD88 molecules
organised in a left-handed helix [44, 45]. Myddosome formation is followed by recruitment
of four Interleukin-1 receptor-associated kinase (IRAK)4 molecules via DD interactions.
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Once IRAK4 has undergone phosphorylation four IRAK1 or IRAK2 molecules are then
recruited to the complex [45]. This complex further recruits the E3 ubiquitin ligase TNF
Receptor associated factor (TRAF)6 [46–48] which recruits the Transforming growth factor
β -activated kinase 1 (TAK1)/TAK-1 binding protein (TAB)1/TAB2/TAB3 complex [49].
The IκB kinase (IKK) complex is recruited [50, 51] and phosphorylates the IKKβ subunit
of the IKK complex, releasing NF-κB for its translocation into the nucleus to initiate gene
transcription [52]. The TRAF6/TAK1 complex also leads to the activation of Activator
protein-1 (AP-1), another transcription factor [52] (Fig. 1.1).
TLR-4 endosomal signalling
The binding of LPS induces conformational changes in the solenoid curvature of TLR-4
[26, 54]. MD-2 is needed for TLR-4 dimerisation prior to its endocytosis [55]. It is plausible
that the change in TLR-4 solenoid curvature reveals a putative “endocytosis motif”, enabling
its endocytosis [56]. TLR-4 is endocytosed in a clathrin- and dynamin-dependent manner
[57]. It was originally proposed that endocytosis terminated TLR-4 signalling [57]. However,
endocytosis was subsequently shown to be required for TLR-4 signalling via the adaptors
TRAM and TRIF from the endosome compartment [14]. Endocytosis of TLR-4 is CD14-
dependent, requiring Syk activation via DAP12, Phospholipase-Cγ2 (PLCγ2) and FcεRγ
[58] and is negatively regulated by CD13, although the exact mechanism of this negative
regulation is unknown [59]. Lipid flippases, proteins that translocate phospholipids from the
extracellular side of the plasma membrane to the cytoplasmic side, induce curvature in the
membrane for endocytosis and have been implicated in attenuating signalling via TLR-4.
Humans express fourteen P4-ATPases (lipid flippases) that mostly function as dimers. Knock
down of CDC50A, a β -subunit of eleven out of fourteen P4-ATPases, and ATP8B1 and
ATP11A, α-subunits, enhanced inflammatory cytokine secretion in human macrophages
due to impaired endocytosis resulting in prolonged signalling of TLR-4 from the plasma
membrane. However, the dynamin-inhibitor dynasore abolished this hyperactive response,
suggesting that lipid flippases do not act purely at the level of endocytosis, although this
could be due to dynamin-independent disruption by dynasore [60].
It has been proposed that the TLR-4 ectodomain adopts a different structure when in
an acidic environment, such as that of endosomes, a conformation more like that of the
tilted conformation characteristic of TLR-3 homodimers [61]. The dimerisation interface
of TLR-4 at the plasma membrane contains a large number of histidine residues. In acidic
conditions the imidazole side-chains will be protonated, which may lead to repulsion of the
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Fig. 1.1 The TLR-4 signaling pathway (Adapted from [53]). 1. LPS binds the MD-2/TLR-4
heterodimer at the plasma membrane, inducing dimerisation and conformational changes
in the TLR-4 TIR domains. 2. The adaptor protein Mal recruits MyD88 to the plasma
membrane where they interact with TLR-4 via TIR-TIR interactions resulting in the formation
of the Myddosome. Upon endocytosis, TRAM and TRIF are recruited to TLR-4. Both the
Mal/MyD88 and TRAM/TRIF pathways induce transcription factor activation. 3. Activated
NF-κB, AP-1 and IRF3, 5 and 7 translocate to the nucleus to intitiate trascription. 4.
Cytokines and effector molecules are transcribed and translated.
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TLR-4 chains and their dimerisation by a different mode. This different mode of dimerisation
may result in a change in TIR domain interaction that could allow recruitment of TRAM.
Although TRAM is present at the plasma membrane due to its myristoylation [62], it cannot
signal from the membrane [14]; thus, a change in TLR-4 conformation upon acidification
may allow its binding once TLR-4 has been endocytosed [61].
Signalling via TRIF results in late-phase NF-κB activation whilst signalling via MyD88
induces early NF-κB translocation to the nucleus [63–65]. Once endosomal, TLR-4 binds
TRAM via TIR-TIR domain interactions. It is proposed that TRAM displaces Mal from the
TIR domain of TLR-4 at the endosome to facilitate its own binding [14]. TRAM interacts
with TRIF leading to gene transcription. The mechanism by which TRIF results in NF-κB
activation is unclear. However, Receptor interacting protein 1 (RIP1) [66], Tumour necrosis
factor receptor type 1-associated DEATH domain (TRADD) [67] and Caspase 8 [68, 69]
have all been implicated as necessary to promote NF-κB activation via this pathway. TRIF
also interacts with TRAF3 [70] that recruits TRAF-associated NF-κB kinase (TANK), and
then the kinases TBK1 and IKKε , which lead to IRF3 activation and transcription of genes
resulting in type I interferon (IFN) production [71] (Fig. 1.1).
1.1.3 TLR-4 ligands
LPS
Gram-negative bacteria produce LPS, the classical bacterial ligand for TLR-4. LPS is
composed of a hydrophobic lipid A region linked to a long branched carbohydrate chain
composed of the O-specific chain and core region. The immunologically active region of
LPS is the lipid A component, which comprises a phosphorylated diglucosamine backbone
attached to between 4 and 7 acyl chains. Different bacterial species produce different
structures of lipid A – the number (4 to 7) and length of the acyl chains can vary as can the
number of phosphate groups which can also be modified by other chemical groups [72].
The number of acyl chains present in lipid A have a marked effect on the ability of
lipid A to activate TLR-4. For example, E.coli lipid A contains 6 acyl chains and is highly
immunogenic whereas the intermediate Lipid IVa, within the biosynthetic pathway, has 4
acyl chains and is an agonist in mice and horse but an antagonist for human TLR-4 [73, 74].
Rhodobacter sphaeroides lipid A has 5 acyl chains and is an antagonist of human and mice
TLR-4 but an agonist of horse TLR-4 [73, 75]. The synthetic ligand Eritoran is composed of
4 acyl chains and has purely antagonistic activity [76]. The crystal structures for MD-2 in
combination with lipid IVa [77] and Eritoran in complex with TLR-4 [78] have been solved.
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In both of these cases, the four acyl chains of lipid IVa and Eritoran are fully accommodated
within the β -sandwich structure of MD-2 [77, 78]. Conversely, lipid A with 6 acyl chains
is unable to fully occupy the binding pocket of MD-2. Five acyl chains bury within MD-2
leaving an acyl chain free to mediate core interactions between TLR-4/MD-2 forming the
dimerisation interface [26]. The importance of acyl chain number in terms of toxicity is
also demonstrated by Y.pestis. At 27°C, as in the flea, Y.pestis produces tri-, tetra-, penta-
and hexa-acyl lipid A. When grown at 37°C, as in the human host, this profile switches to
predominantly tri- and tetra-acyl lipid A, with minimal amounts of penta-acyl lipid A and
undetectable amounts of hexa-acyl lipid A. This change in acylation profile also results in a
change in immunogenic activity, as LPS and lipid A from Y.pestis grown at 27°C is a much
more potent inducer of TNF-α production in human macrophages than LPS and lipid A from
Y.pestis grown at 37°C [79].
The number of phosphate groups present also affects the immunological activity of lipid
A. Monophosphoryl lipid A from Salmonella enterica serovar minnesota has a reduced ability
to activate TLR-4 [80], possibly through weakening of the ionic interaction with positively
charged residue clusters present in an interface with TLR-4/MD-2 and the second TLR-4
molecule present within the complex [26]. Bacteroides thetaiotaomicron LPS (Bt-LPS)
lipid A is monophosphorylated and has 5 acyl chains. Stimulation of immortalised bone
marrow derived macrophages (iBMDMs) with Bt-LPS resulted in delayed, weak myddosome
formation which was enhanced by the addition of another phosphate group, comparable to
induction by E.coli LPS [55]. This finding provides further evidence for the importance of
phosphorylation state for lipid A immunogenicity.
Protein ligands
In addition to its role in PAMP recognition, TLR-4 is also involved in signalling in response
to allergens and a range of damage-associated molecular patterns (DAMPs) that are released
from cells as a consequence of stress or injury or from the extracellular matrix (ECM) (Table
1.2).
Extracellular matrix molecules
A number of ECM molecules have been implicated in signalling via TLR-4 including
Fibronectin[83] (Fig. 1.2) and Tenascin-C [94] (Fig. 1.3). The mechanism by which these
endogenous molecules engage the TLR-4 signalling pathway has yet to be determined.
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Table 1.2 A non-exhaustive list of putative TLR-4 ligands
DAMPs Allergens
HMGB1 [81] Der p 2 [82]
Fibronectin [83] Fel d 1 [84]
Heat Shock Proteins 60 and 70 [85, 86] Nickel [87]
Fibrinogen [88] Pollen allergens [89, 90]
Hyaluronan fragments [91]
Granulysin [92]
Heparan fragments [93]
Tenascin-C [94]
Annexin A2 tetramer [95]
Fibronectin
Fibronectin (FN) is a large dimeric protein comprised of two highly homologous 250 kDa
subunits covalently linked together by two disulphide bonds at their C-termini (Fig. 1.2)
[96]. FN is a major component of the ECM; in fact, an FN matrix is required for ECM
deposition and retention of type I and III collagen [97–99]. FN has been linked to numerous
physiological processes including embryogenesis [100], maintenance of tissue integrity and
wound healing [101]. ECM-cell interactions are incredibly complex and depend on ECM
composition and organisation among other factors including the availability of proteases
within the local environment. For example, for FN to increase cell contractility it must be
interacting with collagen. FN-directed deposition of type I collagen is also necessary for FN
enhanced cell migration [99].
FN consists of three different types of repeating modules: Type I (FNI), II (FNII) and III
(FNIII) domains (Fig. 1.2), all of which are composed of anti-parallel β -sheets. FNI and
FNII domains are composed of approximately 45 amino acids and approximately 60 amino
acids respectively. FNIII domains are larger, composed of approximately 90 amino acids
[102]. Disulphide bonds between cysteine residues present in different domains stabilise FNI
and FNII modules. FNIII modules do not contain disulphide bonds [102] and are more liable
to conformational change upon mechanical stress [103]. The composition of FNIII domains
within FN is determined by alternative splicing. Extra Domain (ED) A can be incorporated
between FNIII11 and FNIII12, EDB can be incorporated between FNIII7 and FNIII8, and
five different sequences within the variable region can be incorporated between FNIII14 and
FNIII15 (Fig. 1.2), greatly increasing the number of possible isoforms [104].
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Soluble dimeric plasma FN does not contain EDA or EDB and one subunit does not
contain residues within the variable region [105]. Plasma FN is produced by hepatocytes and
circulates in the blood before being deposited in tissues where it is incorporated into fibrils
alongside cellular FN [106]. Cellular FN is produced by activated fibroblasts and forms
fibrils in the ECM [101, 107]. Cellular FN is heterogenous, with approximately 50-60%
containing the EDA domain and 15-25% containing the EDB domain [108].
Plasma FN circulates in a compact form, potentially to prevent inappropriate association
with proteins whilst circulating [104]. It is modelled that inter- and intra-molecular long-range
interactions drive this compact structure [104]. FNI4 electrostatically interacts with FNIII3
within the same molecule [109], whilst FNIII2-3 forms ionic interactions with FNIII12-14
[110] of the other molecule in the dimer to form a coiled-in-on-itself structure [104]. This
conformation occludes the asparagine-glycine-aspartic acid (RGD) sequence present in
FNIII10 within the structure, making it inaccessible for α5β1 integrin-driven cell adhesion
[104]. N-terminal (N-FI9) binding of plasma FN to the cell surface and binding of the RGD
motif to the cell surface have been proposed to induce plasma FN extension [104].
FN is regulated by both biochemical and mechanical means. Under conditions of tissue
injury and wound healing, the type III modules EDA and EDB are incorporated into the
protein by alternative splicing [111]. The structure of FN containing EDA or EDB has
not been as extensively studied as plasma FN [104]. Incorporation of EDA, but not EDB,
increases cell spreading, migration and adhesion [112]. When EDA is incorporated into
FN it induces large-scale conformational changes, either increasing access of the RGD
sequence in FNIII10 to α5β1 integrin or by modulating the conformation of FNIII10 to
increase α5β1 integrin binding affinity [112]. Under conditions of mechanical stress, for
example by increased cellular contractility, the more labile Type III domains of FN can be
unfolded [113]. Proteolysis can also result in the release of different FN domains from the
matrix [114, 115].
As well as its role in physiological processes, FN has also been implicated in the devel-
opment of pathological conditions such as the autoimmune diseases scleroderma [116] and
chronic arthritis [117] and is also utilised by bacteria for infection. Bacteria have evolved a
number of different Fibronectin binding proteins (FNBPs) thought to aid non-phagocytic cell
invasion [104]. These proteins are mostly from the microbial surface components recognizing
adhesive matrix molecules family of proteins. A number of FNBPs work by binding to
the FNI modules of FN by a process termed β -zipper formation [118]. Different bacterial
adhesin proteins have different complex stability after binding FN. For example, Strepto-
coccus pyogenes expresses a F1 adhesin that forms a long-lasting complex with FN whilst
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Borrelia burgdorferi, the pathogen responsible for Lyme disease, expresses a BBK32 adhesin
that forms a transient complex with FN. S. pyogenes forms biofilms whilst B. burgdorferi
is migratory. It has been proposed that the strength of the complexes formed between the
bacterial adhesins and FN may determine bacterial pathogenicity [104].
Increasingly it has become apparent that FN is also involved in stimulating innate immu-
nity via TLR-4 activation [83, 116, 117, 119–121]. A number of different FN fragments, (all
of which are FNIII modules) appear to signal via TLR-4 and have been implicated in disease
processes.
FN fragments that appear to signal via TLR-4 include FNIII1c, a stable intermediate of the
FNIII1 module predicted to form in response to mechanical stress [122, 123], FNIII13-14 [121]
and FNIIIEDA [83]. FNIII1c induces the expression of multiple genes in dermal fibroblasts in a
TLR-4 dependent manner [124]. FNIII13-14 has been shown to signal via TLR-4 and induces
aggrecanase activity that may lead to cartilage destruction in a mouse model of chronic
arthritis [121]. It has been suggested that FNIII13-14 may interact with TLR-4 and CD44
to maintain tissue injury [121] as it has been demonstrated that hyaluronan binds a unique
receptor complex of TLR-4, MD-2 and CD44 [125]. FNIIIEDA has been shown to induce
secretion of inflammatory cytokines from mast cells, possibly contributing to rheumatoid
arthritis (RA) pathogenesis [117] and has also been implicated in the development of allergen-
induced fibrosis and airway hyper-responsiveness in mice [126]. More recently, FNIIIEDA
has been implicated in promoting chronic cutaneous fibrosis through TLR-4 signalling
[116]. The intramolecular context of FNIIIEDA also appears to be of importance since when
the FNIIIEDA domain is N-terminally extended (FNIII9-E) its TLR-4 agonizing activity is
enhanced but when it is extended C-terminally, FNIII9-E-14 including the heparin binding
domain, its effect as an enhanced agonist is abrogated. An elastase cleavage site is present
between the FNIIIEDA domain and FNIII12. When FNIII9-E-14 is cleaved with elastase, its
enhanced agonising activity is restored [127]. Thus, whether FNIIIEDA is associated with
different sets of type III repeats determines its immunological activity.
Tenascin-C
The fibrinogen-like globe (FBG) domain of tenascin-C has also been implicated in TLR-4
signalling.
Tenascin-C is a highly regulated hexameric ECM glycoprotein. The expression of
tenascin-C is tightly controlled; it is present in many sites of morphogenesis during em-
bryogenesis but is minimally expressed in adults [128]. It can, however, be induced upon
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Fig. 1.2 The domain structure of fibronectin. Fibronectin is composed of type I, type II
and type III repeats. The type III repeats EDA and EDB and the variable domain (V) are
incorporated by alternative splicing.
Fig. 1.3 The domain structure of tenascin-C. Tenascin-C is composed of a C-terminal
Tenascin assmbly (TA) domain, epidermal growth factor-like (EGF-L) repeats, FNIII-like
domains and a C-terminal fibrinogen-like globe (FBG) domain. The pink FNIII-like domains
are incorporated by alternative splicing.
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pathological stress such as chronic inflammation [129]. Tenascin-C is comprised of four
different domains: the tenascin assembly (TA) domain, epidermal growth factor-like (EGF-L)
repeats, FNIII repeats and an FBG domain (Fig. 1.3). Like FN, alternative splicing regulates
tenascin-C. Nine FNIII repeats can be incorporated between FNIII repeats 5 and 6 [128].
Unlike plasma FN, the structure of tenascin-C does not undergo large conformational changes
[104].
Tenascin-C is also regulated by post-translational modifications. There are a proposed 26
potential N-glycosylation sites [128] and a predicted 34 O-glycolsylation sites [130]. These
carbohydrate moieties contribute significantly to the mass of tenascin-C and likely modulate
cell adhesion, the protein binding functions of tenascin-C and its ability to be degraded [128].
Tenascin-C is also citrullinated in its FBG domain, increasing its immunogenicity [131] and
can also be cleaved by a number of different proteases, including matrix metalloproteinases
(MMPs) [132], a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-
5 [133] and elastase secreted by leukocytes [134]. Cleavage and degradation of tenascin-C
can result in the release of biologically active domains. For example, EGF-L domains, but
not full-length tenascin-C, are able to induce smooth muscle cells to undergo apoptosis [135]
whilst the FBG domain can inhibit FN matrix assembly [136].
The biological role of tenascin-C is very complex, it can bind to other components in
the ECM including integrins, pathogens and soluble factors [137]. The different isoforms of
tenascin-C are proposed to play different biological roles. For example, the smallest isoform
of tenascin-C promotes cell attachment and focal adhesion formation [128] whilst the larger
tenascin-C isoforms promote cell migration [138].
Tenascin-C is associated with a wide variety of autoimmune diseases such as asthma
[139], systemic sclerosis (Ssc) [140] Inflammatory Bowel Disease (IBD) [141] and RA
[142] to name a few. Tenascin-C has also been shown to play a role in cancer. Within
the stroma of solid tumours the levels of tenascin-C have been shown to be elevated, with
a different isoform profile compared to that of healthy tissue. It has been suggested that
different isoforms of tenascin-C may be useful as biomarkers for certain cancers, correlating
with cancer prognosis [128]. However, tenascin-C expression is absent in cases of cervical
carcinoma, a tumour with poor prognosis [143].
The FBG domain of tenascin-C is a DAMP that signals via TLR-4 [94]. FBG can induce
TNF-α , IL-6 and IL-8 production in human macrophages. However, unlike the EDA domain
of FN, FBG can activate TLR-4 within the context of the full-length tenascin-C protein.
FBG activation of TLR-4 is MyD88 dependent [94] indicating that, unlike LPS, FBG does
not signal via the TRAM/TRIF pathway. It is suggested that neither MD-2 nor CD14 are
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required for FBG to signal via TLR-4, indicating different co-receptors may be needed for
different ligands to signal via TLR-4 [94].
1.1.4 TLR-4 in disease
The host immune response against infection needs to be finely balanced: too little in-
flammation results in overwhelming infections whilst too much inflammation can lead to
autoimmunity. TLR-4 has been implicated as a key component in a range of diseases such
as in the control of Salmonella enetrica serovar Typhimurium infection in mice [144, 145].
TLR-4 is also important in the context of sepsis; C3H/HeJ and C57BL/10ScCr mice with
defective TLR-4 signalling are protected from endotoxic shock [21, 146]. Antibodies that
target TLR-4 protect mice from endotoxic shock in response to both LPS and E.coli and may
provide a promising therapeutic strategy in humans [147]. TLR-4 has also been implicated
in autoimmune diseases, cancer and cardiovascular disease [116, 148–150]. Understanding
how TLR-4 signals in response to different ligands is important because this could lead to
the development of therapeutics which could greatly relieve patient symptoms in a number
of diseases. It is possible that ligands induce TLR-4 complex formation with different
stoichiometry specific to different ligands. Understanding the stoichiometry of the TLR-4
signalling complex in response to a range of ligands, therefore, is crucial for understanding
and therapeutically targeting TLR-4 signalling.
1.2 Mal
1.2.1 The role of Mal in signalling pathways
Mal is one of four adaptor proteins recruited for TLR-4 signalling in response to LPS
[10, 11, 151, 152]. It was originally thought that Mal might be responsible for MyD88-
independent signalling in response to LPS. However following the discovery of TRAM
[153, 154, 64] and TRIF [155, 65] it was evident that Mal is only required for the MyD88-
dependent signalling arm of TLR-4.
Mal is located at the plasma membrane in actin-rich membrane ruffles of macrophages
and intracellular vesicles [41]. It is involved in signal transduction downstream of a number
of different receptors. In TLR-4 signalling, Mal is recruited to the plasma membrane
by its PI(4,5)P2 domain [41], delivering MyD88 through TIR-TIR domain interactions.
Mal is also required for optimal TLR-2 signalling [151, 152]; Mal-/- murine peritoneal
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macrophages show impaired NF-κB activation and IL-6, TNF-α and IL-12 production in
response to MALP-2 and peptidoglycan stimulation [152]. Mal is also required for signalling
downstream of TLR-7 and TLR-9 when ligand concentrations are low [43] and has also been
implicated in signalling downstream of TLR-5 in colonic epithelial cells [156]. In addition to
signalling downstream of TLRs, Mal has been implicated in signalling downstream of other
inflammatory receptors including the receptor for advanced glycation end products (RAGE)
[157] and the interferon gamma receptor (IFNGR) where it is important for phagosome
maturation and intracellular killing of Mycobaterium tuberculosis [158]. The promiscuity of
Mal to interact with a number of different immune-related receptors suggests that it plays
an instrumental role in immune signalling. Understanding how Mal functions within these
different signalling pathways could lead to the design of targeted therapeutics.
Fig. 1.4 The domain structure of Mal. Mal contains a PI(4,5)P2 domain, important for its
localisation to the plasma membrane, a PEST domain, which is bound by SOCS-1 and
mediates its degradation, a TIR domain through which most of its protein-protein interactions
occur and a TRAF6 binding domain (T6BD), necessary for transactivation of NF-κB
.
1.2.2 Lipid binding properties of Mal
Mal is composed of a number of different domains (Fig. 1.4) and undergoes a series of
different post-translational modifications. Mal contains a PI(4,5)P2 binding domain from
amino acids 15-35, a region enriched in aromatic and basic amino acids containing 6
conserved lysine residues. Mal can bind a panel of different acidic phospholipids (PI(3,4)P2,
PI(3,5)P2, PI(4,5)P2, phosphatidylserine [PS], PI, PI(3)P, PI(4)P, PI(5)P and PI(3,4,5)P3,
albeit to a much lesser extent). When lysine residues 15, 16, 31 and 32 were mutated, this
binding was abolished. Mal was found to bind PI(4,5)P2 preferentially out of phospholipids
present within the plasma membrane (PI(4,5)P2, PI, PI(4)P and PS), although binding to
PI(4)P and PS was also observed. Use of the PI3Kinase inhibitor Wortmannin determined
that 3’PIs were not necessary for Mal localisation. SopB, a PI phosphatase expressed by
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S.typhimurium, reduces cellular levels of PI(4,5)P2 and disrupted Mal localisation at the
plasma membrane. This process was dependent on SopB catalytic activity. Replacing the
Mal PI(4,5)P2 binding domain with well defined PI binding domains it was determined that
binding to PI(4,5)P2 was responsible for localisation of Mal at the plasma membrane whilst a
PI(4)P binding domain trafficked Mal to endosomes. CD11b, a β2 integrin (the only present
on macrophages), is modelled to induce Mal recruitment to actin rich ruffles through local
PI(4,5)P2 production, as in its absence Mal was dispersed throughout the plasma membrane,
and did not appear to undergo the cycling observed in WT macrophages. Movement of
Mal between the plasma membrane and endosomes was dependent on ADP ribosylation
factor (ARF)6, a GTPase that regulates the activation of PI5K, positively regulating PI(4,5)P2
production. Mal localisation by PI(4,5)P2 binding was necessary for its function as a bridging
adaptor for MyD88 as fusion of PI(4,5)P2 specific binding domain to the C-terminus of
MyD88 negated the requirement of Mal for signalling in response to LPS stimulation.
Recruitment of MyD88 to the plasma membrane is a TIR dependent process, as P125H
Mal was unable to recruit MyD88 to the plasma membrane. Interestingly, a construct
composed of an SH4 domain (targeting Mal to the plasma membrane) and the TIR domain
of Mal was unable to localise MyD88 to the plasma membrane, suggesting that binding
to PI(4,5)P2 specifically is necessary for Mal to localise MyD88 to the plasma membrane
[41]. It is possible that addition of the SH4 domain altered the conformation of the Mal TIR
domain, or that PI(4,5)P2 binding alters the conformation of the Mal TIR domain so that it
is favourable for binding to MyD88. In fact, LPS binding to CD14 induces its clustering
and local accumulation of PI(4,5)P2 and PI5K isoforms Iα and Iγ [39]. LPS binding to
CD14 may result in accumulation of Mal in the local vicinity of ligand-bound complexes so
that it can then bind to the TLR-4/MD-2 heterodimer once TLR-4 has dimerised. The local
production of PI(4,5)P2 by CD14 engagement was biphasic, with peaks around 5-10 minutes
and 60 minutes post-stimulation with LPS that correlated with IκB phosphorylation. It is
possible that Mal is also recruited in a biphasic manner and thus myddosome formation may
also be biphasic.
The promiscuity of the PI(4,5)P2 binding domain in Mal, its ability to bind a number
of different phospholipids, also enabled localisation of Mal to endosomes, where it is
involved in signalling downstream of both TLR-7 and TLR-9 [43]. Mal-/- primary BMDMs
were able to induce IL-1β and IL-6 mRNA expression in response to CpG but not in
response to KosA or KosCE, strains of Herpes Simplex virus (HSV) that only activate TLR-
9. Plasmacytoid DCs, that utilise endosomal TLRs to detect PAMPs, express low levels
of plasma membrane residing TLRs but maintain expression of Mal when compared to
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conventional DCs. Mal-/- pDCs were impaired in their ability to produce INF-α in response
to HSV (TLR-9) or influenza virus (TLR-7) infection, indicating that Mal was required for
TLR signalling transduction from 3’PI-rich endosomes. Mal was found to immunoprecipitate
with both MyD88 and IRAK4 in response to stimulation via LPS or CpG. Mal was required
for signalling in response to CpG in iBMDMs, possibly due to their decreased rate of
phagocytosis, preventing high concentration of CpG accumulating within endosomes.
The phospholipids PI(3)P and PI(3,5)P2 are enriched on endosomes. Interestingly, Mal
targeted specifically to the plasma membrane with a PI(4,5)P2 binding domain was able
to reconstitute signalling in Mal-/- iBMDMs in response to LPS but not CpG stimulation.
However, Mal targeted specifically to endosomes with a PI(3)P binding domain was able
to reconstitute signalling in Mal-/- iBMDMs in response to CpG but not LPS stimulation.
Therefore, the ability of the Mal PI(4,5)P2 binding domain to engage with both PI(4,5)P2
and PI(3)P or PS is important for its signalling function in response to TLR signalling from
both the plasma membrane and endosomes [43].
Binding of the PI(4,5)P2 binding domain to PIs results in its change from an unstructured
in to a U-shaped helical conformation from residues 17-30, as demonstrated by the binding
of Mal to zwitterionic micelles or in the presence of PI(4,5)P2 or PI(3)P. Flexible regions
are present either side of the helix formed and the binding site for both PI(4,5)P2 and PI(3)P
overlap [159]. Recognition of these phospholipids involved the negative charges in the
inositol phosphate head groups and the acyl chains of the lipids. The lysine residues 16,
31 and 32 were important in this interaction; they are located at the boundaries of the helix
with their side chains pointing in the same direction. The N- and C- termini of the PI(4,5)P2
binding domain were solvent exposed and composed of mostly charged residues, whilst the
helix appeared to insert inside micelles and was composed of mostly hydrophobic residues.
In fact, the helix may be amphipathic in nature, as residues A22, F25 and L29 were found to
be buried deep into the micelle whilst the residues G18, K20, D32 and, to a lesser extent, Q27
were near the surface of the micelle. The insertion of this domain into the lipid membrane did
not appear to be affected by acyl chain length. Phosphorylation of T28 within the PI(4,5)P2
binding domain decreased its ability to bind PI(4,5)P2 and prevented formation of the helical
conformation. T28 is located at the end of the helical structure; phosphorylation of this
residue may provide a mechanism for the removal of Mal from the plasma membrane for
subsequent ubiquitination and degradation [159].
The class I family of phosphatidylinositol 3-OH kinases (PI(3)K) convert PI(4,5)P2 to
PI(3,4,5)P3. The p110δ subunit is required for endocytosis of TLR-4 after stimulation with
LPS in DCs and drives signalling via Akt [42]. After LPS stimulation, the p110δ subunit
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co-immunoprecipitated with TLR-4, Mal, MyD88 and also, albeit weakly, with TRAM. The
p110δ subunit associated with MyD88 before its association with Mal. Dissociation of
Mal from the plasma membrane after LPS stimulation was delayed in p110δ D901A bone
marrow derived DCs (BMDCs) (BMDCs with a catalytically inactive p110δ ) compared
to WT cells, resulting in enhanced cytokine production due to prolonged activation at
the plasma membrane and less production of cytokines dependent on the TRAM/TRIF
pathway. Addition of p110δ and ATP to Mal and liposomes resulted in dissociation of
Mal binding PI(4,5)P2 in vitro suggesting that p110δ competes with Mal to bind PI(4,5)P2
lipids, dependent on the kinase activity of p110δ . In the absence of catalytic activity
of p110δ in BMDCs, Mal underwent delayed degradation. The dynamics of PI(4,5)P2
conversion to PI(3,4,5)P3 was more important than total levels of PI(3,4,5)P3 for TLR-4
endocytosis, demonstrated using 3’ phosphatase Phosphatase and tensin homologue (PTEN)
(that converts PI(3,4,5)P3 to PI(4,5)P2) deficient cells and 5’ phosphatase SH2-containing
inositol phosphatase-1 (that converts PI(3,4,5)P3 to PI(3,4)P2) deficient cells. PTEN has
also been shown to control the recruitment of Mal for signalling via TLR-5 in colonic
epithelial cells [156]. Mice which harbour the p110δ D901A mutation were more susceptible
to endotoxin shock, which correlated with increased levels of TNF-α , IL-6 and IL-1β in
their serum and decreased expression of IFN-β and IL-10. These findings demonstrate that
p110δ positively regulates the TRAM/TRIF IRF3-IFN-β -IL-10 signalling axis to prevent
uncontrolled systemic inflammation [42].
The TIR domain of Mal has also been shown to interact with the TIR domain of B-
cell adaptor for PI3K (BCAP) [160], a negative regulator of TLR signalling [161]. BCAP
interacts with the p85 subunit of PI3K and PLCγ2, proteins that both deplete PI(4,5)P2 at
the plasma membrane. BCAP may terminate signalling via Mal at the plasma membrane
by depleting PI(4,5)P2 and thus localisation of Mal and MyD88 to LPS-engaged TLR-4
complexes. BCAP binding to PLCγ2 and Syk provides a link with endocytosis as activation
of Syk by PLCγ2 is required for endocytosis of TLR-4; Mal is also able to interact with
PLCγ2. BCAP inhibits signalling downstream in endosomal TLRs; it has been suggested that
BCAP may function by altering phospholipid composition of endosomes thus influencing
the ability of Mal to enable signalling from this compartment [160]. BCAP can also interact
with TLR-2, TLR-4, MyD88 and SARM [160].
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1.2.3 Mal phosphorylation
Mal is phosphorylated by Bruton’s tyrosine kinase (Btk), a member of the Tec family of
kinases [162]. Btk interacts with a number of TLR signalling components, including TLR-4,
-6, -8 and -9 and MyD88 [163]. Specifically, Btk phosphorylates Mal at the tyrosine residues
Y86 (a tyrosine residue conserved within all TIR domains), Y106 and Y187. Both Y86 and
Y187 when mutated to phenylalanine act as a dominant negative mutant. The role of Y106 is
unclear, as although Y106A was able to decrease NF-κB activation in HEK293 cells it did
not affect TLR-4 signalling in response to LPS. It is possible that phosphorylation of Y106
is important for the function of Mal downstream of different receptors. Phosphorylation
of Y106 and Y187 may result in a conformational change of the Mal TIR domain for
induction of downstream signalling [162]. WT Mal is constitutively bound to Btk; this
interaction increased 5-15 minutes post 100 ng/ml LPS stimulation in concert with increased
Mal phosphorylation 1-5 minutes post stimulation that plateaued after 15-30 minutes [164].
These interactions appear essential for efficient TLR-4 signalling as upon induction of
endotoxin tolerance they are lost, resulting in a loss of downstream signalling. Interestingly,
the P125H mutation also abolished Mal tyrosine phosphorylation similar to the mutants
Y86A, Y106A and Y159A. This is likely due to its inability to constitutively bind Btk. The
mutants P125H, Y86A, Y106A and Y159A displayed increased association with TLR-4
whilst mutants Y86A and Y159A also displayed increased association with MyD88. No
differences in association with IRAK2 or TRAF6 were observed. These mutants all acted as
dominant-negative inhibitors of signalling in response to LPS, but did not affect signalling
in response to overexpression of MyD88, IRAK2 or TRAF6. These results suggest that
they insert their effects at the level of TLR-4 interaction. It is possible that phosphorylation
of these residues could result in structural alterations of important domains such as the
PI(4,5)P2 binding domain and the TIR domain itself inhibiting their function for active
signalling. Furthermore, they may also provide docking sites for other kinases to bind and
induce co-operative phosphorylation for Mal function [164].
The Protein Kinase C (PKC) proteins PKCδ and PKCη can also bind Mal [165]. The
TIR domain of Mal bound constitutively phosphorylated PKCδ , even after stimulation with
LPS. In the absence of PKCδ , phosphorylation of IKK, p38 and IκB was lost following
TLR-4 or TLR-2 stimulation. However, this could be due to increased PI3K and Akt activity
in cells in the absence of PKCδ . The role that PKCδ plays in TLR-4 signalling is unclear,
but it is possible that it may act to inhibit Btk, or that Mal may act as a bridging adaptor so
that when TLR-4 is activated, PKCδ comes into proximity of TRAF6 that binds to substrate
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of PKCδ . The interaction of Mal with PKCη was not further investigated in this particular
study [165].
Mal is also phosphorylated by the serine/threonine kinases IRAK1 and IRAK4. Mal
interacts with IRAK4 via its TIR domain and may be associated with IRAK1 and IRAK4
in resting cells. Upon stimulation with LPS, phosphorylation of Mal results in lysine48-
ubiquitination and subsequent proteasomal degradation, providing a negative feedback loop
after myddosome formation. Both IRAK1 and IRAK4 phosphorylate T28 in Mal. Mutation
of this residue (T28A), however, had no discernable effect on the ability of Mal to activate
NF-κB or on the degradation of Mal. Individual point mutation of all serine residues in Mal
also had no effect, suggesting that multiple phosphorylation events are needed [166]. IRAK1
and IRAK4 differentially phosphorylated Mal, as different bands of phosphorylated Mal
were present on an acrylamide gel depending on which IRAK was present.
1.2.4 Mal degradation
Mal underwent degradation within 15 minutes post stimulation with 1 µg/ml LPS or Pam3Cys
in undifferentiated THP-1 cells. Degradation of Mal was dependent on the 26S proteasome.
Mal contains a PEST domain N-terminal to the TIR domain, so called after the amino
acids present in the motif (Fig. 1.4) [167]. Suppressor of cytokine signalling (SOCS)-1 is
expressed within 15-30 minutes of LPS stimulation. The Src homology 2 (SH2) binding
domain of SOCS-1, which binds phosphorylated tyrosine residues, enabled recognition of
phosphorylated Mal and the SOCS box domain was necessary for SOCS-1 to act as an E3
ligase; Mal phosphorylation by Btk was necessary for its degradation. SOCS-1 binding
resulted in polyubiquitination of lysines 15 and 16 in Mal, targeting it for degradation.
SOCS-1-/- macrophages displayed increased phosphorylation of serine 536 on the p65 subunit
of NF-κB, but did not increase phosphorylation of p38 in response to LPS stimulation.
Enhanced NF-κB transactivation by Mal may be responsible for this observed phenotype.
SOCS-1 degradation of Mal also occurred downstream of TLR-2 signalling [167]. Mal is
also degraded by calpain, a nonlysosomal cysteine protease, in a calcium dependent manner.
The p110δ subunit was required for calpain processing at the plasma membrane after LPS
stimulation to release functional proteolytically active calpain into the cytosol [42].
1.2.5 NF-κB transactivation
The TIR domain of Mal contains a putative TRAF6 binding domain (P-X-E-X-X-Ar/Ac)
from amino acids 188-193 [168]. Mal co-immunoprecipitated with TRAF6 in HEK293T
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cells even when glutamic acid 190 was mutated to an alanine residue (E190A). However, the
E190A mutant was unable to activate a number of downstream signalling events such as JNK
and MAPK p42/p44 activation and p65 transactivation in a HEK293 reporter assay and acted
as a dominant negative mutant downstream of both TLR-2 and TLR-4 signalling in an NF-κB
HEK293 reporter assay. It was concluded that TRAF6 binding to Mal was necessary for p65
transactivation and downstream signalling events [168]. A subsequent study demonstrated
that Mal recruits TRAF6 to the plasma membrane in a time dependent manner post TLR-4
or TLR-2 stimulation in THP-1 cells, critical for NF-κB transactivation [169]. Using 3D
iso-surface rendition, WT Mal was shown to co-localise in transfected HEK293 cells, whilst
Mal E190A did not. Mal also bound TRAF6 in vitro, indicating that this interaction can occur
independently of post-translational modifications. Reconstitution of Mal-/- macrophages with
WT Mal, and not Mal E190A, was able to recover NF-κB transactivation after stimulation
of TLR-2, although Mal E190A could induce partial recovery of NF-κB transactivation in
response to TLR-4 stimulation, possibly through the TRAM/TRIF pathway. Interestingly,
both WT and E190A Mal were able to induce NF-κB translocation to the nucleus. The
interaction between Mal and TRAF6 controls NF-κB dependent expression of cytokines; only
reconstitution with WT Mal recovered inflammatory cytokine production upon stimulation
with Pam3Cys or LPS [169]. Mal is required to interact, therefore, with TRAF6 at the plasma
membrane for induction of transcriptionally active NF-κB, independent of its ability to
translocate to the nucleus.
1.2.6 Glutathionylation of Mal
Glutathionylation of cysteine 91 may also be important for Mal signalling [170]. Cysteine
91 is glutathionylated basally in macrophages, increasing within 5-15 minutes in response
to stimulation with LPS. Mal C91A acted as a dominant negative mutant, inhibiting the
interaction of Mal with MyD88. C91 glutathionylation may be important for protein-protein
interactions and myddosome formation that would occur within this time frame.
1.2.7 The role of caspase-1 in Mal signalling
Caspase-1 was identified as interacting with the TIR domain of Mal in a yeast two-hybrid
screen [171]. LPS treatment disrupted this interaction in THP-1 cells. Caspase-1 deficient
cells exhibited impaired signalling in response to LPS or MALP-2 stimulation. Mal cleavage
by capsase-1 removed the C-terminal portion of Mal after D198, releasing a 4 kDa fragment
corresponding to the α-E helix of the TIR domain, possibly revealing a MyD88 binding
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groove [172]. The mutant D198A was not cleaved by capase-1 but was still able to interact
with caspase-1. Overexpression of D198A was unable to activate NF-κB in transfected
HEK293 cells. It was concluded that cleavage by caspase-1 was necessary for the activation
of Mal to enable signalling [171]. This conclusion is, however, controversial. Using MAPPIT,
a mammalian two-hybrid system where protein binding induces STAT-3 induced luciferase
production, both a Mal mutant that mimics cleaved Mal and Mal D198A were impaired
in binding TLR-4 and MyD88 and lost the ability to activate NF-κB, whilst the mutant
D198E (a mutant resistant to caspase-1 cleavage) was still functional. An acidic amino acid
at position 198, therefore, is essential for Mal function [173]. The equivalent amino acid
positions in both TLR-4 (E796) and MyD88 (D275) were also important for TIR interactions.
A protein-protein interaction site program predicted that the conserved patch of Mal, that
also contains the Btk phosphorylation site Y187 and aligns to that of TLR-4, is part of an
interaction site. Cleavage by caspase-1 may be inhibitory rather than activating.
1.2.8 Mal in disease
Mal is the most polymorphic adaptor protein involved in TLR-4 signalling and a number of
Mal variants have been implicated in disease. The first association of a Mal single nucleotide
polymorphism (SNP) with disease was C558T with meningeal tuberculosis (TB) [174].
C558T is a synonymous SNP (A168A), with an increased frequency of homozygotes present
in Vietnamese patients with meningeal TB. Whole blood samples of the 558TT genotype
produced significantly lower levels of IL-6 compared to the 558CC genotype when stimulated
with diacylated lipopeptide. A similar trend was observed when stimulating with triacylated
peptides, although this was not significant. No difference was observed in IL-6 production
in response to LPS stimulation. Stimulation of whole blood with M.tuberculosis lysates
also showed no difference in IL-6 production between the two genotypes. As C558T is
synonymous, it is possible that the SNP is in linkage disequilibrium with either other SNPs
in the coding region of Mal or SNPs within the non-coding region of Mal affecting its
expression [174], although this is unlikely to be the case as it is deep within an exon [175].
Moreover, this SNP has also been shown to associate with meningeal TB in a mixed ancestry
population [175]. However, C558T did not associate with TB susceptibility in a Chinese
population [176].
A protective effect against invasive pneumococcal disease (UK), bacteraemia (Kenya),
malaria (Gambia, Kenya and Vietnam) and TB (Algeria and West Africa) was observed in
individuals heterozygous for the SNP rs8177374 that encodes S180L [177]. S180L was
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unable to bind TLR-2 but could still bind Mal and MyD88. The ability of S180L to bind
TLR-4 was not tested. S180L was unable to induce IL-6 production in embryonic MEFs in
response to stimulation by LPS or MALP-2 and acted as a dominant negative for activation
in a NF-κB reporter assay. As such, it was suggested that heterozygote individuals might
benefit from intermediate activation levels downstream of TLR-4 and TLR-2 by inducing
a more balanced inflammatory response [177]. However, no phenotype was observed by
Nagpal et al. or George et al. when investigating the effect of S180L in cellular assays,
leading them to suggest that it is a hypomorphic mutation and that overexpression was able
to overcome its signalling deficiencies [178, 179]. Heterozygote protection of S180L against
TB was also observed in a Colombian population [180]. However, no association of S180L
with pulmonary TB was found in a Colombian population [181] or a Chinese population
[176, 182]. In an Italian cohort, heterozygosity of S180L conferred protection against
pulmonary TB [183] whilst in a south Indian population, S180L conferred susceptibility to
pulmonary TB [184]. Protection conveyed by heterozygous S180L against TB was unable to
be replicated in a Russian, Ghanaian or Indonesian population [185]. S180L did not associate
with childhood TB in a South African population or with a mixed ancestry population, but
this may be due to the low frequency of the SNP and small sample size of the study [175].
There was no association of S180L with TB or between pulmonary, pleural, miliary and
extrapulmonary TB in a Peruvian population [186].
Due to conflicting results on whether S180L was protective or induced susceptibility to
TB a meta-analysis was conducted on the 11 aforementioned studies published between 2006
and 2013 [187]. The minor allele frequency among controls varied by ethnicity. This study
concluded that the S180L mutation associated with a reduced risk of TB infection and that
heterozygosity was advantageous. When subgroup analyses were conducted by ethnicity,
only the European population had a significant association of S180L with decreased risk of
TB, not seen in Asian, American or African populations [187].
The S180L mutation has also been suggested to protect against multi-organ dysfunction,
non-cerebral severe malaria and mortality due to Plasmodium falciparum infection when
heterozygous in a population of Indian adults [188]. Both 180SL and 180LL genotypes were
associated with significantly higher levels of TNF-α in plasma compared to 180SS, suggestive
of an increased inflammatory response, not a dampened one. A study of Burundian children
detected no difference in genotype frequency in children with or without P.falciparum malaria,
or between individuals with uncomplicated versus severe malaria [189]. Furthermore, S180L
was found to be associated with development of mild P.falciparum malaria compared to non-
infected individuals in an Iranian population, although the authors suggest high frequency of
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the S180L genotype in patients with mild malaria may support its protective effects from
severe malaria [190]. In a Brazilian population, no association with S180L and mild malaria
was observed [191]. In an analysis of 1095 women from Ghana, a malaria endemic area,
only 1 woman was heterozygous for S180L suggesting that it is not under positive selective
pressure and thus not protective [192].
The S180L mutation has also been associated as heterozygote protective in the context
of Systemic Lupus Erythematosus, but not for other autoimmune diseases such as type 1
diabetes, primary Sjrögens syndrome or RA [180]. S180L has also been associated with
Behçets disease, a disease with unknown aetiology but proposed to be autoimmune, in
patients in the UK but not in patients within the Middle East [193].
In human experimental endotoxaemia, volunteers heterozygous for S180L produced
more inflammatory cytokines upon injection of LPS than S180 homozygous individuals
[194]. This result contrasts that reported by Khor et al. [177] who used transfection of
HEK293 cells to determine the ability of S180L to signal. Instead, it is possible that S180
may be positively regulated by L180 to induce increased cytokine production. Patients with
Gram-negative bacterial sepsis and ventilator-associated pneumonia homozygous for L180
had more severe infections compared to heterozygous and homozygous S180 patients when
analysing clinical pulmonary infection score. These observations suggest that a too large
increase in inflammatory response is deleterious.
Analysing the SNP rs1893352, in close linkage disequilibrium with S180L, found that
post-vaccination development of invasive Haemophilus influenzae serotype b (Hib) in chil-
dren in the UK is also associated with S180L [195]. An excess of recessive homozygous
genotypes was observed in cases versus controls, but only in patients with non-meningitis
forms of Hib vaccine failure.
S180L has been associated with protection, when heterozygous, against severe infections
in Greek patients with HIV that had CD4 T cell counts less than 200 cells/mm3 blood [196].
Heterozygous carriage of S180L has also been associated with protection of individuals
infected with Trypanosoma cruzi from developing severe chronic Chagas cardiomyopathy in
Brazilian patients [197].
Mal has also been shown to transduce signalling in response to INF-γ receptor signalling
[158]. It is possible that defects in this pathway rather than TLR-2 or TLR-4 signalling path-
ways may be responsible for the associations observed above as S200L mouse macrophages
(the equivalent of the human S180L mutation) displayed defective bacterial killing and
phagosomal maturation whilst cytokine production remained in tact. The combination of an
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increased TLR-4 inflammatory response with degreased IFN-γ receptor signalling may be
deleterious for infectious disease outcomes and autoimmune responses.
D96N is a rare mutation within the TIR domain of Mal. Although D96N was able to
interact with TLR-4 and TLR-2, it was unable to interact with MyD88, impairing cytokine
production and NF-κB activation in response to signalling downstream of TLR-2 and TLR-4
[178]. However, using transfected HEK293 cells, George et al. demonstrated that D96N was
able to interact with MyD88, but was not able to relocate MyD88 from foci to the plasma
membrane when co-transfected [179]. The observed hypomorphic phenotype was proposed
to be a result of changes to the surface charge of the TIR domain, as aspartic acid is negatively
charged whilst asparagine is neutral [178]. Interestingly, D96E, a mutation conserving the
negative charge, also displayed a loss of function phenotype. D96N demonstrated reduced
tyrosine phosphorylation compared to WT Mal in HEK293 cells [179]. Instead of a change
in charge, loss of post-translational modification may, therefore, result in the loss of function
observed with D96N [179]. D96N has been associated with susceptibility to TB in a Chinese
population [176].
As well as genetic association studies of Mal within human populations, mouse models
have also been used to determine the necessity of Mal in infection. For example, in Bordatella
pertussis infection, the causative agent of whooping cough, Mal was needed for intracellular
killing of B.pertussis, alveolar macrophage survival and prevention of bacterial build up
in the lungs and subsequent dissemination [198]. Mal was also necessary for combatting
intratracheal infection of E.coli [199] and Klebsiella pneumoniae, but not Psuedomonas
aeruginosa [200]. In a mouse model of Salmonella typhoid, both TLR-4 and MyD88 were
critical for control of infection caused by intra-venous injection of S.typhimurium whilst Mal
was not required. Mal-dependency was only observed at low multiplicities of infection [145].
Mal was, however, necessary for protection against oral infection with S.typhimurium as Mal
contributes to the integrity of the intestinal epithelium through interaction with PKCζ [201].
In a mouse model of M.tuberculosis infection, heterozygous carriage of S200L conveyed
protection against TB whilst homozygous carriage resulted in increased susceptibility [158].
Interestingly, humans homozygous for recessive Mal deficiency caused by the R121W
mutation, a residue strongly conserved across species and TIR domains, have been identified
[202]. One of these individuals had a life threatening Staphylococcus aureus infection, a
Gram-positive bacteria, protection of which is dependent on TLR-2. Seven other relatives
homozygous for R121W did not have life threatening S.aureus infections; these individuals
had developed antibodies specific to lipoteichoic acid (LTA) that protected them from
infection. Administration of monoclonal antibodies against LTA to the first individual
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that had not developed specific antibodies reversed the defective response in this patient.
Production of these LTA specific antibodies, therefore, was able to overcome the genetic Mal
deficiency and rescue immunity to S.aureus infection [202].
1.3 Imaging PRR signalling pathways
1.3.1 Imaging methods
Microscopy based analysis has greatly aided investigations into how PRR signalling pathways
occur in response to stimulation by different ligands and the mechanisms behind them. A
number of different microscopy methods exist, each with advantages and disadvantages
for their particular imaging purpose, from imaging with nanometre to angstrom resolution.
Sanderson et al. [203] offers a comprehensive review on fluorescent microscopy and my
own recently published review discusses the application of microscopy for investigating PRR
signalling [53]. Brief descriptions of the different microscopy techniques that can be used to
investigate signalling are described below.
Confocal microscopy is a widely used technique due to its user friendly interface and
increased resolution – a pinhole aperture ensures that out of focus light is not collected,
sharpening the image obtained in the focal plane of interest [203]. Using confocal microscopy
a number of different investigative methods can be employed for analysing protein behaviour
within cells. These include fluorescent recovery after photobleaching (FRAP) to investigate
protein diffusion dynamics, proximity ligation assays to determine whether proteins are in
the same complex, and Förster resonance energy transfer (FRET) to determine the distance
between proteins [53].
A major limitation of fluorescent microscopy is the diffraction limit of light, imposed
by the point spread function of the microscope; if two fluorophores are within a distance of
approximately 200 nm they cannot be resolved as two distinct fluorophores. In recent years
super resolution imaging methods have been developed to overcome this diffraction barrier.
Total internal reflection fluorescence (TIRF) microscopy is a powerful technique for
imaging proteins present at the plasma membrane of cells due to its improved signal-to-noise
ratio. During TIRF microscopy, a laser is angled to hit the coverslip such that it is totally
internally reflected. This induces the formation of an evanescent wave at the coverslip/sample
interface of the same wavelength as the laser. This wave propagates through the sample,
decaying exponentially in intensity over distance travelled (Fig. 1.5). This exponential
decay ensures that only fluorophores proximal to the coverslip/sample interface (within
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approximately 100 nm) fluoresce, thereby greatly improving the signal-to-noise ratio of the
image [204].
Fig. 1.5 A schematic of Total Internal Reflection Fluorescence (TIRF) microscopy. A laser
beam hits the coverslip at such an angle (the incident angle) that it is totally internally
reflected. An evanescent wave of the same frequency as the laser is formed at the cover-
slip/sample interface and propogates through the sample, decaying exponentially in intensity
over distance. Only fluorophores close to the coverslip/sample interface are excited and
fluoresce.
TIRF microscopy has been coupled to selective fluorophore fluorescing to enable super
resolution imaging. Two different methods have been developed that follow a similar
principle – stochastic optical resolution microscopy (STORM) [205] and photoactivated
localisation microscopy (PALM) [206]. Both of these methods work on the principle of
imaging and bleaching a few fluorophores per frame/cycle so that the localisation of each
fluorophore can be accurately determined. Each frame/cycle image can then be combined to
assemble a super resolution image. Selective fluorophores are imaged through either selective
activation (PALM) or selective photoswitching (STORM).
Electron microscopy techniques have also been developed for deducing the structure of
protein complexes at the angstrom resolution level. The shorter wavelength of an electron
allows improved resolution compared to that of a photon. In negative stain electron mi-
croscopy electrons interact with and are deflected by the stain around the sample of interest
whilst passing through the sample for their detection; good for when the electron absorption
of samples is low. Cryogenic electron microscopy, performed at cryogenic temperatures,
allows the visualisation of protein complexes in their native state without the need of a stain
(reviewed in Macleod & Bryant [53]).
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1.3.2 Methods for determining protein complex stoichiometry
A number of different methods for investigating protein stoichiometry have been developed.
For example, by comparing donor-centric and acceptor-centric ratios in FRET the number
of calmodulin proteins that bound voltage-gated Ca2+ channels has been determined in live
cells [207]. Crystal structures of proteins can also be used to determine the stoichiometry
of complexes. For example, the crystal structure of the DDs from MyD88, IRAK4 and
IRAK2 revealed that these proteins form a left-handed complex composed of 6 MyD88
molecules followed by 4 IRAK4 and 4 IRAK2 molecules (Fig. 1.1 – cartoon schematic)
[45]. TIRF microscopy coupled with photobleaching analysis has also been utilised to
determine complex stoichiometry. This method has been used to determine the stoichiometry
of packaging RNA (pRNA) molecules within a motor complex [208]. When individual
fluorophores are photobleached with enough time between subsequent photobleaching events
so that they can be delineated, the number of photobleaching events at a position within
the cell can be ascertained. The number of photobleaching events reflects the number of
proteins present within a complex. Fluorescently labelled pRNA molecules bound to motor
complexes were imaged and complex stoichiometry was determined by counting the number
of steps present within photobleaching traces [208].
Using TIRF microscopy, it is possible to image single molecules within cells by imaging
cells that have been fixed so that labelled proteins within the sample are static [209]. The
static fluorophores can then be imaged and photobleached. This method is invaluable
for determining changes in the stoichiometry of proteins over time. Unlike stoichiometry
determined by evaluating the crystal structure of purified proteins, complexes are able to
form within the context of a living cell with all of the machinery and post-translational
modifications required for their physiological stoichiometry present.
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1.4 Hypothesis & Aims
TLR-4 signalling plays a central role in many pathologic conditions from infectious dis-
ease, to autoimmunity, to cancer. Although the TLR-4 signalling pathway is well studied
the exact mechanistic details of signalling are still unclear. For example, there is debate
about whether TLR-4 clusters or not in response to LPS. Furthermore, the stoichiometry
of proteins downstream of TLR-4 has not been thoroughly investigated. The hypothe-
sis of this project is that the stoichiometry of TLR-4 and/or its associated signalling pro-
teins may differ when engaged by different ligands. Specifically the stoichiometry of
the adaptor protein Mal is hypothesised to undergo stoichiometric changes upon TLR-4
stimulation. The aims of this project were to investigate the molecular mechanisms com-
paring how TLR-4 signals in response to LPS and to a defined panel of protein ligands.
The specific aims of this project are:
• To develop protein production methods for analysing TLR-4 protein ligands.
• To determine the effect that different fibronectin fragments (FNIII1c, FNIII13-14 and
FNIIIEDA) and tenascin-C FBG domain have on TLR-4 signalling.
• To develop new tools and methodology to investigate how the stoichiometry of TLR-4
signalling complexes change over time with stimulation within the context of a living
cell.
Chapter 2
Materials & Methods
2.1 Materials
2.1.1 Recombinant tenascin-C fibrinogen-like globe (FBG) domain
Preparations of purified recombinant Wild type (WT), Mutant 3 (Mut3), Mutant 5 (Mut5) and
Mutant 7 (Mut7) tenascin-C FBG domains were kindly provided by Professor Kim Midwood
(University of Oxford). All of the mutants have an ablated binding site in loop 5 of the FBG
domain, Mut5 also has a truncated C-terminal tail and Mut7 also has 3 mutated residues in
loop 7 of the FBG domain.
2.1.2 Plasmids
The pGEX-6P-1 plasmid containing murine Extra domain A (mEDA) was kindly provided
by Dr. James Arnold (Kings College London). The pET-22b plasmids that contain inserts
encoding for fragments FNIII9-E and FNIII9-E-14 were kindly provided by Professor Jeffrey
Hubbell (École Polytechnique Fédérale de Lausanne). The pHR-GFP plasmid was kindly pro-
vided by Dr. John James (Laboratory of Molecular Biology, University of Cambridge). The
pHR-MalHALO, pHR-MyD88GFP and pHR-TLR4HALO plasmids were kindly provided by Dr.
Brett Verstak (Department of Biochemistry, University of Cambridge). The pEF6v5histopo
plasmids encoding WT, Mutant R121A, P125H and F193A Mal were kindly provided by
Professor Bostjan Kobe (The University of Queensland, Australia). The pHR-CD28HALO
and pHR-CD86HALO plasmids were kindly provided by Professor Simon Davis (University
of Oxford).
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2.1.3 Cell lines
G9 cells, a RAW264.7-derived cell line expressing enhanced Green Fluorescent Protein
(eGFP)-p65 and a TNF-α promoter-controlled mCherry construct, were kindly provided by
Dr. Iain Fraser (NIH, Washington DC). THP-1 cells expressing Cas-9 and GFP (THP-1/Cas9)
were kindly provided by Genentech (San Francisco, USA).
WT, Mal-/-, Myd88-/-, Tlr-4-/- immortalised bone marrow derived macrophages (iBMDMs)
were kindly provided by Professor Douglas Golenbock (University of Massachusetts, USA),
Professor Kate Fitzgerald (University of Massachusetts, USA) and Professor Eicke Latz
(University of Massachusetts, USA & University of Bonn, Germany).
2.2 Cell culture
2.2.1 HEK293 and HEK293T cell culture
HEK293 cells were maintained in Dulbeccos Modified Eagles Medium (DMEM) complete
medium (DMEM-C) containing 10% foetal calf serum (FCS) (Sigma), 2 mM L-glutamine
(Sigma), 100 U/ml penicillin (Sigma) and 100 µg/ml streptomycin (Sigma) at 37°C, 5% CO2.
2.2.2 G9 cell culture
G9 cells were maintained in DMEM+ containing 10% FCS (Sigma), 2 mM L-glutamine and
20 mM HEPES at 37°C, 5% CO2. Phenol-red free DMEM+ was used for stimulations as
fluorescence of mCherry is measured as a readout for TNF-α transcription.
2.2.3 Immortalised Bone Marrow-Derived Macrophage (iBMDM) cell
culture
Wild type (WT), Mal-/-, MyD88-/- and Tlr-4-/- iBMDMs were maintained in DMEM-C at
37°C, 5% CO2. Phenol-red free DMEM-C was used for imaging.
2.2.4 THP-1/Cas9 cell culture
THP-1/Cas9 cells were maintained in Roswell Park Memorial Institute (RPMI)+ culture
medium containing 10% FCS (Sigma) and 2mM L-glutamine at 37°C, 5% CO2.
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2.2.5 Immortalised Human Bronchial Epithelial cells (iHBECs)
iHBECs were maintained in keratinocyte serum-free media (KSFM)+ containing KSFM,
25 µg/ml bovine pituitary extract, 0.2 ng/ml recombinant epidermal growth factor, 250 ng/ml
puromycin and 25 µg/ml G418 (Fisher Scientific) at 37°C, 5% CO2.
2.3 Cloning of fibronectin fragments
2.3.1 RNA extraction from iHBECs
Supernatant was removed and cells were washed with PBS. RNA protect cell reagent (Qiagen)
was then added and cells were detached via scraping and transferred to RNAse free 1.5 ml
microtubes. Samples were stored at -80°C until required. Total RNA was extracted using
the RNeasy mini kit (Qiagen) as per manufacturer’s instructions. RNA was eluted in 40 µl.
RNase free water and stored at -20°C. The total RNA extracts were treated with DNAse
using the TURBO DNA-free™ kit (Invitrogen) as per manufacturer’s instructions.
2.3.2 Complementary DNA (cDNA) synthesis
cDNA was synthesised using the High-Capacity cDNA Reverse Transcriptase Kit (Applied
Biosystems) as per manufacturer’s instructions. Thermocycling conditions are shown below
(Table 2.1).
Table 2.1 Thermocycling conditions for cDNA synthesis
Step 1 Step 2 Step 3 Step 4
Temperature (°C) 25 37 85 12
Time (minutes) 10 120 5 ∞
2.3.3 Polymerase chain reaction (PCR)
Fibronectin (FN) fragments FNIII1c and FNIII13-14 were obtained using iHBEC derived
cDNA. Fragments FNIII9-E and FNIII9-E-14 were obtained using vectors kindly provided
by Professor Jeffrey Hubbell (École Polytechnique Fédérale de Lausanne). PCR reactions
were carried out in 20 µl volumes (Table 2.2 & Table 2.3). The primers used can be found in
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Appendix A, Table A1. Following amplification, PCR products were analysed by agarose
gel electrophoresis (AGE) at 120 V for 1.5 hours. The DNA bands were visualised on a UV
transilluminator and excised from the gel using scalpel blades. Fragments were extracted
from the agarose gel using Wizard® SV Gel and PCR clean-up system (Promega) as per
manufacturer’s instructions.
Table 2.2 PCR reaction mix
Reagent Volume (µl)
5 x Reaction buffer 4
10 mM dNTPs 0.4
10 µM forward primer 1
10 µM reverse primer 1
10 ng/ml cDNA 2
2000 units/ml Q5 Taq polymerase 0.2
milliQ H2O 11.4
Table 2.3 Thermocycling conditions for PCR
25 cycles
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6
55 (13-14)Temperature (°C) 98 98
60 (all others)
72 72 12
Time (s) 30 10 30 60 240 ∞
2.3.4 Blunt cloning
FN fragments were first inserted into PCR-Blunt vectors using the Zero Blunt® PCR cloning
Kit (Invitrogen) according to manufacturer’s instructions and then transformed into Gold
efficiency DH5α-select competent cells (Bioline) according to manufacturer’s instructions.
Multiple colonies for each construct were picked and plasmid DNA was extracted using
the Qiagen Mini Prep kit. Plasmids were digested using EcoRI to determine if the insert
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was inserted into the blunt vector. All digests were analysed by AGE. 1% agarose gel was
prepared in 1x TAE buffer prepared in milliQ water (0.0484 g Tris base, 1.142 ml glacial
acetic acid, 2 ml 0.5 M EDTA). Electrophoresis was performed at 120 V for 1.5 hours.
Clones with the expected restriction digest pattern were sent for Sanger Sequencing. FN
fragments were excised from the Blunt Vector plasmids by restriction digest (Table 2.4) prior
to insertion into the pCDNA3 expression vector or amplified by PCR (the primers used can
be found in Appendix A, Table A2 and Table A3) and restriction digested for insertion into
the pHR-GFP expression vector or pGEX-6P-1 expression vector.
Table 2.4 Restriction enzymes used to digest each FN fragment for insertion into pCDNA3,
pHR-GFP and pGEX-6P-1
Target plasmid FN fragment Restriction enzyme
pCDNA3 1c & 13-14 BamHI EcoRI
pCDNA3 9-E & 9-E-14 BamHI NotI
pHR-GFP All MluI BamHI
pGEX-6P-1 All BamHI NotI
Restriction digests were carried out sequentially and products were purified using the
QIAquick PCR Purification Kit (Qiagen). The digests were analysed by AGE as described
above. All constructs were extracted from the 1% agarose gel using the Promega kit as
described previously. Constructs were ligated with the digested target plasmid in a 3:1
(insert:vector) ratio using the Quick Ligation Kit (NEB) as per manufacturer’s instructions.
5 µl of the ligation mix were then transformed into Gold efficiency DH5α-select competent
cells (Bioline) as per manufacturer’s instructions. Multiple transformants were picked and
plasmid DNA was prepared using Qiagen Mini Prep kit followed by restriction digestion
using HincII. Plasmid DNA extracted from colonies with the expected digest pattern was sent
for Sanger sequencing (Source Bioscience). pGEX-6P-1 plasmids with correctly inserted
fibronectin fragments were transformed into BL21 (DE3) Competent E.coli (New England
Biolabs, UK) as per manufacturer’s instructions.
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2.4 Cloning Mal mutants into pHR-HALO
2.4.1 PCR of Mal Mutants
The pEF6v5histopo plasmids encoding WT, Mutant R121A, P125H and F193A Mal were
transformed into Gold efficiency DH5α-select competent cells (Bioline) as per manufac-
turer’s instructions. Resulting colonies obtained for each construct were picked and plasmid
DNA was extracted using the Qiagen Mini Prep kit (Qiagen). The Mal variants were am-
plified by PCR and the resultant products were digested using MluI and BamHI to facilitate
insertion into the pHR-HALO expression vector. Details of the PCR reaction mix recipe and
thermocycling conditions are listed in Table 2.5 and Table 2.6, respectively. The primers
used can be found in Appendix A, Table A4.
Table 2.5 PCR reaction mix
Reagent Volume (µl)
5 x Reaction buffer 4
10 mM dNTPs 0.4
10 µM forward primer 1
10 µM reverse primer 1
10 ng/ml DNA 2
2000 units/ml Q5 Taq polymerase 0.2
milliQ H2O 11.4
Table 2.6 Thermocycling conditions for PCR
25 cycles
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6
Temperature (°C) 98 98 60 72 72 12
Time (s) 30 10 30 60 240 ∞
Restriction digests were carried out sequentially and the products were purified using the
QIAquick PCR Purification Kit (Qiagen). The digests were analysed by AGE as described
above. All constructs were extracted from the 1% agarose gel using the Promega kit described
previously.
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2.4.2 Ligation of Mal Mutants into pHR-HALO plasmid
The constructs were ligated with the digested target pHR-HALO plasmid in a 3:1 (in-
sert:vector) ratio using the Quick Ligation Kit (NEB) as per manufacturer’s instructions. 5 µl
of the ligation mix were then transformed into Gold efficiency DH5α-select competent cells
(Bioline) as per manufacturer’s instructions. Plasmid DNA was prepared from a selection of
transformants using the Qiagen Mini Prep kit and subsequently sent for Sanger sequencing
(Source Bioscience).
2.5 Genetic modification of Fosmids
2.5.1 Preparing electrocompetent SW102 cells
5 ml LB broth supplemented with the appropriate antibiotic (12.5 µg/ml chloramphenicol,
25 µg/ml kanamycin or 50 µg/ml ampicillin) were inoculated with a single colony of SW102
cells and incubated overnight at 37°C in a shaking incubator. 500 µl of the overnight culture
were used to inoculate 25 ml low salt LB broth and incubated in a 32°C water bath with
shaking, until an OD600 of approximately 0.55 was obtained. The culture was then transferred
to a 42°C water bath, with shaking, for 15 minutes. The culture was rapidly chilled on ice
followed by centrifugation (3 minutes, 5600 rpm). The supernatant was removed and the
pellet was resuspended in 1 ml ice cold 10% glycerol and then made up to a final volume
of 10 ml with ice-cold 10% glycerol. Following centrifugation (3 minutes, 5600 rpm), the
supernatant was removed and the pellet resuspended in 1 ml ice cold 10% glycerol, and made
up to a final volume of 10 ml with ice-cold 10% glycerol. The bacteria were centrifuged
(3 minutes, 5600 rpm) and following removal of the supernatant the pelleted fraction was
resuspended in the residual volume. The bacteria were centrifuged (1 minute, 10 000 rpm)
and the pellet was resuspended in 250 µl 10% glycerol and aliquoted into 50 µl aliquots.
2.5.2 Fosmid DNA preparation
4.5 ml of bacteria grown overnight in LB broth supplemented with the appropriate antibiotic
(12.5 µg/ml chloramphenicol, 25 µg/ml kanamycin or 50 µg/ml ampicillin) were pelleted by
centrifugation (3 minutes, 5000 rpm). The supernatant was removed and the pellet was
resuspended in 250 µl Buffer P1 (Qiagen miniprep kit) and transferred to a microtube. 250 µl
Buffer P2 (Qiagen miniprep kit) were added followed by inversion to mix and incubated at
room temperature for 3 minutes. 350 µl Buffer N3 (Qiagen miniprep kit) were added and
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mixed by inversion. The solution was centrifuged (10 minutes, 10 000 rpm, 4°C) and the
supernatant was transferred to a new microtube. The solution was centrifuged (5 minutes,
10 000 rpm, 4°C) and the supernatant was transferred to a new microtube. The DNA was
precipitated using 0.7 volumes of isopropanol and centrifuged (10 minutes, 10 000 rpm, 4°C).
The supernatant was discarded and the pellet was washed once with 0.7 volumes 70% ethanol
and centrifuged (5 minutes, 10 000 rpm, room temperature). The ethanol was removed and
the pellet was left to air dry on the bench for 20 minutes at room temperature. The dried
pellet was dissolved in 50 µl TE buffer.
2.5.3 Electroporation of SW102 cells
A 50 µl aliquot of SW102 cells was transferred into an electroporation cuvette. 2 µl of fosmid
DNA (100 ng) were added and the cells were electroporated using a Biorad GenePulsor
electroporator. The conditions for electroporation were 1.75 kV, 25 µF with the pulse
controller set to 200 ohms. After electroporation, 500 µl SOC medium was added to the
bacteria and subsequently transferred into an microtube. The cells were incubated at 32°C
with shaking for 20 minutes. 40 µl of the bacterial culture were spread onto LB plates
with antibiotic selection (12.5 µg/ml chloramphenicol, 25 µg/ml kanamycin or 50 µg/ml
ampicillin) and incubated overnight at 37°C.
2.6 HEK293 Transfection assay
2.6.1 Human TLR-4 signalling components transfection
HEK293 cells were seeded into a 96-well flat-bottomed plate at a density of 1.5x104
cells/200 µl/well and incubated for 48 hours (37°C, 5% CO2). Plated cells were trans-
fected with the reagent mixes indicated in Table 2.7 to yield a total amount of 1 µg DNA/10
wells in a total volume of 50 µl. 50 µl of jetPEI solution (2 µl jetPEI transfection reagent
plus 48 µl 150 mM NaCl) was added to the DNA solution, mixed and incubated at room
temperature for 30 minutes. 900 µl of DMEM-C was added to the DNA transfection mix and
mixed by pipetting. The DMEM-C/DNA transfection mix was added to the HEK293 cells
(100 µl/well) and incubated for 48 hours (37°C, 5% CO2). The transfection medium was
removed and replaced with either 200 µl of serum-free medium, 0.1% FCS medium contain-
ing ligands or with supernatant harvested from HEK293 cells that had been transfected with
FN expression constructs. The cells were incubated for 6 hours (37°C, 5% CO2) and then
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carefully washed with 200 µl of pre-warmed Phosphate Buffered Saline (PBS). 50 µl of 1x
Passive Lysis Buffer (Promega) prepared in PBS were added/well and the plate was stored at
-80°C. When required for assay, the plate was thawed and analysed using a Labtech Fluostar
microplate reader, measuring luciferase activity as a read out for pNF-κB-luc as a proxy for
NF-κB activation. A second measurement for constitutive renilla activation from phRG-TK
activity was also taken, using coelenterazine, to serve as a transfection control standardisation
readout. This is because it is under the control of a housekeeping gene (Human Thymidine
Kinase) promoter.
Table 2.7 Reagents used for the reconstitution of TLR-4 signalling in HEK 293 cells
Reagent Concentration TLR-4/MD-2/CD14 TLR-4/CD14 TLR-4/MD-2
(µl) (µl) (µl)
pCDNA3:hTLR-4 10 ng/µl 1 1 1
pCDNA3:hCD14 10 ng/µl 1 1 -
pEFIRES:hMD-2 10 ng/µl 1 - 1
pNF-κB-luc 10 ng/µl 10 10 10
phRG-TK 10 ng/µl 5 5 5
pCDNA3 100 ng/µl 8.2 8.3 8.3
TE 10x 2.62 2.52 2.52
NaCl 150 mM 21.18 22.17 22.17
2.6.2 Fibronectin fragment transfection
The protocol above was also used to transfect HEK293 cells with plasmids encoding fi-
bronectin fragments. Table 2.8 outlines the reagent mixes for transfection to yield a total
volume of 20 µl/4 wells.
Table 2.8 Reagents used to transfect HEK293 cells with fibronectin fragment encoding
plasmids
Reagent Concentration 100 ng/well 200 ng/well 500 ng/well
(µl) (µl) (µl)
FN fragment encoding plasmid 200 ng/µl 2 5 10
TE 10x 0.2 0.5 1
NaCl 150 mM 17.8 14.5 9
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2.6.3 Protein production in HEK293T cells
HEK293T cells were seeded into a 6-well flat-bottomed plate at a density of 0.5x105 cells/well
in a final volume of 3 ml and incubated for 24 hours (37°C, 5% CO2). Plated cells were trans-
fected with the reagent mixes indicated in Table 2.9 to yield a total amount of 3 µg DNA/well
in a total volume of 100 µl. 100 µl of jetPEI solution (4 µl jetPEI transfection reagent plus
96 µl 150 mM NaCl) were added to the DNA solution, mixed and incubated at room tempera-
ture for 30 minutes. The supernatant in each well containing the adherent HEK293T cells was
replaced with 2 ml fresh DMEM-C and 200 µl of the DNA/jetPEI/medium mix was added
dropwise to each well and mixed by gentle swirling of the plate. The cells were incubated for
48 hours (37°C, 5% CO2). The supernatants were then collected and centrifuged (5 minutes,
1000 rpm). The clarified supernatant was aspirated and used to stimulate HEK293 cells
transfected with hTLR-4 signalling components.
Table 2.9 Reagents used to transfect HEK293T cells with fibronectin fragment encoding
plasmids
Reagent Concentration 3 µg/well (µl)
FN fragment encoding pHR-GFP plasmid 200 ng/µl 15
TE 10x 1.5
NaCl 150 mM 83.5
2.7 Protein production using BL21 E.coli
2.7.1 Protein expression induction in BL21 E.coli
BL21 E.coli cells transformed with the pGEX-6P-1 FN fragment-containing expression
vector were cultured in 10 ml LB broth supplemented with ampicillin (100 µg/ml) overnight
(37°C, 200 rpm). 5 ml of the overnight culture were added to 2 L of LB broth supple-
mented with ampicillin (500 µg/ml) and incubated (37°C, 200 rpm) until an O.D600 of 0.6
was reached. 50 µM Isopropyl β -D-1-thiogalactopyranoside (IPTG) was then added and
incubated for a further 4 hours at 37°C to induce expression of the FN protein. The culture
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was then centrifuged (10 minutes, 4000 rpm), the supernatant was removed and the pellet
was resuspended in 25 ml lysis buffer [GST binding buffer (50 mM Tris pH7, 150 mM NaCL,
1 mM EDTA, 1 mM DTT adjusted to pH7) with 0.8% Triton X-100 and 1x Protease Inhibitor
Cocktail IV (Calbiochem, Millipore Sigma)] and stored at -20°C.
2.7.2 Purification of mEDA
The frozen pellet resuspended in lysis buffer was thawed on ice. Polyethylenimine was added
[10 µl of 10% polyethylenimine (dissolved in water and pH adjusted to 7.5)/25 ml lysate]
and incubated on ice for 10 minutes. The solution was then sonicated for 10 minutes (5s
on, 10s off) and centrifuged (30 minutes, 17 700 x g, 4°C). The supernatant was removed
and incubated with 6 ml of Glutathione sepharose high performance GST-binding beads
(Sigma Aldrich, UK) that had previously been equilibrated as per manufacturer’s instructions
in a column for 1 hour, at 4°C with constant rotation. The supernatant was allowed to flow
through the column twice under gravity. The beads were washed using 5 volumes of GST
binding buffer and then incubated with PreScission protease (0.5 ml at 1.7 mg/ml) purified
by Dr. Olaniyi Opaleye (Department of Biochemistry, University of Cambridge) and 2 ml
GST binding buffer (4°C, overnight with constant rotation). The soluble mEDA was eluted
under gravity and the beads were washed with 15 ml GST binding buffer. Both the wash and
eluted mEDA were collected and concentrated using Vivaspin 20 3 KDa MWCO centrifugal
concentrators (GE Healthcare Life Sciences).
2.7.3 Removal of endotoxin from protein preparations
Endotoxin was removed from protein preparations using Detoxi-Gel Endotoxin Removing
Columns (ThermoFisher Scientific) as per manufacturer’s instructions.
2.8 Characterisation of proteins
2.8.1 SDS-Polyacrylamide gel electrophoresis (PAGE)
Proteins were separated by electrophoresis on 4-12% NuPAGE Bis-tris polyacrylamide
gels (Invitrogen, Thermofisher) using the Novex SureLock electrophoretic gel apparatus or
12% tris-glycine polyacrylamide gels (Table 2.10) using the Mini-PROTEAN® Tetra-Cell
apparatus (BioRad) in 1x Running Buffer (Trizma base: 3.02g, Glycine: 14.4g, SDS: 1g,
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made up to a final volume of 1 litre with MilliQ water). Electrophoresis was performed at
100 V for 30 minutes, then 140 V for 1 hour.
Table 2.10 SDS-PAGE gel constituents
Reagent 12% Resolving gel 5% Stacking gel
40 % Acrylamide 1.5 ml 250 µl
MilliQ water 2.15 ml 1.45 ml
1.0 M Tris-HCl, pH 6.8 - 250 µl
1.5 M Tris-HCl, pH 8.8 1.25 ml -
10% SDS 50 µl 20 µl
10% Ammonium persulfate 50 µl 20 µl
TEMED 2 µl 2 µl
2.8.2 Protein sample preparation
Cell lysates were diluted in 2x Laemmli sample buffer and heated for 10 minutes at 100°C.
The samples were cooled on ice, briefly centrifuged and loaded onto the gel.
2.8.3 Coomassie blue staining of SDS-PAGE gels
SDS-PAGE gels were washed in MilliQ water then immersed in Coomassie blue stain (90 ml
methanol, 90 ml MilliQ water, 20 ml glacial acetic acid, 0.25 g Coomassie brilliant blue) with
agitation for 40 minutes at room temperature. The gels were destained in multiple washes of
destain solution (90 ml methanol, 90 ml MilliQ water, 20 ml glacial acetic acid) until protein
bands became clearly visible. Stained proteins were imaged using the Bio-rad Gel Doc™
XR+ system.
2.8.4 Western blotting
Once samples had been resolved by SDS-PAGE, proteins were transferred to a PVDF
membrane by semi-dry transfer (Sigma) 1 hour 45 minutes, 45 mA, room temperature or by
wet transfer (BioRad MiniTrans Blot apparatus), 15 hours, 55 mA, 4°C. Following transfer,
the membranes were blocked in 5% milk in 1x Tris-buffered saline (TBS) for 16 hours at
4°C or 1.5 hours at room temperature. All subsequent staining and washing steps were
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carried out on a rocking platform. Appropriate dilutions of primary and secondary antibodies
were prepared in TBS plus 0.05% Tween 20 (TBS-T) containing 1% milk. The membranes
were then washed and incubated with primary antibody (5 ml Goat α-GFP, 1/5000 [ab5449,
Abcam], 10 ml 1 µg/ml Rabbit α-TIRAP polyclonal [PA5-20028, ThermoFisher Scientific],
10 ml 1 µg/ml Mouse α-HaloTag monoclonal [G9211, Promega] or 10 ml 0.1 µg/ml Mouse
α-β -Actin [AB3280, Abcam]) for 2 hours at room temperature. The membranes were then
washed six times in 10 ml TBS-Tween (TBS-T) for 5 minutes at room temperature prior
to incubation with secondary antibody (4 ml 0.08 µg/ml α-Goat IgG-HRP, [sc-2922, Santa
Cruz], 10 ml 0.17 µg/ml α-mouse IgG-HRP [7076, Cell Signaling] or 10 ml 0.17 µg/ml
α-rabbit IgG-HRP [A24537, ThermoFisher Scientific]) for 2 hours at room temperature.
The membranes were washed six times in 10 ml TBS-T for 5 minutes and incubated with
Enhanced Chemiluminesence reagent (ECL) for 5 minutes prior to being imaged using a
western blot imager (GeneGnome, Syngene). The membranes were then stripped following
incubation with Restore Western blot stripping buffer (ThermoFisher Scientific) for 15
minutes at room temperature. Stripped membranes were washed twice in 20 ml TBS-T for
30 minutes and subsequently re-probed with different antibodies using the aforementioned
protocol.
2.8.5 LPS measurement
The EndoSafe-PTS assay (Charles River Laboratories, Margate, U.K.) was used to measure
endotoxin contamination according to the manufacturer’s instructions.
2.9 G9 cell stimulation Plate reader assay
G9 cells were plated in a 96-well flat-bottomed plate at a density of 2x105 cells/200 µl/well
in phenol-red free DMEM+ and incubated overnight (37°C, 5% CO2). Medium was removed
and replaced with phenol-red free DMEM+ containing the ligand of interest. Cells were
stimulated for 24 hours, after which the fluorescent intensity of mCherry was measured using
a microplate reader (Labtech Fluostar Omega) at 584/620BP12 nm (excitation/emission
filter).
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2.10 iBMDM stimulation for cytokine analysis by ELISA
The iBMDMs of interest were plated in a 96-well flat-bottomed plate at a density of 2x105
cells/200 µl/well in DMEM-C and incubated overnight (37°C, 5% CO2). Medium was
removed and replaced with 0.1% FCS DMEM-C containing ligands (200 µl/well) or 10%
FCS DMEM-C containing 10 ng/ml ultrapure E.coli LPS (200 µl/well). Cells were then
stimulated for 2, 6 or 24 hours, after which supernatant was removed and stored at -80°C for
future analysis of cytokines by ELISA.
2.11 Lentiviral transduction of iBMDMs
2.11.1 HEK293T cell transfection
HEK293T cells were plated at a density of 0.5x105 cells/ml/well in a 12 well plate and
cultured overnight (37°C, 5% CO2). A DNA mix containing 0.5 µg p8.91 plasmid, 0.5 µg
pMDG plasmid (plasmids encoding proteins for lentivirus production) and 0.5 µg pHR-
MalHALO, pHR-MyD88GFP or pHR-TLR4HALO (the gene of interest) was prepared and made
up to a total volume of 20 µl/reaction with sterile filtered milliQ water. 4.5 µl genejuice
(Novagen) was added dropwise to 100 µl DMEM, vortexed and incubated for 5 minutes,
at room temperature. The DMEM/genejuice mix was added to the DNA and incubated
for 30 minutes at room temperature. HEK293T medium was replaced with 1ml of fresh
DMEM-C and 124.5 µl/well of the DMEM/genejuice/DNA mix was added dropwise to
each well containing the HEK293T cells. The plate was gently swirled and the cells were
incubated for 72 hours (37°C, 5% CO2).
2.11.2 Transduction of iBMDMs
Mal-/-, MyD88-/- or Tlr-4-/- iBMDMs were plated at a density of 0.25x105 cells/ml/well in a
12 well plate and cultured for 72 hours (37°C, 5% CO2). Supernatant containing lentivirus
was aspirated from the transfected HEK293T cells and centrifuged (1000 rpm, 5 minutes).
Clarified supernatants were then added to DMEM-C at the appropriate dilutions (Neat, 1/2,
1/4, 1/5, 1/8, 1/10, 1/16, 1/20, 1/32 and 1/64) to yield a 1 ml final volume. The medium
was removed from the Mal-/-, MyD88-/- or Tlr-4-/- iBMDMs and replaced with the diluted
lentiviral supernatant. An additional 500 µl of DMEM-C medium was added per well. Cells
were incubated for 24 hours (37°C, 5% CO2) after which the lentiviral medium was removed
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and replaced with 1 ml fresh DMEM-C and incubated for a further 24 hours (37°C, 5% CO2)
prior to imaging.
2.12 Sample preparation for imaging
2.12.1 Coverslip preparation
Glass coverslips were cleaned using an Argon based plasma cleaner (PDC-002, Harrick
Plasma), for a minimum of 15 minutes. The coverslips were placed into a petri dish lined
with lens tissue paper and a circle was drawn on the glass using a hydrophobic pen. One
drop of a 1 mg/ml solution of PLL(20)-g[3.7]-PEG(2.3)/PEG(3.4)-RGD(12%) (PLL-PEG)
(SuSoS, AG, Switzerland) was added per slide and the coverslips were left covered at room
temperature for 25-30 minutes. The coverslips were washed twice using drops of filtered PBS
and left with a drop of PBS on until required. Prior to use, PBS was removed from the coated
coverslip and replaced with the transduced cell suspension. For subsequent experiments,
CellView cell culture dishes (Greiner Bio-One) were used instead of glass coverslips. The
dishes were briefly washed with 200 µl of phenol-red free DMEM before use.
2.12.2 Sample preparation
Medium was aspirated from each well containing iBMDM and 300 µl Halo-TMR (5nM)
(Invitrogen) or Halo-R110 (100 nM) (Promega) dye prepared in phenol-red free DMEM
were then added in order to label the halo tag. Cells were incubated with the substrates
for 30 minutes (37°C, 5% CO2). Substrate solutions were then removed and cells were
washed twice with 500 µl/well phenol-red free DMEM. After washing, 1 ml phenol-red
free DMEM/well was then added and the cells were incubated for 1 hour (37°C, 5% CO2).
Cells were then washed once with 500 µl phenol-red free DMEM/well. 1 ml phenol-red free
DMEM/well was then added and cells were further incubated for 30 minutes (37°C, 5%
CO2). The medium was aspirated and cells were washed twice with 500 µl phenol-red free
DMEM/well, resuspended in 1 ml phenol-red free DMEM-C/well and centrifuged (2 minutes,
200 x g, room temperature). The supernatant was removed and cells were resuspended in
750 µl phenol-red free DMEM-C containing the ligand of interest. A single drop of the
labelled cell suspension was placed onto the coverslip (or 250 µl were plated on the CellView
dish) and incubated for 5, 10 or 15 minutes (37°C, 5% CO2) to allow cell adhesion to the
coverslip.
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2.12.3 LPS preparation
A 5000 ng/ml stock preparation of ultrapure E.coli LPS (Invivogen, LPS-EB) was thawed,
sonicated (1 minute water bath sonication) and diluted to a final concentration of 10 ng/ml in
phenol-red free DMEM-C.
2.12.4 LPS stimulation
Cells were resuspended in phenol-red free DMEM-C containing 10 ng/ml LPS and incubated
for a period of 5, 10 or 15 minutes (37°C, 5% CO2) prior to incubation with 4% paraformalde-
hyde at room temperature for 15 minutes. Fixative was then replaced with PBS prior to
imaging.
2.12.5 TIRF microscope assembly
Prismless, objective-based TIRF microscopy was used to image the iBMDMs. A 60X 1.45
NA objective (60x Plan Apo TIRF, NA 1.45, Nikon Corporation, Tokyo, Japan) was used.
The excitation source was a 488 nm or 561 nm laser (Excelsior, 20 mW, Spectra Physics,
Newport, US). Photons were collected using a CCD camera (Cascade II: 512, Photometrics
or Prime (scMOS), Photometrics, or Evolve 512 Delta emCCD, Photometrics).
2.13 THP-1 NF-κB reporter cell line generation
2.13.1 Lentiviral transduction of THP-1 cells
A 10 cm cell culture plate was gelatinised by adding 5 ml of 0.2% gelatin solution. The
plate was incubated at room temperature for 10 minutes after which the gelatin solution
was removed. The plate was seeded with 2.5x106 HEK293T cells prepared in plating
medium (High-glucose DMEM, 10% FCS and 2 mM L-glutamine). Cells were incubated
overnight at 37°C in order to achieve 80-90% confluency. HEK293T medium was replaced
with 10 ml of plating medium. A Lipofectamine 2000 mixture was prepared by adding
230 µl Lipofectamine 2000 (Invitrogen) to 2.27 ml Optimem (2 µl of lipofectamine/µg DNA).
The mixture was incubated for 5 minutes at room temperature. A plasmid DNA mix was
prepared by combining 5 µg of expression plasmid (pLENTI6.3 plasmid with either an RFP,
RFP-PEST, BFP or BFP-PEST NF-κB reporter construct), delta 8.9 and VSVG at a molar
ratio of 1:2.3:0.2 (Table 2.11) to a total volume of 500 µl in OptiMem I reduced serum
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medium (Invitrogen). The mixture was incubated for 20 minutes at room temperature. 500 µl
lipofectamine mixture were mixed with 500 µl plasmids in OptiMem and incubated for
20 minutes at room temperature. 1 ml of transfection mix was added to the 10 cm plate
containing HEK293T cells, gently rocked to mix and then incubated for 72 hours (37°C, 5%
CO2).
The 10 ml supernatants were then harvested and clarified by filtering through a 0.45 µm
syringe. The clarified supernatants were concentrated down to a final volume of 500 µl in
PBS using Lenti-X concentrator (Clontech) as per manufacturer’s instruction. Supernatant
containing lentivirus was then added to THP-1/Cas-9 cells in a 96 well plate. A total of
5x104 THP-1/Cas9 cells were plated per well in 100 µl of culture medium. 100 µl of 8 µg/ml
polybrene plus 25 µl of concentrated virus were added to each well and incubated for 48
hours (37°C, 5% CO2). Six wells of THP-1/Cas9 cells were transduced per reporter. 100 µl
of supernatant were removed from each well of transduced THP-1 cells and replaced with
100 µl of RPMI+ containing 2 µg/ml Blasticidin to achieve a final concentration of 1 µg/ml to
select for successful transduction. Transduced THP-1/Cas9 cells were then maintained in
RPMI+ supplemented with 1 µg/ml Blasticidin (37°C, 5% CO2).
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2.13.2 THP-1 cell stimulation
THP-1 cells were seeded at a density of 1x105 cells/100 µl/well in a flat bottomed 96 well plate
and stimulated with ligands by adding 100 µl of ligand at 2x final concentration. Cells were
stimulated for 3, 6 or 24 hours prior to harvesting of supernatants for ELISA, measurement
of LDH (cell viability) or analysis by flow cytometry.
2.14 Enzyme-linked immunosorbent assay (ELISA)
2.14.1 ELISA for murine TNF-α
Post-stimulation, supernatants were assayed for the secreted pro-inflammatory cytokine
murine Tumour necrosis factor (TNF)-α using the DuoSet ELISA Development kit (R&D
Systems, USA) as per manufacturer’s instructions.
2.14.2 ELISA for human TNF-α
Supernatants collected from THP-1 cells were assayed for TNF-α using the human TNF-α
Base Kit (Meso Scale Diagnostics) as per manufacturer’s instructions.
2.15 Cell viability assay
2.15.1 Cell viability assay of iBMDMs
Cell viability post stimulation was assayed using the CytoTox 96 Non-radioactive Cyto-
toxicity Assay (Promega, USA) as per manufacturer’s instructions. Cells were washed 3x
with 200 µl/well PBS and lysed following incubation with 150 µl/well 1.23% Triton/PBS
at 37°C for 30 minutes. A 1:5 dilution of the cell lysate (10 µl cell lysate plus 40 µl PBS)
was then added to 50 µl of Cytotox reagent and incubated at room temperature in the dark.
The reaction was stopped and the amount of endogenous Lactate dehydrogenase (LDH) was
measured using a microplate reader (Labtech Fluostar Omega).
2.15.2 THP-1 viability assay
Cell viability post stimulation was assayed using the CytoTox 96 Non-radioactive Cytotoxic-
ity Assay (Promega, USA) as per manufacturer’s instructions. Control cells were totally lysed
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with 1x lysis reagent and incubated for 45 minutes prior to the end point of ligand stimulation.
Post stimulation, cells were centrifuged (5 minutes, 1000 rpm) and the supernatant collected.
Cytotox reagent was then added to the supernatants followed by stop solution. The amount
of released LDH was quantified using a microplate reader (Labtech Fluostar Omega).
2.16 Flow Cytometry
2.16.1 Sample preparation for flow cytometry
Cells labelled for FACS anaylsis were resuspended in 1 ml of filtered MACs buffer (PBS, 2%
FCS and 1 mM EDTA), centrifuged (2 minutes, 200 x g) and resuspended in 500 µl MACs
buffer containing 2% PFA. They were analysed immediately or stored at 4°C until required.
2.16.2 Flow cytometry of THP-1 cells
THP-1/Cas9 cells were centrifuged (2 minutes, 4000 x g) and the cell pellet was resuspended
in 400 µl FACs buffer (0.2% FBS in PBS, filtered) prior to further centrifugation (2 minutes,
4000 x g) and resuspension in 300 µl FACs buffer. Cells were strained through a mesh-topped
flow cytometry tube and analysed by flow cytometry. THP-1/Cas9 cells were prepared in
the same way for FACS sorting, and collected in microtubes containing RPMI, 1 µg/ml
Blasticidin, 100 U/ml penicillin and 100 µg/ml streptomycin.
2.17 Statistical Analysis
The unpaired two-tailed Student’s t-test or one-way ANOVA with Tukey’s post test (Prism,
GraphPad Software) was used to determine whether there was statistical significance between
two groups of data. **** = p < 0.0001, *** = 0.0001 < p < 0.001, ** = 0.001 < p < 0.01 * =
0.01 < p < 0.05.
Chapter 3
Fibronectin
3.1 Introduction
The role of FN interactions within physiology is incredibly complex. Alternative splicing
results in an array of possible FN isoforms with the inserted FNIII domains determining
FN structure and function. FN has a wide range of binding partners, including other ECM
associated molecules, growth factors and receptors [210]. Recently, a number of FNIII
domains have been shown to induce cell signalling via TLR-4. These interactions have
been implicated in the pathogenesis of a number of different diseases such as scleroderma
[116] and chronic arthritis [117]. Determining the molecular mechanisms that underlie these
interactions may facilitate the design of targeted therapeutics that could potentially improve
patients’ quality of life.
3.1.1 FNIII1c
The FNIII1 domain of FN contains an atypical hydrogen-bonding network. It is composed of
two anti-parallel β sheets; one of which is made up of 3 strands (A, B, E) and the other is
comprised of 4 strands (G, F, C, D). The 3-strand β sheet is unusually weak compared to
other FNIII domains, whilst the 4-strand sheet in comparison is strengthened. This disparity
in sheet strength results in the formation of distinct intermediate states when the FNIII1
domain is mechanically unfolded [123]. The core structure of intermediate I3 favourably
complements that of Anastellin, a peptide of FNIII1 (herein referred to as FNIII1c) in which
the A and B strands are absent from the N-terminal region [122].
FNIII1c can initiate fibrillogenesis, a process involving the formation of FN fibrils by
disulphide cross-linking, in vitro [211]. Gao et al. propose that after mechanical stretching,
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the straightened A and B strands in the I3 intermediate structure could swap with other
unfolded FNIII domains thereby promoting binding within different FN modules [123]. This
supports a proposed model whereby β strands within partially unfolded modules swap with
one another in order for fibrillogenesis to occur [212]. Thus, the unfolding of FNIII1 into
its different intermediate states reveals cryptic sites involved in fibrillogenesis [123]. The
role of FNIII1c in fibrillogenesis, however, is not so straightforward as FNIII1c has also been
suggested to cause the disassembly of preformed FN matrix [213] although this is not always
observed [214].
Following the addition of FNIII1c to fibroblasts and endothelial cells, Bourdoulous et al.
observed inhibition of cell migration and proliferation [213]. Upon stimulation, Cdc42 was
activated thereby activating p38, leading to the production of filopodia. The aforementioned
inhibition of migration and proliferation was attributed to a loss of FN from the matrix
[213]. Conversely, addition of FNIII1c to monolayers of human skin fibroblasts led to its
incorporation into the FN matrix. This incorporation resulted in a conformational change of
the FNIIIEDA domain within 30 minutes of adding FNIII1c, at approximately the same time
point that p38 was phosphorylated. This phenomenon was also observed by Bourdoulous et
al., as was fibroblast filopodia formation at around 12 hours post-FNIII1c stimulation [214].
FNIII1c increases the adhesive properties of FN, leading to a decrease in cell migration [211].
This could be due to increased accessibility or avidity of integrin binding sites [214], rather
than a loss of FN [213]. The discrepancy in observed FN loss from the matrix has been
attributed to the antibody used for detecting FN as some antibodies are no longer able to
detect conformational epitopes upon addition of FNIII1c due to induced structural changes
[214].
It is possible that the addition of FNIII1c could be stimulating fibroblasts to induce p38
activation, either by increasing the accessibility or avidity of integrin binding sites [214], or
through signalling via TLR-4. Kelsh et al. have shown that, in human dermal fibroblasts, p38
activation by FNIII1c is TLR-4 dependent [124]. The conformational change in FNIIIEDA
upon FNIII1c addition [214] may also allow it to induce TLR-4 signalling and thus p38
activation, as FNIIIEDA also activates TLR-4 [83].
FNIII1c has also been implicated in resistance to TNF-related apoptosis inducing ligand
(TRAIL)-induced apoptosis in non-small cell lung cancer cells [215]. FN is enriched in the
stroma of tumours [216], where it exists in a more rigid, unfolded conformation [217].
As well as its role in fibrillogenesis, the FNIII1c fragment has also been implicated in
TLR-4 signalling. This has led to the proposal that changes in the secondary structure of the
FN matrix, for example stiffening that occurs in a number of disease progression states, such
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as tumourigenesis, could promote immune system activation and lead to chronic inflamma-
tion [120]. Stimulation of human dermal fibroblasts with recombinant FNIII1c resulted in
an NF-κB and TLR-4 dependent production of IL-8 and TNF-α , whilst stimulation with
FNIII13 did not. Thus, mechanical unfolding of FNIII1 also reveals a cryptic site involved
in TLR-4 activation of stromal cells. Remodelling of the ECM, therefore, may induce
cytokine production within that microenvironment [120]. FNIII1c also acts synergistically
with FNIIIEDA to enhance production of IL-8 in dermal fibroblasts [124]. Activation of the
p38/MK2 pathway stabilised IL-8 mRNA. Both FNIIIEDA and FNIII1c induced a similar
cytokine expression profile, although FNIIIEDA induced IL-8 production at a slower rate.
When the two fragments were combined, a synergistic increase in IL-8 production was evi-
denced. The synergistic, rather than additive, behaviour suggests that FNIII1c and FNIIIEDA
may not share the exact same mechanism of TLR-4 activation, but that these independent
mechanisms may interact with one another. Neither tenascin-C nor LPS were able to induce
IL-8 production in dermal fibroblasts; therefore the co-receptors necessary for signalling via
TLR-4 may be different between different FNIII domains of FN, tenascin-C and LPS [124].
Both FNIII1c and FNIIIEDA may be released from FN by MMP-2 cleavage [218]. Therefore,
it is possible that under the conditions where MMP-2 is present, their simultaneous cleavage
from FN is a signal for an enhanced inflammatory response.
FNIII1c can also induce CXCL13, IL-8 and TNF-α production in adult human lung
fibroblasts, although this cytokine production is dependent on TLR-2 and not TLR-4 [216].
The ability of FNIII1c to signal via both TLR-4 and TLR-2 could point to FNIII1c not directly
interacting with the TLRs but having an interaction with the TLR signalling complexes via
another protein [216].
3.1.2 FNIII13-14
The FNIII13-14 fragment within the heparin binding region of FN has also been shown to
activate TLR-4 signalling and has been implicated in the pathogenesis of chronic arthritis.
When porcine articular explants were stimulated with FNIII13-14, aggrecanase activity and
expression of ADAMTS-5 and ADAMTS-4, to a lesser extent, was increased. In murine hip
cartilage this was shown to be dependent on the TLR-4/MyD88 pathway and not TLR-2.
Furthermore, stimulation of porcine cartilage with FNIII13-14 in combination with either
TNF-α or IL-1-α enhanced aggrecanase activity in a synergistic manner [121]. FNIII12-14
was able to induce cartilage-degrading activity; FNIII12 alone was not capable but both
FNIII13 and FNIII14 were. The ability of FNIII13 to activate TLR-4 was not investigated,
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but given FNIII13-14 could induce TLR-4 activation to produce aggrecanase activity it is
likely that the ability of FNIII13 to induce aggrecanase activity is also dependent on TLR-4
activation. Interestingly, a number of studies have used FNIII13 as a negative control when
investigating the ability of FN fragments to activate TLR-4 [120, 124, 215]. It is possible that
the ability of FNIII13 to activate TLR-4 is specific to certain cell types as it activates TLR-4
on chondrocytes, but is unable to activate TLR-4 on fibroblasts. Stimulation of chondrocytes
with FNIII13-14 induced the expression of other endogenous TLR-4 activating proteins such
as HSP70 and S100, possibly contributing to a positive feedback loop of TLR-4 activation.
Sofat et al. suggest that FNIII13-14 may interact with both TLR-4 and CD44 to maintain
tissue injury [121] as hyaluronan has been shown to bind a unique receptor complex of
TLR-4, MD-2 and CD44 [125].
3.1.3 FNIIIEDA
FNIIIEDA was the first FN fragment to be shown to activate TLR-4 signalling. FNIIIEDA
strongly induced pro-MMP-9 release in non-differentiated THP-1 cells. Interestingly, FNIII1c
was unable to induce pro-MMP-9 release. Using a transfected HEK293 system (HEK293
cells were transfected with TLR-4, MD-2 and a NF-κB responsive E-selectin promoter
coupled to luciferase) it was shown that FNIIIEDA induced NF-κB translocation was TLR-4
and MD-2 dependent. Addition of soluble CD14 enhanced NF-κB activation, although this
was abrogated in the presence of polymixin B (an LPS-binding antibiotic) or E5564 (an LPS
antagonist), suggesting it was possibly caused by LPS contamination. However, addition
of polymixin B and E5564 did not affect the ability of FNIIIEDA to activate NF-κB in the
absence of soluble CD14 [83].
FNIIIEDA also activates mast cells in a TLR-4 dependent manner to produce the cy-
tokines TNF-α , IL-6 and IL-1β without inducing mast cell degranulation [117]. Injection
of FNIIIEDA into the ankle joints of mice induced paw swelling and inflammatory cell in-
filtration in a TLR-4 and mast cell dependent manner. Some inflammation, however, was
still present in the absence of mast cells suggesting that FNIIIEDA stimulation of other cells
contributes to the inflammatory response. Mast cells do not express CD14. In agreement with
Okamura et al., FNIIIEDA was shown to induce cytokine production in the absence of FCS,
suggesting that CD14 is not necessary for its activation of TLR-4. TLR-4 recognition of
FNIIIEDA, therefore, may be different to that of LPS as different combinations of co-receptors
are required. Production of TNF-α and IL-1β correlated with ankle swelling in the short
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period of inflammation; mast cell cytokine production induced by FNIIIEDA may contribute
to the pathogenesis of RA [117].
Migration of neutrophils by FNIIIEDA stimulation may be another mechanism contribut-
ing to the pathogenesis of RA. Human FNIIIEDA was able to prime both human monocytes
and neutrophils before FMLP (a chemotactic peptide) stimulation to produce the inflamma-
tory lipid mediator leukotriene B4, in a TLR-4 dependent manner [119]. FNIIIEDA enhanced
stimulation of human neutrophils was reduced by approximately 50% through inhibition of
the LTB4 receptor BLT1 Receptor, suggesting that other chemotactic factors are involved
in FNIIIEDA enhanced migration. Enhanced neutrophil migration was confirmed in vivo
using a mouse air pouch model. FNIIIEDA stimulation induced neutrophil migration in mice
expressing functional TLR-4 (C3H/HeOuJ) but not in those expressing a non-signalling
TLR-4 receptor (C3H/HeJ).
FNIIIEDA is elevated in both the serum and skin lesion biopsies of patients suffering from
scleroderma, an autoimmune disease associated with aberrant tissue fibrosis [116]. Using a
cutaneous fibrosis model in mice, fibrosis was increased in the presence of FNIIIEDA, an effect
dependent on its inherent ability to activate TLR-4. This effect may be mediated through
suppression of miR29, a microRNA implicated in the control of fibrogenesis that is reduced in
patients with scleroderma. Both transgenic mice lacking FNEDA and wild type mice injected
with the TLR-4 inhibitor CLI-095 exhibited an attenuated fibrosis response compared to
wild type mice [116]. FNIIIEDA stimulation increased myofibroblast differentiation, α-1
type 1 collagen production (a fibril forming collagen found in most connective tissues)
and α-smooth muscle actin expression in vitro. FNIIIEDA stimulation also increased the
mechanical stiffness of 3D organotype human skin equivalents. This increase in stiffness
could potentially lead to increased inflammation as more cryptic TLR-4 signalling domains
hidden within the native fold of full-length FN may be revealed. Immunoprecipitation
experiments demonstrated a direct interaction between FNIIIEDA and TLR-4 in unstimulated
dermal fibroblasts. This association was increased when fibroblasts were stimulated with
Transforming Growth Factor (TGF)-β ; dermal fibroblasts produce FNIIIEDA in response
to TGF-β . Disruption of this interaction may break the feed-forward cycle of fibrosis in
scleroderma patients [116].
At the time of writing this thesis a manuscript has been accepted that describes the gene
expression dynamics induced by FNIIIEDA stimulation of human dermal fibroblasts [219].
When human dermal fibroblasts were plated onto wells coated with plasma FN (10 µg/ml) in
combination with FNIIIEDA (40 µg/ml) inflammatory gene expression (VCAM-1 and TNF-α)
was increased after 2 hours followed by a second wave of increased fibrotic gene (TGF-β1,
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IL-10 and IL-13) expression after 24 hours. The expression of these genes was dependent on
both TLR-4 and the α4 integrin subunit. Increased incorporation of EDA into FN produced
by fibroblasts was also observed, dependent on both TLR-4 and the α4 integrin subunit,
suggesting a positive-feedback mechanism. Detection of TNF-α within the serum was not
observed after 5 hours culture with FNIIIEDA; however, FNIIIEDA stimulation primed the
fibroblasts for production of TNF-α in response to FNIII1c stimulation (10 µM), which was
also dependent on the α4 integrin subunit. Therefore it was concluded that TLR-4 and the
α4β1 integrin act synergistically upon stimulation of fibroblasts by EDA for the induction of
pro-fibrotic gene expression in human dermal fibroblasts [219].
The intra-molecular context of FNIIIEDA is an important determinant for its ability
to activate TLR-4. FNIIIEDA can induce MMP-1 release from rabbit chondrocytes and
rabbit synovial cells via IL-1 production, whilst FNIII11 and FNIII12 cannot. Addition of
either FNIII11 or FNIII12 to either side of FNIIIEDA reduced its ability to stimulate MMP-1
release, and this release was abolished when both domains were present on either side of
FNIIIEDA [220]. With respect to TLR-4 activation, when FNIIIEDA is N-terminally extended
(FNIII9-E) its ability to activate TLR-4 is increased. This phenomenon is independent of
which FNIII module is N-terminal to EDA as both FNIII11-EDA and FNIII9-10-EDA enhanced
activation of TLR-4. However, when this enhanced fragment is C-terminally extended
(FNIII9-E-14) its ability to activate TLR-4 returns to the level of activation exhibited by the
single FNIIIEDA domain [127]. An elastase-2 (also known as neutrophil elastase) cleavage
site is present between FNIIIEDA and FNIII12. Enzymatic digestion releasing FNIII9-E
from FNIII9-E-14 restored the enhanced activation. This enzymatic digestion may be a
pathophysiological mechanism enabling FNIIIEDA to activate TLR-4 in diseases such as
psoriasis and scleroderma, disorders characterised by neutrophil infiltration [127].
As well as a role in the pathogenesis of autoimmune disorders, FNIIIEDA is also necessary
for allergen-induced hyperresponsiveness and fibrosis in mice [126]. FNIIIEDA is required
for the development of subepithelial fibrosis and subsequent airway hyper-responsiveness
in response to OVA sensitisation in mice. FNIIIEDA-/- mice had decreased collagen deposi-
tion, lung stiffness and decreased TGF-β1 and IL-13 production, important mediators of
pulmonary fibrosis in asthma [221] after OVA sensitisation compared to WT mice [126].
FNIIIEDA-/- lung fibroblasts had impaired activation and differentiation after OVA sensi-
tisation, displaying decreased proliferation and migration as well as decreased collagen
deposition and contractility when compared to WT lung fibroblasts. FNIIIEDA activation
of fibroblast differentiation into myofibroblasts may be dependent on its ability to signal
via TLR-4. Interestingly, lack of FNIIIEDA had no effect on the total number of eosinophils
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recruited to the lung over a period of 1 week or 5 weeks. Moreover, it had no effect on IL-4
or GM-CSF production, suggesting that, in this context, it has not affected the Th2 allergic
inflammatory response.
The immunogenic properties of FNIIIEDA have made it an ideal candidate as an adjuvant
in vaccine development. Previous studies have utilised FNIIIEDA as a soluble protein, and
found that the presence of other TLR ligands have been necessary for its adjuvant activity
[222]. FNIIIEDA synergises with CpG (a TLR-9 ligand) to increase production of TNF-α
and IL-12p70 in murine bone marrow derived dendritic cells. The ability of FNIIIEDA to
synergise with CpG has been suggested to indicate that FNIIIEDA may signal via TRIF as
well as MyD88 [222]. However, Julier et al. determined that the requirement for other
TLR ligands is no longer necessary when FNIIIEDA is combined into a matrix (along with
FNIII9-10 for enhanced integrin activation of cells once they enter the matrix) with an antigen
[222]. FNIIIEDA fixed in a fibrin matrix with the H2kb MHC-immunodominant OVA peptide
was able to induce a CD8+ T cell response in mice. Furthermore, FNIIIEDA fixed in a fibrin
matrix with antigen in a thymoma tumour model was able to induce tumour cell killing
[127]. Implanting fibrin matrices into humans as a form of vaccine, however, may not be
straightforward, particularly as the matrices were resorbed in mice, with improved results
obtained following weekly administration. Fusion of proteins to FNIIIEDA has also been
demonstrated as an effective way to induce a cytotoxic T cell response [223, 224].
Activation of the TLR-4 signalling pathway by a number of FN fragments has been
implicated in a number of different pathological diseases involving fibrosis, primarily autoim-
mune diseases. Given the importance of these signalling interactions an understanding of the
molecular mechanism behind these signalling pathways may provide therapeutic targets for
alleviating patient symptoms. This chapter describes the investigation of the aforementioned
FN fragments in their ability to activate TLR-4 and strategies for producing these fragments
for investigation.
3.2 Results
3.2.1 HEK293 generated FN fragments activate TLR-4
The majority of studies that have investigated the ability of FN fragments to induce TLR-4
signalling have used bacteria to produce the required FN fragments. LPS is the canonical
ligand for TLR-4. As a consequence, proteins produced using Gram-negative bacteria are
likely to harbour LPS that is able to activate TLR-4. Therefore, I decided to test whether
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FN fragments could be produced using the HEK293 mammalian cell line and whether they
retained the capacity to activate TLR-4.
Firstly, FNIII1c and FNIII13-14 were cloned into the pCDNA3 expression vector, used
by the Bryant laboratory for transient transfection assays in HEK293 cells. Total RNA
was extracted from immortalised human bronchial epithelial cells, reverse transcribed into
cDNA and FNIII1c and FNIII13-14 were amplified by PCR. Amplified products were then
inserted into the TOPO blunt vector. Once the sequences of the PCR products were confirmed
by Sanger sequencing, the FNIII fragments were restriction digested and subcloned into
the pCDNA3 vector. In conjunction with this work, inserts encoding for FNIII9-E and
FNIII9-E-14 within the pET-22b vector, (kindly provided by Professor Jeffrey Hubbell), were
also subcloned into the pCDNA3 vector. The FNIII9-11 and FNIII12-14 present in these
constructs were the human version, which can mediate normal functions in mice without
inducing an immune response. The FNIIIEDA was murine and marginally better than human
FNIIIEDA in its ability to activate murine TLR-4, although murine and human FNIIIEDA was
shown to produce comparable results in vitro (personal communication with Ziad Julier).
There are only three amino acid differences in murine versus human FNIIIEDA. These
substitutions are at position 44, an arginine in mice and histidine in humans, at position 54,
an aspartic acid in mice and glutamic acid in humans and at position 87, an isoleucine in
mice and threonine in humans.
In order to determine whether the FN fragments produced in HEK293 cells were able
to activate TLR-4 a series of transient transfection experiments were undertaken. This
entailed co-transfection of HEK293 cells with the following vectors: pCDNA3:hTLR-
4, pEFIRES:hMD-2, pCDNA3:hCD14 and pNF-κB-luc (an NF-κB inducible Firefly lu-
ciferase reporter) and phRG-TK (a constitutively active Renilla luciferase reporter) or with
empty vector (pCDNA3) or with FN Fragments pCDNA3:FNIII1c, pCDNA3:FNIII13-14,
pCDNA3:FNIII9-E or pCDNA3:FNIII9-E-14 (250 [closed circles] or 500 [open circles]
ng/well). Forty-eight hours post transfection, cell culture supernatant was removed from the
HEK293 cells reconstituted with the components needed for TLR-4 signalling and replaced
with supernatant from the HEK293 cells expressing the FNIII fragments and stimulated for 6
hours (Fig. 3.1).
All of the fragments were cloned with a Gaussia luciferase signal sequence assigned at
the N-terminus to ensure they were readily secreted into the cell culture supernatant.
The confluency of HEK293 cells immediately prior to transfection affected whether a
significant difference in NF-κB activation was observed between supernatant from vector
only transfected cells or supernatant derived from FNIII fragment transfected cells. When
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Fig. 3.1 HEK293 generated fibronectin fragments activate TLR-4. HEK293 cells were
transiently transfected with the full complement (A, B and C) or with a combination (D) of
pCDNA3:hTLR-4, pEFIRES:hMD-2, pCDNA3:hCD14 and (A, B, C & D) pNF-κB-luc (an
NF-κB inducible Firefly luciferase reporter) and phRG-TK (a constitutively active Renilla
luciferase reporter). A), B) and C) Transfected cells were stimulated with supernatant derived
from HEK293 cells transfected with either empty vector (pCDNA3), pCDNA3:FNIII1c,
pCDNA3:FNIII13-14, pCDNA3:FNIII9-EDA or pCDNA3:FNIII9-EDA-14 (250 [closed circles]
or 500 [open circles] ng/well) for 6 hours. Cells were either A) 70% confluent or B) 80-90%
confluent when transfected. (D) Transfected cells were stimulated with supernatant harvested
from HEK293 cells transfected with either empty vector (pCDNA3), pCDNA3:FNIII1c,
pCDNA3:FNIII13-14, pCDNA3:FNIII9-EDA or pCDNA3:FNIII9-EDA-14 (500 ng/well) for 6
hours. The cells were then lysed and the level of NF-κB luciferase activation was measured
using a microplate reader. Data is repesented as normalised luminescence calculated by
dividing Firefly luciferase counts by those obtained for Renilla luciferase. Each data point
represents one well. A), B) and D) Data from one representative experiment with triplicate
wells for each condition. C) Data pooled from five experiments with triplicate wells for each
condition. Data represents mean ± SD. P-value calculated using one-way ANOVA, **** = p
< 0.0001, *** = 0.0001 < p < 0.001, ** = 0.001 < p < 0.01, * = 0.01 < p <0.05.
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Fig. 3.2 Fibronectin fragments generated in HEK 293 cells using pHR-FNIII-GFP con-
structs activate TLR-4. HEK293 cells were transiently transfected with pCDNA3:hTLR-4,
pEFIRES:hMD-2, pCDNA3:hCD14, pNF-κB-luc (an NF-κB inducible Firefly luciferase
reporter) and phRG-TK (a constitutively active Renilla luciferase reporter). Transfected
cells were stimulated with either medium only, KDO-2 Lipid A (10 ng/ml) or supernatant
derived from HEK293 cells transfected with A) pHR-GFP:FNIII1c, B) pHR-GFP:FNIII13-14,
C) pHR-GFP:FNIII9-EDA or pHR-GFP:FNIII9-EDA-14 or D) transfection reagent only (TR
only) or vector only (pHR-GFP) (100, 250 or 500 ng/well) for 6 hours. The cells were then
lysed and the NF-κB luciferase activation was measured using a microplate reader. Data is
represented as normalised luminescence calculated by dividing Firefly luciferase counts by
those acquired for Renilla luciferase. Each data point represents one well. Data from one
representative experiment with triplicate wells for each condition. Data represents mean ±
SD. P-value calculated using one-way ANOVA, ** = 0.001 < p < 0.01, * = 0.01 < p < 0.05.
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cells were 70% confluent at the time of transfection a significant difference in activation
was observed (Fig. 3.1A) whereas if cells were 80-90% confluent upon transfection, this
difference was abolished (Fig. 3.1B). This finding may be due to reduced transfection
efficiency. When all data sets were combined (Fig. 3.1C) significance was lost, although a
t-test comparison of FNIII13-14, FNIII9-E and FNIII9-E-14 against empty vector demonstrated
a statistically significant TLR-4 stimulating ability (p-values of 0.0444, 0.0168 and 0.0370
respectively). Furthermore, when tested for co-receptor dependency it appears that both
MD-2 and CD14 were required for the observed TLR-4 activation of NF-κB (Fig. 3.1D).
Given that expression of the FNIII fragments within the pCDNA3 vector was unreliable,
I subcloned the fragments into the more highly expressed pHR-GFP vector to determine
whether a more robust response could be achieved. Consequently, HEK293 cells were
transiently transfected with the constructs required for TLR-4 signalling as described above
or with pHR-GFP (Fig. 3.2D), transfection reagent only (Fig. 3.2D) or with FN fragments
pHR-GFP:FNIII1c (Fig. 3.2A), pHR-GFP:FNIII13-14 (Fig. 3.2B), pHR-GFP:FNIII9-E or pHR-
GFP:FNIII9-E-14 (Fig. 3.2C) (100, 250 or 500 ng/well). Forty-eight hours post transfection,
supernatant was removed from HEK293 cells reconstituted with the components needed for
TLR-4 signalling and replaced with supernatant from either HEK293 cells expressing the
FNIII fragments or with 10 ng/ml KDO-2 Lipid A, as a positive control, for 6 hours. All
four FNIII fragments tested activated TLR-4 in a dose dependent manner when increasing
amounts of plasmid were used to transfect the HEK293 cells (Fig. 3.2A, B, C). Stimulation
with supernatant from HEK293 cells transfected with either transfection reagent alone or
increasing concentration of empty vector (pHR-GFP) did not induce NF-κB activation (Fig.
3.2D). This suggests that the NF-κB activation observed when HEK293 cells were stimulated
with supernatant from FNIII transfected HEK293 cells was due to FNIII domains secreted
into the cell culture supernatant. Interestingly, using this system FNIII9-E-14 appeared to have
a similar capacity to activate TLR-4 as FNIII9-E. These results contradict those reported by
Julier et al [127]. However, the amount of FNIII fragments within the supernatants was not
quantified, so direct comparison of activation levels cannot be made. In order to compare
the ability of the different FNIII fragments to activate TLR-4 and to obtain accurate dose
response measurements purified FN fragments would be required.
3.2.2 Production of FNIII fragments using HEK293T cells
The previously described results showing that supernatant derived from HEK293 cells
transfected with pHR-mGFP:FNIII was able to activate TLR-4 confirmed that mGFP:FNIII
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was being expressed and secreted into the culture supernatant. Consequently, HEK293T cells
were utilised in an attempt to produce the FNIII fragments for protein purification using GFP-
TRAP (Chromotek) for extraction of the FNIII fragments from the supernatant. HEK293T
cells were transfected with either the pHR-mGFP vector containing FNIII1c, FNIII13-14,
FNIII9-E or FNIII9-E-14. The supernatant was then harvested and used to stimulate HEK293
cells that had been transiently transfected with the components necessary for reconstitution
of TLR-4 signalling. Only supernatant containing FNIII13-14 significantly induced NF-κB
activation compared to media only supernatant when analysed using one-way ANOVA (Fig.
3.3). However, when analysed using the t-test each of the secreted FNIII domains from the
transfected HEK293T cells were able to activate TLR-4 signalling (p-values of 0.0006 for
FNIII1c, 0.0002 for FNIII13-14, 0.0293 for FNIII9-E and 0.0091 for FNIII9-E-14).
I then tried to detect the FNIII fragments in the supernatant by western blot (Fig. 3.4).
The supernatants were loaded into a 12% SDS-PAGE gel either neat (Fig. 3.4A) or after
they had been precipitated using chloroform/methanol (Fig. 3.4B) for protein resolution
by electrophoresis. FNIII fragments could not be detected in either blot, most likely due
to the abundance of other proteins present within the supernatant (Fig. 3.4). Due to time
constraints this method for protein production was not further investigated. Had there
been more time, different transfection conditions would have been tested with the aim of
optimising production and extraction of FNIII by exploiting GFP tag pull down using the
GFP-TRAP system (Chromotek).
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Fig. 3.3 Fragments of fibronectin produced in HEK293T cells activate TLR-4. HEK293 cells
were transiently transfected with pCDNA3:hTLR-4, pEFIRES:hMD-2, pCDNA3:hCD14,
pNF-κB-luc (an NF-κB inducible Firefly luciferase reporter) and phRG-TK (a constitu-
tively active Renilla luciferase reporter). Transfected cells were stimulated with either
medium only, KDO-2 Lipid A (10 ng/ml) or supernatant from HEK293T cells in a 6 well
plate transfected with pHR-GFP:FNIII1c, pHR-GFP:FNIII13-14, pHR-GFP:FNIII9-EDA or
pHR-GFP:FNIII9-EDA-14 (3 µg/well) for 6 hours. The cells were then lysed and the NF-κB
luciferase activation was measured using a microplate reader. Data is represented as nor-
malised luminescence calculated by dividing Firefly luciferase counts by those acquired for
Renilla luciferase. Each data point represents one well. Data from one experiment with
triplicate wells for each condition. Data represents mean ± SD. P-value calculated using
one-way ANOVA, ** = 0.001 < p < 0.01.
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Fig. 3.4 Western blot detection of fibronectin fragments in culture supernatants used to
stimulate transiently transfected HEK293 cells. Supernatants from HEK293 cells transfected
with pHR vectors containing fibronectin fragments were resolved on a 12% tris-glycine gel.
The lanes correspond to 1. ladder, 2. transfection reagent only sample, 3. pHR-GFP:FNIII1c
100 ng/well sample, 4. pHR-GFP:FNIII1c 250 ng/well sample, 5. pHR-GFP:FNIII1c 500
ng/well sample, 6. pHR-GFP:FNIII13-14 100 ng/well sample, 7. pHR-GFP:FNIII13-14
250 ng/well sample, 8. pHR-GFP:FNIII13-14 500 ng/well sample, 9. ladder, 10. pHR-
GFP:FNIII9-E 100 ng/well sample, 11. pHR-GFP:FNIII9-E 250 ng/well sample, 12. pHR-
GFP:FNIII9-E 500 ng/well sample, 13. pHR-GFP:FNIII9-E-14 100 ng/well sample, 14. pHR-
GFP:FNIII9-E-14 250 ng/well sample, and 15. pHR-GFP:FNIII9-E-14 500 ng/well sample.
Proteins were transfered to a PVDF membrane by semi-dry transfer for 1h45 at 45 mA. The
membranes were blocked for 16hr, 4°C with 5% milk in Tris-buffered saline. The membranes
were washed in TBS-T and incubated with anti-GFP atibody (1/5000) for 2 hours in 1% milk
and then washed and incubated with anti-goat-HRP antibody (1/4000) for 2 hours in 1%
milk. Membranes were washed and ECL reagent was added for 5 minutes prior to imaging
using a Syngene GeneGnome western blot imager. Samples were either A) neat supernatant
or B) supernatant precipitated using methanol/chloroform.
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3.2.3 Production of FNIII fragments using BL21 E.coli
Most studies conducted exploring the ability of FNIII fragments to activate TLR-4 used
recombinant protein produced in bacteria. This is a relatively rapid method of protein
production that can yield high quantities of protein. The downside to this method is inevitable
endotoxin contamination; endotoxin needs to be removed from preparations before subjecting
proteins to tests regarding TLR-4 activation to prevent confounding results.
Dr. James Arnold kindly provided murine EDA (mEDA) in the pGEX-6P-1 bacterial
expression vector. This vector was transformed into BL21 (DE3) E.coli and conditions
required for efficient mEDA induction using Isopropyl β -D-1-thiogalactopyranoside (IPTG)
were tested (Fig. 3.5).
BL21 E.coli containing pGEX-6P-1:mEDA were cultured until an OD600 of 0.6 was
reached. After which, the cultures were stimulated with 50 µM IPTG to induce the production
of mEDA. The cultures were then incubated at 37°C for either four hours (Fig. 3.5 lane 3)
or overnight (Fig. 3.5 lane 5) or incubated at 22°C for either four hours (Fig. 3.5 lane 7)
or overnight (Fig. 3.5 lane 9). Equal amounts of bacterial culture were loaded into a 12%
SDS-PAGE gel, electrophoresed and stained by Coomassie Blue staining. Each stimulation
condition induced mEDA-GST (approximately 39 kDa) production at approximately equal
levels (Fig. 3.5). As such, the induction condition of culturing bacteria at 37°C for 4 hours
post IPTG addition was used for induction of mEDA expression in BL21 E.coli.
The protein content at each stage of the purification process using GST-binding glu-
tathione beads was visualised using SDS-PAGE and Coomassie Blue staining (Fig. 3.6A).
Briefly, once BL21 E.coli had been cultured to induce mEDA production the bacteria were
centrifuged, the supernatant was removed and the remaining pellet was resuspended in lysis
buffer and stored at -20°C. The lysed pellet was then thawed and sonicated (Fig 3.6 lane
2). The sample was then incubated with GST-binding glutathione beads and incubated for 1
hour at 4°C. The supernatant was passed over the glutathione beads twice (Fig 3.6 lane 3),
GST-binding buffer and PreScission protease was then added to the column and incubated
overnight at 4°C. PreScission protease cleaved mEDA off from the GST tag, allowing the
mEDA to be eluted (Fig 3.6 lane 4) whilst the GST was still bound to the glutathione beads.
The GST-bound glutathione beads were washed, and this was added to the eluted mEDA
sample. The GST-bound glutathione beads (Fig 3.6 lane 5) were then regenerated (Fig 3.6
lane 6); bound GST was removed for future use. The eluted mEDA was then concentrated
(Fig 3.6 lane 7). To check that the eluted protein was mEDA, a sample from each purification
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Fig. 3.5 mEDA production induction conditions. BL21 E.coli containing pGEX-6P-1:mEDA
were incubated in 5 ml LB broth supplemented with 100 µg/ml Ampicillin overnight (37°C,
200 rpm). The following day 100 µl of starter culture was inoculated into 10 ml LB broth
supplemented with 500 µg/ml Ampicillin and grown until an OD600 of 0.6 was reached. The
cells were then induced to produce protein by the addition of 50 µM IPTG. The cells were
incubated at 37°C for 4 hours (lane 3), 37°C overnight (lane 5), 22°C for 4 hours (lane 7) or
22°C overnight (lane 9). Lanes 1 and 10 correspond to protein ladder whilst lanes 2, 4, 6
and 8 are samples of bacteria prior to IPTG induction. Samples were diluted 2x in Laemmli
sample buffer and boiled for 10 minutes. 20 µl sample was loaded per well. The samples
were resolved on a 12% tris-glycine gel and coomassie stained for visualisation of protein
bands.
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step was analysed by Coomassie Blue staining (Fig. 3.6A) and by western blot using an
antibody raised against the his-tag present at the C-terminus of mEDA (Fig. 3.6B).
Once the sample had been passed through the endotoxin removal column three times,
two samples were collected and the levels of LPS contamination were determined using the
Charles River Endosafe-PTS system. Sample 1 and sample 2 contained 54.17 pg/ml LPS
and 14.73 pg/ml LPS respectively.
Following the success of producing FNIIImEDA using BL21 E.coli, the FN fragments
FNIII1c, FNIII13-14, FNIII9-E and FNIII9-E-14 were subcloned into the pGEX-6P-1 vector
and transformed into BL21 (DE3) E.coli for protein production. The ability of each FNIII
fragment to be produced in E.coli was then tested. E.coli containing each FNIII fragment in
pGEX-6P-1 were cultured until an OD600 of 0.6 was reached, and were induced with 50 µM
IPTG. Each of the FNIII fragments were produced under this induction condition (Fig. 3.7).
Unfortunately due to time constraints bacterial production of FNIII1c, FNIII13-14, FNIII9-E
and FNIII9-E-14 was not taken further.
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Fig. 3.6 Purification of recombinant mEDA. BL21 E.coli containing pGEX-6P-1:mEDA
were incubated in 10 ml LB broth supplemented with 100 µg/ml Ampicillin overnight (37°C,
200 rpm). The following day 5 ml of starter culture was inoculated into 2 L LB broth
supplemented with 500 µg/ml Ampicillin and grown until an OD600 of 0.6 was reached. The
cells were then induced to produce protein by the addition of 50 µM IPTG. The cells were
incubated at 37°C for 4 hours, centrifuged, resuspended in lysis buffer and stored at -20°C.
The sample was then thawed, sonicated and protein was purified using GST-binding beads.
Lane 1) protein ladder, 2) pre-purification sample, 3) flow through off the GST beads, 4)
cleaved mEDA, 5) GST beads, 6) flow through off the GST beads and 7) concentrated mEDA.
Samples were diluted 2x in Laemmli sample buffer and boiled for 10 minutes. 20 µl sample
was loaded per well. The samples were resolved on a 18% tris-glycine gel and A) coomassie
stained for visualisation of protein bands or B) transferred to a PVDF membrane and blotted
for the presence of His-tag using an anti-His antibody.
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Fig. 3.7 Protein production test of recombinant fibronectin fragments. BL21 E.coli containing
pGEX-6P-1:mEDA, pGEX-6P-1:FNIII1c, pGEX-6P-1:FNIII13-14, pGEX-6P-1:FNIII9-E or
pGEX-6P-1:FNIII9-E-14 were incubated in 5 ml LB broth supplemented with 100 µg/ml
Ampicillin overnight (37°C, 200 rpm). The following day 100 µl of starter culture was
inoculated into 10 ml LB broth supplemented with 500 µg/ml Ampicillin and grown until an
OD600 of 0.6 was reached. The cells were then induced to produce protein by the addition
of 50 µM IPTG. The cells were incubated at 37°C for 4 hours to produce protein. Lanes 1
and 10 correspond to protein ladder whilst lanes 2, 4, 6, 8 and 11 correspond to cultures
of pGEX-6P-1:mEDA, pGEX-6P-1:FNIII1c, pGEX-6P-1:FNIII13-14, pGEX-6P-1:FNIII9-E
and pGEX-6P-1:FNIII9-E-14 respectively prior to IPTG stimulation. Lanes 3, 5, 7, 9 and 12
correspond to samples of pGEX-6P-1:mEDA, pGEX-6P-1:FNIII1c, pGEX-6P-1:FNIII13-14,
pGEX-6P-1:FNIII9-E and pGEX-6P-1:FNIII9-E-14 after 4 hours induction with IPTG. Samples
were diluted 2x in Laemmli sample buffer and boiled for 10 minutes. 20 µl sample was
loaded per well. The samples were resolved on a 12% tris-glycine gel and coomassie stained
for visualisation of protein bands.
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3.2.4 Purified recombinant mEDA activates TLR-4 signalling
The ability of recombinant mEDA to activate TLR-4 signalling was tested using transiently
transfected HEK293 cells reconstituted for TLR-4 signalling as described previously. The
cells were stimulated with increasing doses of mEDA (sample 1 or sample 2) or 10 ng/ml
KDO-2 Lipid A, as a positive control, for 6 hours. Stimulation by both purified samples
of mEDA increased NF-κB activation in a dose-dependent manner. Both mEDA samples
produced a similar activation profile (Fig. 3.8). As sample 2 contained lower amounts of
endotoxin this sample was used for further experimentation. Activation by KDO-2 Lipid A
was not significantly different compared to media when analysed using one-way ANOVA,
most likely due to being in 0.1% FCS, rather than the usual 10% FCS used to stimulate
transfected HEK293 cells. When the data was analysed using the t-test there was a significant
difference in activation between KDO-2 Lipid A and the media only control (p = 0.0182).
To verify that recombinant mEDA stimulated TLR-4 in a physiological cell the ability
of recombinant mEDA to activate TLR-4 was also tested using iBMDMs. WT and Tlr-4-/-
iBMDMs were used to determine whether mEDA could activate TNF-α production in a
TLR-4 dependent manner. Samples of mEDA were pre-incubated with 1 µg/ml polymixin B
for 5 minutes before addition to the cells. Five minutes incubation with polymixin B was
shown to be insufficient as production of TNF-α by WT iBMDMs in response to 100 ng/ml
LPS was only marginally reduced by the presence of polymixin B, not fully reduced (Fig.
3.9A). When analysing the data by one-way ANOVA mEDA did not significantly increase
TNF-α expression above that of media alone. However, when analysed using a t-test 1 µM
mEDA did induce significant expression of TNF-α (p = 0.0441). None of the stimulation
conditions tested induced cell death (Fig. 3.9B).
These experiments need to be repeated to determine biological significance and samples
need to be incubated with polymixin B for a greater period of time to determine unequivocally
that contaminating LPS is not affecting TNF-α produced in response to mEDA stimulation.
Given that the Charles River Endosafe-PTS system measured the endotoxin contamination in
the sample as 14.73 pg/ml LPS it is unlikely that endotoxin contamination is the cause of
TNF-α production by mEDA in these sets of experiments.
NF-κB dynamics are thought to relate to efficiency of TLR-4 signalling. G9 cells, kindly
provided by Dr. Iain Fraser (NIH, Washington DC), are a RAW264.7-derived cell line
expressing enhanced Green Fluorescent Protein (eGFP)-p65 (a subunit of NF-κB) allowing
tracking of NF-κB location within the cell and a TNF-α promoter-controlled mCherry
construct dependent on NF-κB providing a measure of TNF-α transcription. These cells
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Fig. 3.8 Purified recombinant mEDA activates TLR-4. HEK293 cells were transiently
transfected with pCDNA3:hTLR-4, pEFIRES:hMD-2, pCDNA3:hCD14, pNF-κB-luc (an
NF-κB inducible Firefly luciferase reporter) and phRG-TK (a constitutively active Renilla
luciferase reporter). The cells were stimulated with KDO-2 Lipid A (10 ng/ml) or sample
1 or 2 of recombinant mEDA (0.001, 0.01, 0.1 or 1 µM) for 6 hours. The cells were then
lysed and the NF-κB luciferase activation was measured using a microplate reader. Data is
represented as normalised luminescence calculated by dividing Firefly luciferase counts by
those obtained for Renilla luciferase. Each data point represents one well. Data has been
pooled from two experiments with triplicate wells for each condition. Data represents mean
± SD. P-value calculated using one-way ANOVA, **** = p < 0.0001, ** = 0.001 < p < 0.01.
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Fig. 3.9 The EDA domain of fibronectin induces TNF-α production in iBMDMs in a TLR-4
dependent manner. WT and Tlr-4-/- iBMDMs were left untreated (control) or stimulated with
either 100 ng/ml LPS or EDA (0.1 or 1 µM) with or without 1 µg/ml Polymixin B (incubated
for 5 minutes at room temperature pre-stimulation) for 24 hours. A) TNF-α production. B)
Cellular viability (by measurement of LDH in culture supernatant) of iBMDMs in response
to EDA stimulation. Each condition represents triplicate wells from one experiment. Data
represents mean ± SD. P-value calculated using one-way ANOVA, **** = p < 0.0001.
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can be imaged using confocal microscopy to follow single cell NF-κB translocation events
between the cytosol and nucleus and also mCherry production over time. A plate reader
assay was used to determine whether stimulation of G9 cells with mEDA resulted in mCherry
production. Stimulation of G9 cells with mEDA induced the production of mCherry (Fig.
3.10A) without being cytotoxic (Fig. 3.10B). Due to time constraints the data presented is
from one experiment. Should the results shown be replicated, G9 cells will provide a suitable
model for analysing NF-κB translocation and mCherry production dynamics at the single
cell level in response to the mEDA domain of FN.
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Fig. 3.10 The EDA domain of fibronectin induces mCherry production in G9 cells. G9 cells
were left untreated (control) or stimulated with either 10 ng/ml LPS or 1 µM EDA for 24
hours. A) mCherry levels were analysed using a microplate reader. B) Cellular viability (by
measurement of LDH in culture supernatant) of G9 cells in response to EDA stimulation.
Each condition represents triplicate wells from one experiment. Data represents mean ± SD.
P-value calculated using one-way ANOVA, **** = p < 0.0001.
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3.3 Discussion
The data described in this chapter demonstrates that the fragments FNIII1c, FNIII13-14,
FNIII9-E, FNIII9-E-14 and FNIIImEDA are able to activate the TLR-4 signalling pathway.
The majority of studies testing whether proteins activate TLR-4 have used recombinant
proteins produced in bacteria, predominantly E.coli. E.coli are Gram-negative bacteria that
produce LPS, the classical ligand for TLR-4 activation. Thus, contamination of protein
preparations with LPS has the potential to confound results, implicating an activating role of
a protein when there may be none. As such, a HEK293 transfection system was used to assess
whether FNIII fragments have the ability to activate TLR-4. FNIIII fragments were linked to
a Gaussia luciferase signal sequence to ensure that they were secreted into the supernatant.
The supernatant containing the FNIII fragment was then transferred onto HEK293 cells
that had been reconstituted with the proteins required for TLR-4 signalling. The transferred
supernatant should be free of LPS contamination. Therefore, results regarding TLR-4
activation are not confounded by LPS contamination in this context. Using the pCDNA3
vector to express the FNIII fragments initially yielded promising results. However the NF-κB
activation profiles were unreliable, possibly due to low expression of the fragments using
this vector. Once the FNIII fragments were subcloned into the pHR-mGFP vector more
reliable results were obtained. Having GFP-tagged constructs is beneficial as the proteins
can be purified from the supernatant using the GFP-TRAP system (Chromotek), extracting
proteins by binding GFP, followed by washing and elution. The GFP tag will also allow FNIII
fragments to be visualised over the course of stimulation experiments to investigate their
transit through the cell and determine whether co-localisation is observed with TRAM/TRIF,
for example. Interestingly, when using the HEK293 transient transfection system to produce
proteins, all of the FNIII fragments were able to induce NF-κB activation. In particular,
FNIII9-E and FNIII9-E-14 had similar activation profiles. Although the concentration of
the fragments within the supernatant could not be determined, FNIII9-E-14 is larger than
FNIII9-E so its expression upon transfection might be expected to be less than that of FNIII9-E.
Using purified preparations it will be of interest to determine whether FNIII9-E-14 has the
same activation profile as FNIII9-E or whether C-terminal extension is able to decrease the
activation ability of FNIII9-E back to that of FNIIIEDA alone, as observed by Julier et al
[127]. Having determined that the FNIII fragments produced in HEK293 cells could elicit
TLR-4 activation I decided to test the production of FNIII fragments in HEK293T cells as
SV40 enhancers are present in the pHR-mGFP vector. HEK293T cells contain the large
T antigen of the SV40 virus; the large T antigen binds to SV40 enhancers present within
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expression plasmids to increase protein production. Using a 6-well plate setup I managed
to produce FNIII fragments in the cell culture supernatant that were capable of activating
TLR-4. However, I could not detect these fragments in the supernatant using western blot,
most likely due to the abundance of other proteins within the supernatant. Due to time
limitations, production of FNIII fragments using HEK293T cells was discontinued. Given
more time, production of FNIII fragments using HEK293T cells would have been optimised.
Purified fragments would be tested to assess TLR-4 activating capability, adaptor dependency,
their effect on the stoichiometry of TLR-4 signalling components and their effect on NF-κB
translocation dynamics.
As most studies investigating FNIII fragments expressed recombinant protein using
bacteria I decided to also employ this method of protein production, as it is a relatively
quick process that can provide a high yield of protein. I produced mEDA using BL21 (DE3)
E.coli. This was a simple purification process only using GST-binding glutathione beads and
produced a high yield of protein. The caveat of this production method is that endotoxin
needs to be removed from the samples, a process that results in some loss of protein. I
have shown that recombinant mEDA is capable of inducing NF-κB activation. Furthermore,
purified recombinant mEDA was also capable of stimulating TNF-α production in iBMDMs,
which was dependent on TLR-4. Unfortunately pre-incubation with 1 µg/ml polymixin B
for 5 minutes prior to stimulation of cells was not enough to completely abrogate TNF-α
production in response to 100 ng/ml LPS. Therefore these experiments needs to be repeated
with polymixin B pre-incubation conditions that abrogate TNF-α production in response to
LPS stimulation to ensure that endotoxin contamination of the recombinant mEDA samples
is not confounding results. Due to time limitations these experiments were not repeated.
However, the initial results were promising, especially given the low levels of endotoxin
detected using the Charles River Endosafe-PTS system.
Recombinant mEDA was able to activate NF-κB. Consequently, G9 cells, that express
eGFP-p65 (for tracking NF-κB translocation) and mCherry under control of the TNF-α
promoter (as a measure of NF-κB-induced TNF-α transcription), were used to investigate
NF-κB translocation dynamics upon stimulation with mEDA and whether this differed to
dynamics observed in response to LPS stimulation. I have demonstrated that G9 cells produce
mCherry in response to mEDA stimulation, and that this is devoid of any cytotoxic effect on
the cells. These data suggests that G9 cells will provide a suitable model to investigate how
mEDA affects NF-κB translocation and transcription of TNF-α at the single cell level.
I have also developed an analysis pipeline for analysing protein stoichiometry at the
plasma membrane, as discussed in chapter 5. It will be of interest to investigate the effect
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that mEDA has on TLR-4, MyD88 and Mal stoichiometry and whether this differs to the
stoichiometry induced by LPS. Should activation of TLR-4 in response to mEDA stimulation
differ in stoichiometry, it may be possible to determine the differing interfaces responsible,
which could then be targeted therapeutically to improve the lives of patients suffering from
aberrant fibrosis.
The ability of the different FNIII fragments to activate TLR-4 has previously been tested
in a range of different cell types for the different fragments, with some differences becoming
apparent for the ability of each fragment to induce TLR-4 signalling depending on the cell
type investigated. For example, FNIIIEDA is able to induce proMMP-9 expression in THP-1
cells, whereas FNIII1c is not able to [83]. However, it is possible that FNIII1c is capable of
activating THP-1 cells via TLR-4, but that it may induce a different cellular output to that of
FNIIIEDA. The ability of FNIII1c to activate TLR signalling also appears to be dependent
on cell type origin. For example, FNIII1c activates TLR-4 to produce IL-8 in human dermal
fibroblasts [124], but not in human lung fibroblasts, in this context FNIII1c signals via TLR-
2 to induce IL-8 production [216]. This suggests that there may be different co-receptors
expressed on the cell surface of these two different types of fibroblasts that dictate which TLR
signalling pathway is activated by FNIII1c. Stimulation studies of all the FNIII fragments on
a range of different cell types need to be assessed to gain clarity on how signalling induced
by these different fragments differs in the response generated by each fragment and how the
response differs across different cell types. Interestingly, Bhattacharyya et al. demonstrated
a direct interaction with FNIIIEDA and TLR-4 in unstimulated fibroblasts [116]. It will be
interesting to investigate whether this interaction can be replicated in other cell types and
whether other FNIII fragments directly interact with TLR-4. In order to fully delineate
co-receptors necessary for FNIII fragments to induce NF-κB activation I have developed a
THP-1/NF-κB reporter cell line for use in a CRISPR screen, discussed in chapter 6.

Chapter 4
FBG
4.1 Introduction
Tenascin-C is a large hexameric glycoprotein, the expression of which is induced upon
pathological stress [225]. A number of domains within tenascin-C are biologically active
including the FBG domain, which activates TLR-4 signalling [94]. Unlike the EDA domain
of FN, FBG can signal within the context of the whole protein, and does not need to be
proteolytically released for its immunological activity.
The FBG domain of tenascin-C is capable of inducing inflammation in the joint of
mice when injected intra-articularly and enhances cytokine production from the synovial
membranes of RA patients, suggesting it may play a pathological role within this disease
[94]. Tenascin-C is not normally expressed in the joints of healthy individuals; however,
in RA patients tenascin-C expression is increased in the synovia [226], synovial fluid and
cartilage [227]. Interestingly, in two different mouse models of joint inflammation, tenascin-
C was not needed for the initiation of inflammation, but was required for the persistence of
inflammation [94]. Tenascin-C is also responsible for persistent fibrosis in systemic sclerosis
(Ssc) [140]. Skin fibroblasts treated with tenascin-C increased their fibrotic gene expression
(for example of type I collagen and α-smooth muscle actin) and expression of TLR-4 itself
in a TLR-4 dependent manner. Tenascin-C also increased the rate of fibroblast migration and
the mechanical stiffness of skin raft cultures [140].
The FBG domain of tenascin-C activates human macrophages in a TLR-4 and MyD88
dependent manner. This activation does not require the TLR-4 co-receptors CD14 or MD-2,
as neither CD14 blocking antibodies nor antagonistic LPS from msbB E.coli, which competes
for binding MD-2, were able to prevent TNF-α production [94].
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Tenascin-C is post-translationally modified. In vitro, peptidylarginase deaminases 2
(PAD2) and 4 (PAD4) can both citrullinate arginine residues within the FBG domain of
tenascin-C at five distinct sites. An epitope containing 4 of these residues is recognised by
anticitrullinated protein antibodies within the sera of patients with RA and even in the sera of
patients (approximately 1 in 5 individuals) before disease onset [131]. Citrullinated-FBG
has a lower melting temperature than FBG meaning that, once citrullinated, FBG undergoes
partial unfolding. Whether citrullination affects the ability of FBG to activate TLR-4 [131]
or whether citrullination necessitates the requirement of different co-receptor proteins when
compared to non-citrullinated FBG has yet to be investigated.
Given the increasingly important role of tenascin-C in the maintenance of chronic in-
flammation within the context of autoimmune disease, it is important to understand the
underlying molecular mechanisms involved. This chapter investigates how FBG activates
TLR-4 signalling and which co-receptors are required in this process. This chapter also
describes the foundations laid to investigate NF-κB translocation dynamics and TLR-4
dimerisation profiles in response to FBG stimulation.
4.2 Results
4.2.1 Tenascin-C FBG induces TLR-4 signalling
Preparations of purified recombinant tenascin-C FBG domain were kindly provided by
Professor Kim Midwood (University of Oxford). HEK293 cells were transiently transfected
with the components required for TLR-4 signalling as described in chapter 3. Transfected
HEK293 cells were stimulated with WT FBG or 10 ng/ml KDO-2 Lipid A as a positive
control, for 2, 6 or 24 hours prior to lysis and luciferase quantification. The WT FBG
domain of tenascin-C activated TLR-4 in a dose-dependent manner (Fig. 4.1A). Stimulating
transfected HEK293 cells for a longer period of time resulted in increased NF-κB activation
(Fig. 4.1C). The endotoxin level of the WT FBG domain preparation was tested using the
Charles River Endosafe-PTS system. The preparation contained <2.99 pg/ml LPS, below
the detection limit for human macrophages, synovial fibroblasts and murine embryonic
fibroblasts [94]. Furthermore, when tested in the HEK293 transient transfection assay,
1 ng/ml LPS stimulation results in a substantially lower NF-κB activation profile when
compared to that obtained after stimulation with the FBG domain (Fig 4.1B).
It has been reported that neither MD-2 nor CD14 are required for FBG to activate TLR-4
signalling (Midwood et al., 2009). To test this, HEK293 cells transfected with different
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Fig. 4.1 The FBG domain of tenascin-C activates TLR-4 in a dose-dependent manner.
HEK293 cells were transiently transfected with pCDNA3:hTLR-4, pEFIRES:hMD-2,
pCDNA3:hCD14, pNF-κB-luc (an NF-κB inducible Firefly luciferase reporter) and phRG-
TK (a constitutively active Renilla luciferase reporter). Transfected cells were stimulated
with A) KDO-2 Lipid A (10 ng/ml) or tenascin-C FBG (0.001, 0.01, 0.1 or 1 µM) for 6 hours
B) with or without E.coli ultrapure LPS (1, 10 or 100 ng/ml) for 6 hours or C) KDO-2 Lipid
A (10 ng/ml) or Tenascin-C FBG (0.1 or 1 µM) for 2, 6 or 24 hours. The cells were then
lysed and the NF-κB luciferase activation was measured using a microplate reader. Data is
represented as normalised luminescence calculated by dividing Firefly luciferase counts by
those acquired for Renilla luciferase. Each data point represents one well. Data has been
pooled from three experiments with triplicate wells for each condition. Data represents mean
± SD. P-value calculated using one-way ANOVA, **** = p < 0.0001.
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combinations of TLR-4, MD-2 and/or CD14 were stimulated with FBG. Activation of NF-κB
by WT FBG was dependent on TLR-4 and both MD-2 and CD14 were required for optimal
activation of NF-κB in the HEK293 transient transfection assay (Fig. 4.2). In the absence of
CD14, activation of NF-κB was only observed when high concentrations of FBG were used,
similarly in the absence of MD-2 (Fig. 4.2). When using the t-test to analyse significance, in
the absence of MD-2 0.1 µM of FBG induced statistically significant activation of NF-κB
(p=0.0018), suggesting that the presence of CD14 may be more important than MD-2 for
FBG activation of TLR-4.
A number of mutated FBG domains of tenascin-C (from a panel of mutants previously
tested by Professor Kim Midwood) were also provided. FBG mutant 3 (Mut3) and mutant 7
(Mut7) do not activate TLR-4 but bind to it with moderate affinity while FBG mutant 5 (Mut5)
does not activate TLR-4 and binds to it with the lowest affinity of all mutants previously
tested (Kim Midwood, personal communication). When used to stimulate TLR-4 in the
transient HEK293 transfection assay all three mutants tested exhibited a similar activation
profile albeit lower compared to that obtained with WT FBG (Fig. 4.3). The Charles River
Endosafe-PTS system was used to test the level of LPS present in each FBG preparation. The
WT sample contained <0.46 ng/ml LPS, Mut3 contained <0.22 ng/ml LPS, Mut5 contained
<0.08 ng/ml LPS and Mut7 contained <0.52 ng/ml LPS. Due to the limited amounts of each
sample, it was not possible to acquire a more accurate endotoxin level reading; therefore,
it is probable that the samples contained less LPS than stated here. Even though the WT
FBG sample tested in Fig. 4.1 was measured to contain over 150 times less LPS that the WT
sample used in Fig. 4.3 (<2.99 pg/ml vs. <0.46 ng/ml, respectively), the activation profile
of the two samples is very similar (Fig. 4.1 versus Fig. 4.3), suggesting the newer samples,
including the mutants, were contaminated with much less LPS than that measured due to
sample size limitations.
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Fig. 4.2 The co-receptors MD-2 and CD14 are required for optimal activation of TLR-4 by the
FBG domain of tenascin-C. HEK293 cells were transiently transfected with pCDNA3:hTLR-
4, pEFIRES:hMD-2, pCDNA3:hCD14, pNF-κB-luc (an NF-κB inducible Firefly luciferase
reporter) and phRG-TK (a constitutively active Renilla luciferase reporter). Transfected cells
were stimulated with KDO-2 Lipid A (10 ng/ml) or tenascin-C FBG (0.1 or 1 µM) for 6
hours. The cells were then lysed and the NF-κB luciferase activation was measured using a
microplate reader. Data is represented as normalised luminescence calculated by dividing
Firefly luciferase counts by those acquired for Renilla luciferase. Each data point represents
one well. Data has been pooled from two experiments with triplicate wells for each condition.
Data represents mean ± SD. P-value calculated using one-way ANOVA, **** = p < 0.0001,
*** = 0.0001 < p < 0.001, * = 0.01 < p < 0.05.
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Fig. 4.3 Mutant domains of tenascin-C have an impaired ability to activate TLR-4.
HEK293 cells were transiently transfected with pCDNA3:hTLR-4, pEFIRES:hMD-2,
pCDNA3:hCD14, pNF-κB-luc (an NF-κB inducible Firefly luciferase reporter) and phRG-
TK (a constitutively active Renilla luciferase reporter). Transfected cells were stimulated
with KDO-2 Lipid A (10 ng/ml) or tenascin-C FBG WT, Mut3, Mut5 or Mut 7 (0.001, 0.01,
0.1 or 1 µM) for 6 hours. The cells were then lysed and the NF-κB luciferase activation
was measured using a microplate reader. Data is represented as normalised luminescence
calculated by dividing Firefly luciferase counts by those acquired for Renilla luciferase. Each
data point represents one well. Data has been pooled from three experiments with triplicate
wells for each condition. Data represents mean ± SD. P-value calculated using one-way
ANOVA, **** = p < 0.0001.
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4.2.2 The effect of FBG on TLR-4 clustering and NF-κB translocation
dynamics
Having established that FBG signals via TLR-4, I decided to investigate the effect FBG has
on TLR-4 stoichiometry and its activation of NF-κB.
G9 cells, described in chapter 3, were kindly provided by Dr. Iain Fraser (NIH, Washing-
ton DC). A plate reader assay was used to determine whether stimulation of G9 cells with
WT and mutant FBG resulted in mCherry production. WT FBG induced mCherry production
in G9 cells whilst the Mut3 and Mut5 FBG domains were unable to do so above background
levels. Mut7 was able to minimally induce mCherry production (Fig. 4.4A). None of the
FBG domains were shown to induce cell death (Fig. 4.4B). Due to time constraints the data
presented is from one experiment. Should these results be repeated, G9 cells will provide a
suitable model for analysing NF-κB translocation and mCherry production dynamics at the
single cell level in response to the WT FBG domain of tenascin-C.
A preliminary experiment has been carried out to investigate the stoichiometry of TLR-4
upon stimulation with WT FBG. Tlr-4-/- iBMDMs were lentivirally transduced with hTLR-
4HALO, stained with HALO-R110 dye and stimulated with or without WT FBG for 15 minutes.
Cells were fixed and imaged using TIRF microscopy and imaged until all fluorophores had
photobleached. I have developed a computer-based analysis pipeline to analyse such data in
order to determine protein stoichiometry at the plasma membrane, as discussed in chapter
5. In brief, the analysis functions by determining the positions of fluorescent maxima
within the acquired images and tracking their fluorescent intensity over time. Each intensity
drop associated with photobleaching events can be measured and used to determine the
stoichiometry of proteins within fluorescent maxima. Preliminary data suggests that 0.01 µM
WT FBG induces TLR-4 clustering after 15 minutes post stimulation into clusters of roughly
4, 8 and 12 TLR-4 proteins in size. Higher concentrations of FBG (0.1 µM and 1 µM) result
in TLR-4 stoichiometry similar to that of non-stimulated cells (Fig. 4.5A, B, C and D).
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Fig. 4.4 The WT FBG domain of tenascin-C induces mCherry production in G9 cells. G9
cells were left untreated (control) or stimulated with either 10 ng/ml LPS or 1 µM WT, Mut3,
Mut5 or Mut7 tenascin-C FBG for 24 hours. A) mCherry levels were analysed using a plate
reader. B) Cellular viability of G9 cells in response to FBG stimulation measured using the
Promega non-radioactive cytotoxicity assay. Each condition represents triplicate wells from
one experiment. Data represents mean ± SD. P-value calculated using one-way ANOVA,
**** = p < 0.0001, * = 0.01 < p < 0.05.
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Fig. 4.5 TLR-4 clusters in response to stimulation with WT FBG. Tlr-4-/- iBMDMs were
lentivirally transduced with hTLR-4HALO, stained with 100 nM HALO-R110 dye, stimulated
with or without WT FBG (0.01, 0.1 or 1 µM) for 15 minutes or left untreated (control)
and fixed with 4% PFA. The cells were photobleached and imaged using TIRF microscopy.
Histograms show the number of TLR-4 proteins per maxima in A) control (blue) and 0.01 µM
FBG (orange) stimulated cells, B) control (blue) and 0.1 µM FBG (orange) stimulated cells
and C) control (blue) and 1 µM FBG (orange) stimulated cells. D) The empirical cumulative
distribution function (eCDF) of the number of TLR-4 proteins per maxima in control (blue),
0.01 µM FBG (orange), 0.1 µM FBG (yellow) and 1 µM FBG (purple) stimulated cells.
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4.3 Discussion
I have shown that WT FBG stimulates TLR-4 signalling in a dose-dependent manner over
time (Fig. 4.1). I have also shown that both MD-2 and CD14 are required for optimal TLR-4
activation in response to FBG (Fig. 4.2). This result is contradictory to data presented by
Midwood et al., where neither CD14 nor MD-2 were required for FBG to induce TNF-
α production in human macrophages, suggesting that FBG may signal via different co-
receptors [94]. Midwood et al. used CD14 blocking antibodies and a competitive MD-2
binding inhibitor (msbB E.coli LPS), measuring TNF-α production as the readout for TLR-4
activation [94]. In the HEK293 transient transfection assay NF-κB activation is measured as
the readout for TLR-4 activation. My data suggests that both MD-2 and CD14 are required for
optimal NF-κB activation by FBG in HEK293 cells. It is possible that human macrophages
and HEK293 cells have different signalling requirements for NF-κB activation and thus
TNF-α production. The proximal TNF-α promoter contains binding sites for a number
of different transcription factors [228]; it is possible that different transcription factors are
activated in response to FBG stimulation that allows transcription of TNF-α . Midwood et
al. also reported production of the cytokines IL-6 and IL-8 in response to FBG stimulation
in human macrophages. It would have been interesting to investigate whether expression
of these cytokines were also affected by CD14 blockade and MD-2 competitive binding.
Sakai et al. demonstrate that it is possible to have NF-κB translocation events without
TNF-α promoter activation but did not observe TNF-α promoter activation in the absence of
NF-κB translocation with their tested ligands [63]. FBG was able to induce TNF-mCherry
production in G9 cells (Fig. 4.4). Given that, in these cells, mCherry is downstream of
the TNF-α promoter, this would suggest that transcription factors necessary for TNF-α
production are activated upon FBG stimulation in RAW264.7 cells. This cell model will be
used to investigate whether FBG can activate NF-κB in murine cells and whether the TNF-α
promoter is activated in the presence of NF-κB activation at the single cell level. Whether
this process is affected by CD14 blockade and MD-2 competitive binding will also be tested.
All of the mutant FBG domains tested have a decreased but equal ability to activate
TLR-4 compared to WT FBG when using the HEK293 transient transfection assay. All
of the mutant FBG domains have an ablated TLR-4 binding site in loop 5, whilst Mut5
also has a truncated C-terminal tail and 3 residues in loop 7 are mutated in Mut7. The
Midwood group have observed decreased cytokine production by human macrophages in
response to the mutated FBG domains compared to WT FBG. They also observed decreased
activation of NF-κB by the mutant FBG domains compared to WT FBG using a THP-1
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reporter cell line. A solid-phase binding assay was used to determine the binding of the
FBG mutants to the extracellular domain of TLR-4. All of the mutants had significantly
(p<0.05) decreased ability to bind TLR-4 compared to WT FBG. The dissociation constant
was determined as 60 nM for WT, 121 nM for Mut3, 336 nM for Mut5 and 123 nM for
Mut7 (Professor Kim Midwood, personal communication). Interestingly, although Mut5
has a lower binding affinity for TLR-4 than Mut 3 and 7, their ability to activate TLR-4 was
very similar. Given that FBG activates NF-κB in the HEK293 assay, investigating whether
NF-κB translocation dynamics induced by FBG differs from those induced by LPS will be
of interest. I have demonstrated that G9 cells will be an appropriate model for investigating
NF-κB translocation dynamics in response to FBG stimulation (Fig. 4.4). G9 cells were
able to induce TNF-mCherry production in response to FBG. Stimulation with FBG was not
toxic to these cells. It will be interesting to determine whether the mutant domains of FBG
induce NF-κB translocation from the cytosol into the nucleus of cells without concomitant
mCherry production, as work from our laboratory has shown that low doses of ligands such
as CRX555 can induce TLR4-dependent NF-κB translocation without much induction of
TNF-mCherry (Latty et al., submitted).
It is increasingly apparent that different cell types produce different responses when
stimulated with the same ligand; human macrophages are able to produce TNF-α in response
to FBG stimulation whilst synovial fibroblasts do not [94]. The ability of the same receptor to
produce different outputs in response to different ligands hints towards different co-receptors
being used for signalling. The use of different co-receptors could result in differences in
the transcription factors activated downstream of each signalling pathway. Different ligands
activating the same receptor are also able to produce different responses within a cell type;
LPS is able to induce both IL-6 and IL-8 production in synovial fibroblasts whilst FBG can
only induce IL-6 production [94]. I have developed an NF-κB reporter cell line on a THP-1
background for use in a CRISPR screen (discussed in chapter 6) to determine which proteins
are necessary for NF-κB activation by FBG stimulation.
The effect of FBG stimulation on the stoichiometry of the TLR-4 signalling complex will
also be investigated. Unpublished data from our laboratory suggests that TLR-4 dimerises
in response to LPS stimulation and does not cluster. This is contradictory to work by
Triantafilou et al. that describes TLR-4 clustering into microdomains upon stimulation
with LPS [229]. FRAP has been used to measure TLR-4 diffusion dynamics in human
monocytes by labelling TLR-4 with OG-Fab molecules. Upon stimulation, the TLR-4
diffusion coefficient decreased and an immobile population was induced. When combined
with a calcium signalling assay, they were able to demonstrate that cells with TLR-4 cluster
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formation, indicated by an immobile fraction of TLR-4, also signalled more strongly in
response to LPS stimulation [28]. Using STORM, a form of super resolution imaging, it
has also been shown that immunostimulatory LPS induces larger cluster formation than
immunoevading LPS in P388D1 murine macrophage-like cells [29]. In this case, cells were
stimulated, fixed and labelled with a fluorescently labelled α-TLR-4 monoclonal antibody.
Neither of these methods dissected the stoichiometry of TLR-4 within the clusters formed. I
have developed a computer-based analysis pipeline to analyse photobleaching data of single
molecules to determine protein stoichiometry at the plasma membrane, discussed in chapter
5. I decided, therefore, to investigate whether FBG would induce TLR-4 dimerisation and/or
clustering using this analysis pipeline. My model system is comprised of Tlr-4-/- iBMDMs
transduced with TLR-4HALO, a TLR-4 construct with a halotag genetically encoded to its
C-terminus. The halotag is an enzyme that covalently binds to a fluorescent dye molecule,
providing a 1:1 ratio of protein to dye molecule [230]. This allows single molecules to be
imaged and analysed to determine the stoichiometry of proteins within a complex.
Preliminary data suggests that 0.01 µM WT FBG induces TLR-4 clustering after 15
minutes post stimulation into cluster sizes of approximately 4, 8 and 12 TLR-4 proteins
per cluster whereas higher concentrations of FBG (0.1 µM and 1 µM) resulted in a TLR-4
stoichiometry similar to that of non-stimulated cells (Fig. 4A, B and C). Upon stimulation
with 100 ng/ml LPS, TLR-4 is rapidly endocytosed in murine macrophages; within 30
minutes antibody surface staining of TLR-4 is decreased, as shown by flow cytometry
analysis [14]. The decrease in surface staining is suggestive of active signalling TLR-4
molecules being endocytosed whilst inactive TLR-4 molecules either remain at the surface
or have been transported to the surface within that time frame. It is possible that TLR-4
molecules signalling in response to higher concentrations of FBG have been endocytosed
within 15 minutes, leaving non-engaged TLR-4 molecules at the plasma membrane with a
similar stoichiometry to that observed in unstimulated cells. Interestingly, endocytosis of LPS
was shown to be dependent on CD14 [58]. However, Midwood et al. determined that CD14
is not required for FBG to signal via TLR-4 [94] whilst my results show that CD14 is required
for FBG to signal via TLR-4 and induce NF-κB activation. Tenascin-C-induced signalling
has been shown to be MyD88 dependent, suggesting it may mainly induce TLR-4 signalling
at the plasma membrane. Therefore, it would be interesting to investigate whether CD14 is
required for FBG internalisation and how the FBG/TLR-4 complex is handled within the cell;
whether it is immediately degraded or whether there is some interaction with TRAM/TRIF.
The dependency of tenascin-C signalling on MyD88 was only tested measuring IL-6 as the
readout for signalling competency [94]. It is possible that the TRAM/TRIF pathway does
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play a role in the production of other cytokines in response to tenascin-C stimulation. For
example, TRAM/TRIF also contributes to the production of TNF-α in response to LPS
stimulation [63].
The clustering of TLR-4 observed in response to FBG stimulation could indicate that
different co-receptors are utilised for TLR-4 activation and signalling. It is possible that
such proteins induce TLR-4 clustering in response to FBG but not to LPS. Work describing
TLR-4 clustering in response to LPS using FRAP analysed TLR-4 at the population level,
the clusters formed were not characterised for their exact stoichiometry [28]. The use of
antibodies to determine TLR-4 cluster size could also produce artefacts [29]. It is possible that
more than one antibody binds to a single TLR-4 molecule depending on the epitope that the
antibody recognises, although use of monoclonal antibodies reduces this possibility. Addition
of LPS may enhance the probability of more than one antibody binding which could be
analysed as an increase in the number of TLR-4 molecules present within a cluster. This work
made use of TLR-4HALO, singly labelled TLR-4 molecules, to determine the stoichiometry
of TLR-4 at the plasma membrane. This allows more direct analysis of TLR-4 complex
composition upon stimulation. It is possible, however, that TLR-4 in transduced iBMDMs
behave differently upon stimulation when compared to murine P388D1 macrophage-like
cells or human monocytes.
This work will be repeated using different concentrations of FBG to stimulate transduced
iBMDMs for a time course of 5, 10 and 15 minutes. Should FBG stimulation induce different
TLR-4 stoichiometries than those induced by LPS stimulation, it will be of interest to identify
the residues on TLR-4 associated with these differences and whether these can be targeted
therapeutically. It will also be of interest to investigate whether the mutants tested here differ
in their ability to induce TLR-4 clustering and, therefore, determine whether loop 5, the
C-terminal tail and residues within loop 7 of the FBG domain affect this process. It will
also be of interest to determine whether citrullinated-FBG affects TLR-4 stoichiometry upon
stimulation, as antibodies against citrullinated-FBG are present in patients with RA and
before disease onset [131]. Many therapies used to treat autoimmune disease involve cytokine
inhibition [231], an expensive approach due to the requirement of repeated treatments whilst
increasing the risk of infection. The importance of tenascin-C activation via TLR-4 in
the maintenance of chronic inflammation has been demonstrated in a number of diseases
[94][140]. A more targeted therapeutic approach against FBG and its interaction with TLR-4
may be beneficial to patients, leaving their innate defence against infection unaffected.

Chapter 5
Investigating the stoichiometry of
Mal/TIRAP using single molecule
imaging
5.1 Introduction
5.1.1 Mal signalling
Mal has been implicated in signalling downstream from TLR-4 [10, 11, 151, 152], -2
[151, 152], -5 [156], -7 and -9 [43] and RAGE [157] and IFNGR [158] and undergoes post-
translational modifications such as phosphorylation [162, 166] and glutathionylation [170].
The exact mechanism of how Mal interacts with proteins within these signalling pathways
is unclear. For example, the stoichiometry of Mal within active signalling complexes and
how this stoichiometry changes over time is unknown. Whether Mal forms complexes of the
same stoichiometry downstream of different receptors is also unknown. Structural analysis
of the Mal TIR domain has led to the proposal that Mal signals as a dimer, however this has
yet to be confirmed within the context of a living cell.
5.1.2 The structure of Mal
The crystal structure of the Mal TIR domain was first determined in 2011 with 3 angstrom
resolution [232] (Fig. 5.1 column 1). The TIR domain crystal structure is comprised of a
5-stranded parallel β -sheet enclosed within 4 α-helices. Instead of a BB loop as in most
other TIR domains, the crystal structure of the Mal TIR domain contains an AB loop, as it
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is lacking a helix between the B and C β -strands. The AB loop shares a similar sequence
to the BB loop present in other TIR domains. Two internalised disulphide bonds formed
between C89-C134 and C142-C174 stablise this structure [232]. Interestingly C91 is surface
exposed and therefore could be accessible for glutathionylation. Two different dimers were
detected within the crystals. The first showed two-fold symmetry with an extensive interface
and both AB loops of Mal facing outwards, the second was composed of an asymmetric
dimer, with the AB loop involved in the interaction interface. Importantly, in the first dimer
both N-termini are facing the same way, so could allow the PI(4,5)P2 binding domain of Mal
to be in close proximity for insertion into the plasma membrane, and is thus likely to be the
physiologically relevant dimer [232].
It has been suggested that MyD88 recruitment to TLRs is via electrostatic interactions.
The surface of Mal has significant acidic patches, whilst the TLR-4 and MyD88 TIR domains
consist of mostly basic patches. D96 is within one of these acidic patches. Its mutation to
D96N could disrupt this acidic interface, neutralising it, attributing to its decreased interaction
with MyD88. The S180 residue of Mal is also positioned at the end of stand βD and is solvent
exposed. It is hypothesised that mutation from serine to leucine, which has a bulkier side
chain could result in steric occlusion of a cavity at the edge of an acidic patch [232]. Both
D96 and S180 are within close proximity, 10 angstroms apart. Using docking models, 10 of
the best complexed models docked MyD88 close to the surface of Mal containing D96 and
S180 with the residue R196 in the MyD88-TIR domain being important for the interaction, a
residue previously demonstrated by mutation as necessary for TIR-TIR interactions. Mutating
individual residues from 162-166 decreased the ability of Mal to coimmunoprecipitate with
MyD88 in cotransfected HEK293T cells, suggesting that these residues are critical for the
TIR-TIR interaction. D96N was able to form dimers with Mal but did not bind MyD88 whilst
S180L was unaffected. Addition of the reducing agent DTT decreased the interaction of Mal
with MyD88, but not with itself or TLR-4 [232].
Within the structural model of the Mal TIR domain, Y86 and Y106 are solvent exposed
and Y106 and Y187 are predicted to be near the interface important for interaction with
MyD88. Cleavage by caspase-1 is predicted to remove the αE helix, modifying the predicted
MyD88 interaction surface. The TRAF6 binding site is also present in the region connecting
βD to βE, an area exposed at the base of the first proposed dimer of Mal. A preliminary
docking analysis involving TLR-4, MyD88 and Mal TIR proposes that Mal binding to
MyD88 enables MyD88 TIR to form a second interaction with the TLR-4 TIR domain [232].
The crystal structure of Mal was subsequently determined to 2.4 angstrom resolution
in 2012 [234]. This structure confirmed the back-to-back dimer proposed by Valkov et al.
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Fig. 5.1 The structure of the Mal TIR domain. A) The structure of the Mal TIR domain,
B) highlighting the position of residues D96 and S180, C) highlighing the position of the
tyrosine residues Y86, Y106 and Y187 and D) highlighting the position of residue C91. The
following structures were downloaded form the PDB and imaged using molsoft: column 1:
2Y92 - crystal structure [232], column 2: 2NDH - NMR structure [170], column 3: 5UZB -
filament structure [233].
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and also the presence of the AB loop. Mutation of the residues W156A and Y159A present
within the interface of the back-to-back dimer decreased Mal dimerisation, confirming that
this is the physiologically important dimer structure. A HEK293T NF-κB luciferase assay
was used to determine the effect of mutated solvent exposed residues of Mal. The residues
P125H and R121A decreased NF-κB activation compared to WT when overexpressed. The
residue R121 is within the AB loop. Mutation of 7 out of 15 amino acids within the AB loop
resulted in decreased NF-κB activation. Lin et al. conclude that the AB loop is important
for the simultaneous interaction of Mal with both MyD88 and TLR-4, as determined in the
docking model of Mal with TLR-4 by Valkov et al.
The crystal structure of D96N and S180L Mal were also resolved. Interestingly, both
structures showed similar structure to WT and the D96N TIR did not have an obviously
different electrostatic surface compared to WT. Binding of D96N to MyD88-TIR and TLR-4-
TIR was also observed, therefore loss of function is not due to charge changes on the TIR
surface, but may be due to impaired post-translational modifications. The S180L mutation
resulted in a change from a negatively charged surface into a positively charged surface and
a concurrent change from hydophillic to hydrophobic. Whilst the surface containing D96
and S180 were proposed important for binding MyD88 by Valkov et al., Lin et al. did not
observe loss of MyD88 binding by mutation of D96N and S180L residues. Thus, the AB
loop was important for interaction with MyD88 instead of this patch containing D96 and
S180 [234].
Recently, the structure of the Mal TIR domain in solution under reducing conditions
has also been resolved by NMR spectroscopy [170] (Fig. 5.1 column 2). Under reducing
conditions, disulphide bonds did not form, resulting in a structural rearrangement compared
to the crystal-resolved structures of Mal. Mal TIRC116A was used to determine the structure
of Mal as it was highly expressed and remained monomeric at high concentrations. Its
structure was found to be representative of WT Mal based on secondary structure analysis
and chemical shift assays. The structure of this construct was more consistent with the
typical TIR domain fold. TIR domains are usually composed of a 5-stranded parallel β -
sheet surrounded by 5 α-helices. The solution structure of Mal TIRC115A contained this
5 β -sheets surrounded by 5 α-helices, compared to the crystal structure which contained 5
β -sheets surrounded by 4 α-helices. The solution structure of Mal also contained a shorter
AB loop and a long BB loop between strand βB and helix αB, a conserved feature of TIR
domain structure, in contrast to the crystal structure of Mal. Within the TIR domain, cysteine
91 (conserved in many different species) was the most reactive under redox conditions and
it was thus determined that C91 undergoes basal glutathionylation that increases after LPS
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stimulation, necessary for its signalling ability. As most modelling studies have used the
crystal-determined structure of Mal, Hughes et al. question the validity of these models given
their findings that Mal does not contain disulphide bonds and instead of an AB loop, contains
the conventional TIR domain BB loop. The C91 residue is in close proximity to the BB loop,
possibly influencing its structure upon glutathionylation [170].
Electron microscopy (EM) has also been used to determine the structure of Mal and the
interaction interfaces involved in TLR signalling [233]. Mal was found to form temperature
dependent filaments in vitro that were reversible as they disassembled at 4°C. Cryo-EM
was used to determine the structure of the Mal TIR filaments, revealing helical left-handed
filaments. Each filament contained 12 protofilaments assembled by two parallel strands of
Mal TIR domains. The structure of Mal TIR within the filaments was significantly different
from crystal and NMR determined Mal TIR structures, attributed to the use of flexible
regions within Mal for the filament assembly, although the AB loop and BB loop are similar
to that obtained using NMR (Fig 5.1 column 3). The major interactions between the TIR
domains were the BB loop of one subunit interacting with the EE surface (composed of
the βD and βE strands and the αE helix) of another subunit above it. Each TIR domain
in the protofilament interacts with two other Mal TIR domains, through the BC surface
(composed of residues in the αB and αC helices of one subunit) and CD surface (composed
of αD and the CD loop of one subunit) (interstrand interaction). As the N-termini are on
opposite sides of the protofilament, filament assembly is not possible in vivo at the plasma
membrane, thus only the TIR-TIR interactions observed in protofilaments are likely to be
physiological. R121A in the BB-loop disrupted both Mal filament formation and MyD88
TIR assembly, possibly through altering the BB-loop conformation. The distribution of
full length Mal in HEK293 cells was affected by R121A, P125H and F193A. The residues
R121A, P125A and P125H disrupted clustering of V5-tagged MyD88 into puncta in HEK293
cells measured using flow cytometry to compare the pulse height versus pulse area for V5-
MyD88 [233]. The intrastrand interaction was determined to be more important for MyD88
binding and myddosome formation than the interstrand interactions. Modelling has also led
to the suggestion that the TLR-4 TIR domain interacts with other TLR-4 TIR by intrastrand
interactions and interacts with Mal via interstrand surface interactions. It is proposed
that the formation of dimers and trimers of Mal are energetically unfavourable, however,
once a larger interface has been created, addition of more Mal TIR domains is rapid and
cooperative. Therefore, small filaments may form allowing binding of MyD88 molecules
to form Myddosomes. The effects of mutations S180L and D96N were not commented
on in this model [233]. Interestingly, a natural mutation R121W has been observed in a
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number of individuals. It was found that Mal with the R121W mutation had an impaired
ability to interact with both TLR-2 and MyD88 compared to WT Mal, this mutant impairs
human fibroblast IL-6 production in response to TLR-2 or TLR-4 stimulation [202], further
supporting the importance of residue R121 in the interaction between Mal and MyD88.
As demonstrated in Figure 5.1, the currently available structures of Mal differ in their
3D conformation. The stoichiometry of Mal in vivo has yet to be determined. Studies
investigating the stoichiometry of Mal within the context of a living cell could help determine
which structural interfaces of Mal are important within a physiological setting and help
pin-point which determined structure most accurately accounts for the observed effects.
5.1.3 Computational analysis to determine protein stoichiometry
Fluorescence microscopy can be used to determine the properties of proteins within the con-
text of a living cell. The resolution of microscopes is diffraction limited; if two fluorophores
are within approximately 200 nm of each other they will be visualised as one fluorescent spot
because their images overlap due to the point spread function of the microscope. A number of
different techniques have been developed to use fluorescence microscopy to resolve objects
on the nanometer scale; these techniques mostly rely on image processing for their super
resolution ability. For example, both STORM and PALM function by imaging only a few
fluorophores in an image at any given time and computing the centre of each fluorophore.
An image is then constructed from multiple frames in which the fluorophores have been
precisely located; PALM has been used to determine complex stoichiometry [235–237]. It
is possible, however, that not every fluorophore is activated using this technique, therefore
underestimating stoichiometry [238].
Photobleaching events of single molecules can also be used to determine complex stoi-
chiometry. Since fluorophores photobleach with a quantised step size, photobleaching events
can be used to determine the stoichiometry of complexes, a method not restricted by a need
for photoactivatable fluorophores [238] (Fig. 5.2). Single fluorophore labelling of proteins
is incredibly important when conducting this analysis in order for one photobleaching step
to correspond to one protein molecule; this is mainly achieved by fusion of fluorophores
to the protein of interest by genetic modification. Two main methods have been adopted to
analyse stoichiometry using photobleaching steps, direct counting of photobleaching steps
and pooling photobleaching steps to determine monomer step size value, described in brief
below.
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Fig. 5.2 A schematic of photobleaching events. Each Mal molecule within a dimer (modelled
by Martyn Symmons) is labelled with a fluorophore. Over time (δ t) a fluorophore photo-
bleaches, resulting in a decrease in fluorescence intensity. Over another period of time (δ t)
another fluorophore photobleaches, resulting in a further decrease in fluorescence intensity.
Photobleaching events create a step-like intensity trajectory. Each step can be counted to
determine the stoichiometry of molecules within the fluorescent maxima being analysed.
Direct counting of photobleaching events
A benefit of directly counting photobleaching events is that mathematical extrapolation is
not required [238]. Fluorophores photobleach over time in a step-like discrete fashion (Fig.
5.2). Each photobleaching event (step) can be directly counted to determine the number
of proteins within a complex. The number of packaging RNA (pRNA) molecules within a
DNA-packaging motor complex present in bacteriophage phi29 has been determined by using
this method [208]. Purified Cy3-labelled pRNA was imaged using TIRF microscopy and the
photobleaching steps at each fluorescent spot were counted manually. The height of each
photobleaching step was almost equal indicating that each step was due to photobleaching
of a single fluorophore. 1736 fluorescent spots were analysed in total. It was determined
that the pRNA ring was hexameric, not pentameric even though a larger number of spots
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contained 5 photobleaching events instead of 6. This was due to the labelling efficiency,
which was about 70% (calculated as the molar concentration of Cy3 divided by the molar
concentration of pRNA). The labelling efficiency of molecules needs to be accounted for
when conducting these analyses; statistical analysis can reveal the true complex stoichiometry
[238]. The distribution of photobleaching steps observed can be predicted by applying a
binomial distribution model that depends on the experimental labelling efficiency [239].
However, this method is not perfect. The probability of more than one fluorophore
photobleaching at the same time increases with complex size, making it more difficult to
obtain an accurate complex size by direct counting as multiple photobleaching events at the
same time would result in an underestimation of complex stoichiometry [238].
Dividing total intensity drop by single fluorophore photobleaching value
Another method to determine complex stoichiometry is by dividing the total intensity of a
fluorescent complex by the intensity of a single fluorophore. This value can be determined by
analysing photobleaching traces of monomers. This method has been used to determine the
size of amyloid-β oligomers [240, 241] and the number of MotB molecules present within a
flagella motor [242]. However, care needs to be taken when using this method; the intensity
drop observed depends on the proximity of the fluorophore to the coverslip/sample interface.
The intensity drop observed for photobleaching of a fluorophore on a coverslip, therefore,
may not be representative of an intensity drop observed for photobleaching of a fluorophore
within the context of a cell. Discrepancies between these values would result in an inaccurate
estimation of complex stoichiometry.
Pooling of photobleaching events to determine monomer step size
Another method to combat fluorophore photobleaching intensity discrepancies (such as be-
tween monomer photobleaching intensities observed in different environments to the complex
being analysed) is to determine the fluorophore monomer photobleaching intensity from
within the entire photobleaching dataset obtained for determining complex stoichiometry.
Instead of counting photobleaching steps, the fluorescent intensity drop of each photobleach-
ing step can be measured, pooled and used to determine the intensity drop generated by
photobleaching of a single fluorophore. The total intensity of a complex can then be divided
by this determined monomer value to determine complex stoichiometry. For example, this
method has been used to determine the number of cellulose synthase (CESA)-3 isoform
present within the cellulose synthase complex in Arabidopsis thaliana [243]. Having ob-
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tained the photobleaching traces for GFP-CESA3, the height of each intensity drop was
measured. Chen et al. assumed that the intensity of fluorescence from a single fluorophore
follows a Gaussian distribution [243]. Assuming that fluorophores fluoresce independently,
their distributions are additive; the mean intensity (µ) of two fluorophore fluorescing together
becomes 2µ . The data of all photobleaching step sizes was fitted to a mixed Gaussian
distribution model to determine the intensity size of a single photobleaching event. The
data was fitted to models differing in the number of Gaussian distributions present and the
Bayesian information criterion (BIC) value was used to determine which model had the best
fit with the data; the lower the BIC value, the better the fit. In order to avoid bias in their
calculations, the first intensity value at each position was chosen as the maximum intensity
value with which to divide the monomer value. Using this method it was concluded that a
lower limit of 10 CESA-3 molecules are contained within each cellulose synthase complex
[243].
This chapter describes the development of a viral transduction experimental cell model to
visualise fluorescently labelled Mal using TIRF microscopy to determine the stoichiometry of
Mal upon LPS stimulation. This chapter also describes the development of a computer-based
analysis pipeline to analyse the resulting photobleaching data. All of the software used within
this chapter can be found on the accompanying CD (See Appendix B.2).
5.2 Results
5.2.1 Optimisation of Mal expression
In order to investigate the stoichiometry of Mal and how this changes upon stimulation with
LPS I have developed a viral transduction experimental cell model to visualise fluorescently
labelled Mal. The pHR:MalHALO vector, kindly provided by Brett Verstak, was used for
this purpose. The halotag, genetically encoded at the C-terminus of Mal, was used due
to its ability to covalently bind with a reactive linker attached to a number of different
fluorescent substrates, providing flexibility in the fluorophore that can be used for imaging.
Covalent binding of the halotag to a dye substrate also provides a one-to-one stoichiometry
of fluorescent signal to protein, a crucial feature when trying to determine the stoichiometry
of proteins within a complex [230]. It was important to determine that addition of the
halotag did not affect the function of Mal. The ability of MalHALO to signal was tested in
a HEK293 transient transfection assay as overexpression of Mal induces NF-κB activation
[10]. HEK293 cells were transiently transfected with the components required for TLR-4
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signalling (as described in chapter 3) or increasing amounts of pHR:MalHALO (1, 2.5, 5, 10,
25 or 50 ng per well) in combination with pNF-κB-luc and phRG-TK (Fig. 5.3).
Having established that MalHALO is able to induce signalling in the context of HEK293
cells, transduction of Mal-/- iBMDMs with lentivirus containing pHR:MalHALO was opti-
mised. A schematic of the process can be found in Figure 5.4.
Briefly, HEK293T cells were transfected with a DNA mix containing 0.5 µg p8.91
plasmid, 0.5 µg pMDG plasmid (plasmids encoding proteins for lentivirus production) and
0.5 µg pHR:MalHALO (the construct of interest). After 72 hours culture, culture supernatant
containing lentivirus was aspirated from the transfected HEK293T cells, clarified, diluted
(Neat, 1/2, 1/5, 1/10 or 1/20) and used to transduce Mal-/- iBMDMs. After 24 hours
incubation, the lentivirus supernatant was removed and replaced with fresh media. The
transduced Mal-/- iBMDMs were ready for stimulation assays and analysis the next day. Both
Mal-/- and transduced Mal-/- iBMDMs were stained using HALO-R110 dye. Flow cytometry
(Fig. 5.5) and TIRF microscopy (Fig. 5.6) were used to assess which lentiviral dilution was
optimal for transduction. Transduction of Mal-/- iBMDMs with increasing concentrations of
lentivirus not only increased the number of Mal-/- iBMDMs expressing MalHALO, but also
increased the expression level within the successfully transduced iBMDMs (as shown by
an increase in median fluorescence intensity value) in a dose-dependent manner (Fig. 5.5
& Table 5.1). Addition of higher concentrations of lentivirus resulted in expression levels
in transduced Mal-/- iBMDMs that were not suitable for analysis using TIRF microscopy,
the fluorescent molecules were too close together and could not be distinguished from one
another (Fig. 5.6A&B). Regardless of the concentration of lentivirus used, however, there
was some variation between the expression levels of MalHALO per cell within transduced
populations (Fig. 5.6C). The lentiviral dilution of 1/10 was used for further experimentation
as this provided the best expression level of resolvable MalHALO in cells within the transduced
population.
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Fig. 5.3 Overexpression of MalHALO activates NF-κB. HEK293 cells were transiently
transfected with constituents for TLR-4 signalling (pCDNA3:hTLR-4, pEFIRES:hMD-
2, pCDNA3:hCD14 and pNF-κB-luc (an NF-κB inducible Firefly luciferase reporter) and
phRG-TK (a constitutively active Renilla luciferase reporter)) or increasing amounts of
pHR:MalHALO (1, 2.5, 5, 10, 25 or 50 ng per well) and pNF-κB-luc and phRG-TK. After
48 hours the cells were lysed and the NF-κB luciferase activation was measured using a
microplate reader. Data is repesented as normalised luminescence calculated by dividing
Firefly luciferase counts by those obtained for Renilla luciferase. Each data point represents
one well. Data from two experiments with triplicate wells for each condition. Data represents
mean ± SD. P-value calculated using one-way ANOVA, **** = p < 0.0001, ** = 0.001 < p
< 0.01.
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Fig. 5.4 A schematic of iBMDM transduction. First, HEK293T cells are transfected with
plasmids encoding the gene of interest (pHR:MalHALO) and packaging plasmids (pMDG
& p8.91) for the production of lentivirus. This lentivirus is then used to transduce Mal-/-
iBMDMs. After 24 hours incubation, the lentivirus is removed from the now Mal+ iBMDMs
which can then be stained using HALO-R110 dye and analysed for transduction efficiency
using flow cytometry or visualised using TIRF microscopy.
Table 5.1 Mal-/- iBMDMs transduced with MalHALO flow cytometry statistics
Sample % R110 positive Median fluorescence intensity
Non-transduced 4.17 262
Non-transduced stained 5.59 272
Transduced 1/20 20.21 302
Transduced 1/10 28.48 327
Transduced 1/5 38.59 390
Transduced 1/2 56.64 533
Transduced Neat 69.89 653
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Fig. 5.5 Expression levels of MalHALO in transduced Mal-/- iBMDMs assessed by flow
cytometry. Mal-/- iBMDMs were transduced with or without virus, neat or diluted 1/2,
1/5, 1/10 or 1/20. The Mal-/- and transduced Mal-/- iBMDMs were stained using 100 nM
R110-HALO dye and assessed for MalHALO expression using flow cytometry.
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Fig. 5.6 Expression levels of MalHALO in transduced Mal-/- iBMDMs assessed by TIRF
microscopy. Transduced Mal-/- iBMDMs were stained using 100 nM R110-HALO dye and
assessed for MalHALO expression using TIRF microscopy. Images of A) good and B) too
high expression levels of MalHALO for image analysis by TIRF microscopy. C) Different
expression levels of MalHALO in different cells present within the same transduced population.
Scale bar, 10 µm.
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Having established that MalHALO can be expressed in Mal-/- iBMDMs at appropriate
levels for image analysis, I assessed whether MalHALO could reconstitute TLR-4 signalling
in Mal-/- iBMDMs. Mal-/- iBMDMs transduced with a 1/10 dilution of pHR:MalHALO
containing lentivirus are hereon referred to as Mal+ iBMDMs. Use of a 1/10 dilution meant
it was possible that iBMDMs were transduced with the same lentiviral supernatant for all
conditions tested. Mal-/-, Mal+ and WT iBMDMs were plated in a 96 well plate, incubated
overnight and stimulated with or without 10 ng/ml LPS for 2, 6 or 24 hours after which
the supernatants were probed for TNF-α content by ELISA (Fig 5.7). Transduction with
pHR:MalHALO reconstituted TLR-4 signalling in Mal-/- iBMDMs. Mal-/- iBMDMs produce
some TNF-α in response to LPS stimulation, albeit to a lesser extent than WT iBMDMs,
as the TRIF signalling pathway is still intact. The decrease in TNF-α production observed
between Mal+ and WT iBMDMs is due to the Mal+ iBMDMs being composed of a mixed
population; i.e. not all of the Mal-/- iBMDMs have been successfully transduced.
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Fig. 5.7 MalHALO reconstitutes TLR-4 signalling in Mal-/- iBMDMs. WT, Mal-/- and Mal-/-
iBMDMs transduced with pHR:MalHALO (Mal+) were plated at a density of 2x105 cells/well
in a 96 well plate and incubated overnight. The cells were stimulated with or without 10
ng/ml ultrapure E.coli LPS for 2, 6 or 24 hours. After stimulation the supernatants were
collected and stored at -80°C before being assayed for TNF-α by ELISA. Data pooled from
two experiments with triplicate wells for each condition. Data represents mean ± SD.
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5.2.2 Analysis of Mal stoichiometry by counting photobleaching steps
Having established a functional viral transduction experimental cell model, the stoichiometry
of Mal was investigated by TIRF microscopy. In order to investigate Mal stoichiometry,
Mal+ iBMDMs were stained using HALO-R110 dye, plated onto a clean coverslip, incubated
for 15 minutes (37°C, 5% CO2) and fixed using 4% PFA. The Mal+ iBMDMs were then
imaged using TIRF microscopy with a 20 mW 488 nm laser, with an exposure time of 35
ms. 700 frames were imaged to ensure that all R110 fluorophores were fully photobleached.
Images were collected using an electron CCD camera cooled to -70°C to reduce thermal
noise. Initially, a code created by Dr. Laura Weimann (Department of Chemistry, University
of Cambridge) [244], from hereon referred to as the “counting code”, was used to analyse the
resulting image data. This code provides an unbiased, quantitative approach to determining
stoichiometry. An outline of the analysis pipeline can be found in Figure 5.8.
In this code, the position of maxima in the image are determined and then tracked over
each frame. An intensity trajectory is created for each of the maxima over all frames; a
stepwise plot is obtained and each step corresponds to photobleaching events (Fig. 5.9A).
A Chung-Kennedy filter [245] is then applied to the trajectories to reduce noise. The
implementation used in the counting code was written by Nigel Reuel [246] and uses the
default parameters proposed by Chung & Kennedy [245] (Fig. 5.9B). A step change function
(change point algorithm), based on the algorithm by Watkins & Yang [247] and Boudjellaba
et al. [248] is then used to detect steps within the trajectories (Fig 5.9C). This algorithm
was written by Yan Jiang and implemented by Dr. Weimann. Each of the trajectories are
split into windows of time and the likelihood of a step occurring at the end of the window is
determined using the log-likelihood ratio LM. The larger the LM ratio, the more likely there
is a step. The user defines the parameter θLM; ratios of steps above this θLM threshold are
kept for analysis. A quality control measure then takes place; trajectories are rejected if they
are likely to display artefacts such as positive steps (Fig. 5.9C) or no steps. Photobleaching
steps are also rejected if the trajectories do not fit well with the change point finder trace.
The number of steps per trajectory is then counted in the remaining trajectories to determine
the stoichiometry of proteins within the maxima (Fig. 5.9C) [244].
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Fig. 5.8 Pipeline for determining the stoichiometry of proteins by counting photobleaching
steps.
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Fig. 5.9 Representative photobleaching traces. Intensity trajectories were created from
photobleaching data at positions of fluorescent maxima within TIRF images (blue) and fitted
with a step change function to create a change point finder trace (red). A) An intensity
trajectory created using raw data. B) A Chung-Kennedy filtered intensity trajectory. C)
Change point finder algorithm applied to a Chung-Kennedy filtered intensity trajectory.
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Unfortunately attempts using this code to analyse the stoichiometry of Mal were un-
successful. The counting code was unable to handle the large number of frames needed to
photobleach all fluorophores within Mal complexes. In order to analyse all frames together,
the initial threshold (the threshold that determines whether a maxima is detected or not)
was increased (Fig. 5.10A, Appendix B, Table B.1), effectively reducing the total number
of maxima to be analysed by only detecting maxima with the highest fluorescent intensity.
Analysing maxima above a certain intensity threshold reduced the data that needed to be
processed, possibly losing pertinent information on smaller complex sizes. The results
obtained are presented Figure 5.10 and can be found in Appendix B, Table B1. Also, of
the fluorescent maxima analysed, a large number of trajectories that were detected were
discarded (Fig. 5.10B), an average of 85.68%. Of the trajectories that were analysed for the
number of photobleaching steps present, only monomers, dimers and trimers were detected
(Fig. 5.10C). There was no obvious ratio of these oligomers when the data was analysed on a
cell-to-cell basis.
There were a number of possibilities for why a large proportion of trajectories were
being discarded, primarily based on the fit between the change point finder trace and the
filtered intensity trajectories. I hypothesised that changing the exposure may improve the
quality of the intensity trajectory trace by increasing the number of photons collected per
frame, potentially decreasing noise between frames. I conducted an experiment imaging
fixed transduced Mal+ iBMDMs using exposure times of 35, 70 and 100 ms to determine
whether increasing exposure time affected the number of trajectories that could be analysed
(Fig. 5.11; Appendix B, Table B3, Table B4 & Table B5). Once again, all 700 frames could
not be analysed together; the initial threshold had to be adjusted per cell in order to analyse
all 700 frames at once. Splitting individual images into quadrants for analysis was considered,
as this would reduce the amount of data being analysed per execution of the code. However,
although this method may have biased the analysis less than increasing the threshold this
would also result in maxima not being analysed due to falling along the edges of the images
and so was not taken further. As expected, the initial threshold increased with exposure time;
maxima had higher intensities due to more photons being collected per frame (Fig. 5.11A).
Unfortunately, most of the trajectories detected were still discarded (Fig. 5.11B; 35 ms -
91.63%, 70 ms – 91.42%. 100 ms – 89.73%). Once again, of the trajectories that could be
analysed, no obvious ratio of monomers, dimers and trimers per cell was observed across all
exposure conditions (Fig. 5.11C).
As the counting code was unable to analyse 700 frames together increasing the laser power
to decrease the number of frames needed for complete photobleaching of all fluorphores was
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Fig. 5.10 Analysing Mal stoichiometry by counting photobleaching steps. Transduced Mal+
iBMDMs were suspended in media and incubated on coverslips for 15 minutes, after which
they were fixed in 4% PFA and imaged using a TIRF microscope. The images were analysed
using a custom written MATLAB code. A) The initial threshold values used to analyse
individual cells. B) The number of trajectories detected and discarded. C) The number of
monomers, dimers and trimers detected per cell.
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Fig. 5.11 Different exposure times does not improve the ratio of trajectories detected to
trajectories discarded. Transduced Mal+ iBMDMs were suspended in media and incubated
on coverslips for 10 minutes, after which they were fixed in 4% PFA and imaged using a
TIRF microscope. The images were analysed using a custom written MATLAB code. A) The
spread of values for the initial threshold needed to analyse individual cells. B) The number of
trajectories detected and discarded. The number of monomers, dimers and trimers detected
per cell using C) 35, D) 70 or E) 100 ms exposure times.
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considered. When reviewing the raw intensity trajectories, however, I noticed that a large
number of trajectories contained a large initial drop in intensity within very early frames. This
large intensity drop was not being fitted by the change point finder function. I hypothesised
that the steep intensity drop not being detected by the change point finder function was the
cause for the large number of trajectories being discarded. The discrepancy between the
change point finder trace and the intensity trajectory would correlate with a poor fit, and
thus the trajectory would be discarded based on the R2 value of that fit. The large size of
the intensity drop also indicated that more than one fluorophore could be photobleaching
at once, therefore could be inaccurately counted as one photobleaching event leading to an
underestimation in complex stoichiometry if relying on counting individual photobleaching
steps. In order to better delineate photobleaching events, by increasing the number of frames
between each photobleaching step, the intensity of the laser used for imaging must be
decreased. A decrease in laser intensity would result in an increase in the number of frames
to be imaged to ensure complete photobleaching of all R110 fluorophores within the sample.
Given that the counting code used was unable to analyse 700 frames I decided to create a
new code to analyse the new photobleaching data acquired using reduced laser power to
determine Mal stoichiometry.
5.2.3 Developing a photobleaching analysis code to determine the stoi-
chiometry of Mal
In order to analyse the large number of frames necessary to completely photobleach MalHALO
in Mal+ iBMDM cells a new code needed to be developed. A collaboration was set up with
Anna Lippert, a PhD student in Professor David Klenerman’s laboratory (Department of
Chemistry, University of Cambridge) and with Sophie Ip, a PhD student in Professor Julia
Gog’s group (Department of Applied Mathematics and Theoretical Physics, University of
Cambridge). Having discussed the requirements of the code and a strategy for determining
the stoichiometry of Mal, Anna Lippert provided the backbone code for analysis (Appendix
B2). First, the positions of maxima within a tiff image are determined using the imageJ script
SpotFin.ij. This stores the coordinates of all of the maxima detected within an image. The
user can adjust the threshold for maxima detection. The saved coordinates are then fed into
the MATLAB script StepBleachingCountCode.m. Briefly, this script uses the pre-determined
coordinates of each maxima and extracts the intensity values at each of these points over
all of the frames one maxima at a time and creates an intensity trajectory. The step change
function used in the counting code is then applied to the intensity trajectories to determine
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where photobleaching events take place. Instead of counting the photobleaching events, the
intensity drop size of each of these photobleaching events is determined and plotted to a
histogram. The mean value of these step sizes is then calculated to determine the monomer
step size value (monomer value), that is, the intensity drop that would occur due to a single
fluorophore photobleaching. The background is calculated and is subtracted from the initial
trajectory intensity value. This total intensity drop value is then divided by the monomer
value to determine the number of proteins within each of the maxima. This new analysis
method went under a number of iterations, described below. The analysis pipeline is outlined
in Figure 5.12.
Fig. 5.12 Pipeline for determining the stoichiometry of proteins by using photobleaching
step size to determine the monomer intensity value.
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Transduced Mal+ iBMDMs were stimulated with 10 ng/ml LPS for 5, 10 or 15 minutes
or without LPS for 15 minutes in a cellview dish before fixation. A 0.4 neutral density
filter was used to decrease the laser power used for imaging and 2500 frames were imaged
in order for complete photobleaching of all R110 fluoropohores present within the image.
These imaging conditions were used for all further imaging. The newly developed analysis
pipeline, hereon referred to as “new code” was able to analyse all 2500 frames at once
without the need for increasing the spot detection threshold to reduce the number of maxima
analysed. This was an improvement over the previous analysis method as there was no
automatic bias towards only analysing complexes with higher fluorescent intensities. The
first iteration of this code used the mean step size value as the monomer value to determine
the number of Mal proteins per maxima assuming that all detected steps were due to single
fluorophore photobleaching events. The background value last detected for a maxima after
photobleaching was determined by either averaging the last 100 frames of each intensity
trajectory to determine the average background value which was subtracted from the initial
intensity value (column 1 Fig. 5.13) or by using the average of the last 100 frames of each
trajectory as the trajectory-specific background value for subtraction from each trajectory
(column 2 Fig. 5.13).
All of the conditions were analysed separately. The benefit of this method of analysis
is that the monomer value is determined from within the dataset itself rather than relying
on measurements of individual fluorophores on a coverslip. Using the intensity value of
fluorophores on a coverslip could result in error due to the distance of the fluorophores from
the coverslip. The distance of fluorophores from the coverslip will affect the intensity value
recorded and the local environment around the fluorophore within the cell could also affect
the intensity value detected. Histograms of complex stoichiometry for unstimulated (Fig.
5.13A), 5 minutes (Fig. 5.13B), 10 minutes (Fig. 5.13C) and 15 minutes stimulation with 10
ng/ml LPS (Fig. 5.13D) were produced.
The stoichiometry of Mal appears to change over time upon stimulation with 10 ng/ml
LPS. Unstimulated cells show a peak of approximately 2-3 Mal per maxima, which bifurcates
upon 5 minutes stimulation into three populations which then contracts again at 10 minutes
post LPS stimulation to approximately 4-5 Mal molecules per maxima and returns to between
2-3 Mal per maxima after 15 minutes stimulation. The use of average background or the
individual background of each trajectory does not appear to have a considerable effect on the
results, except for minor differences, such as observed after 15 minutes stimulation with LPS
where a maximum complex size of 6 Mal per maxima was observed when using the average
background value whilst a maximum complex size of 5 Mal per maxima was observed when
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Fig. 5.13 Initial stoichiometry results using mean step size as the monomer value. The Mal+
iBMDMs analysed were A) unstimulated for 15 minutes, or stimulated with 10 ng/ml LPS
for B) 5, C) 10 or D) 15 minutes. A) 18, B) 13, C) 19 and D) 17 cells were analysed per
condition. The average last 100 frames taken from all maxima (column 1) or the individual
last 100 frames of each maxima (column 2) was used for the background value to calculate
total fluorescent intensity drop of each maxima.
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using individual trajectory background values. The distributions of complex sizes would be
expected to be Gaussian in nature as fluorophores fluoresce with a Gaussian distribution.
The attempt to extract the monomer value from all of the step size data within the dataset,
however, was not optimal. I further investigated the method to determine the monomer
value used to calculate complex stoichiometry. When reviewing the profiles of the step
size histograms produced it appeared that they could be composed of multiple Gaussian
distributions, indicating photobleaching profiles of 1, 2 or 3+ fluorophores photobleaching at
the same time, resulting in larger intensity step drop sizes. I discussed this idea with Sophie
Ip and she suggested using the Gaussian Mixed Distribution Model (GMModel) function
fitgmdist within MATLAB to pull out the individual Gaussian distribution components.
Using this function the step size data from all cells combined was modelled as containing 1
(Fig. 5.14A, as would be observed by taking the mean), 2 (Fig. 5.14B), 3 (Fig. 5.14C) or 4
(Fig. 5.14D) Gaussian distributions. The fitgmdist function works by undergoing a number
of iterations to converge on a model with the best fit. Visually, using the GMModel provides
a much better fit to the step size data than using the mean alone. As such, I sent Anna Lippert
the GMModel code that I created and she included it in the analysis pipeline. The next issue
was determining which model was the best fit to use. Initially Anna coded in the use of the
Malhalanobis statistic to determine the best fit of model. This statistic compares the distance
of the data from the model distribution; the smaller the value, the closer the model is to
the data. However, using this statistic consistently picked GMModel 1 as best, because the
number produced was smaller due to their only being one Gaussian distribution modelled.
Discussions with Sophie Ip led to use of the Akaike information criterion (AIC) value to
determine which model is best to use for analysis. The AIC value estimates the quality
of each model; it is a measure of goodness of fit that penalises over-fitting and is used to
compare a number of different models of the same scenario. The lower the AIC value, the
better the model. Should the AIC value determine that a model with more than one Gaussian
distribution is the best fit, the mean of the Gaussian distribution with the lowest values will
be used as the monomer value as a monomer is the smallest unit that is able to photobleach.
GMModel 3 was determined as the best as it had the lowest AIC value and converged within
100 iterations (Table 5.2).
Using the fitgmdist function to determine the monomer step size value resulted in the
determined monomer value between the data sets being much closer in value than when
using the mean value of step sizes (Table 5.3).
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Fig. 5.14 Mixed Gaussian distribution models using photobleaching data of all unstimulated
cells to determine the monomer step size value. The photobleaching data set was modelled
with A) 1, B) 2, C) 3 or D) 4 Gaussian distributions present within the data set.
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Table 5.2 Gaussian model parameters
Gaussian model (GMModel) AIC Number of Iterations
1 11945 3
2 11439 52
3 11214 88
4 11145 100
Table 5.3 A comparison of monomer sizes using mean value compared to mean of first
Gaussian distribution determined using GMModel 3
Condition Mean monomer size GMModel 3 monomer size
Unstimulated 15 minutes 4.7252 1.6897
10 ng/ml LPS 5 minutes 2.2817 1.8633
10 ng/ml LPS 10 minutes 4.069 1.8205
10 ng/ml LPS 15 minutes 4.164 1.9073
When analysing the individual traces obtained with the new optimised imaging conditions
it became apparent that the code could be improved further (Fig. 5.15). Ideally, an intensity
trajectory will consist of well-delineated photobleaching steps (Fig. 5.15A). However, some
intensity trajectories still contain large photobleaching drop sizes at the beginning of the
trajectory (Fig. 5.15B) further demonstrating the need of the fitgmdist function to determine
monomer fluorescence intensity size, as the larger the number of fluorophore present within
a maxima the greater the probability that more than one fluorophore will photobleach at the
same time. Also, the blinking behaviour of fluorophores can implicate the ability of a trace
to be analysed. For example, blinking of fluorophores may result in an intensity trajectory
not reaching background levels by the end of 2500 frames (Fig. 5.15C).
As the last 100 frames are currently being used to determine the background intensity
value, the increased intensity value will result in miscalculations of stoichiometry size, as it
is not the true background value, resulting in an underestimation of stoichiometry. Although
the number of trajectories that are not fully photobleahed will be small, I decided to use
the average value of a 20 pixel square from the four corners of each image (which do not
contain fluorophores) for determining the background intensity, a method used in the previous
counting code. Blinking of fluorophores can also reveal the true maximum intensity of a
maxima within the trace (Fig. 5.15D). Initially, the intensity in the first frame was used as the
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Fig. 5.15 Representative photobleaching traces. Intensity trajectories were created from
photobleaching data at positions of fluorescent maxima within TIRF images (blue) and fitted
with a step change function to create a change point finder trace (red). A) A well delineated
photobleaching trace. B) Larger photobleaching step sizes observed when more fluorescent
molecules are present. C) Blinking behaviour of fluorophores resulting in maxima position
not fully photobleached by the end of 2500 frames. D) Blinking behaviour results in highest
point of fluorescence within the trace, not at the beginning.
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maximum intensity value as it usually correlates with the highest point of intensity within
a trace and is unbiased. However, due to the observation of the maximum intensity being
observed within some of the intensity trajectories, I changed the maximum intensity value to
now be the maximum intensity value within the trace, rather than the first intensity value of
the trace.
With all of these modifications included into the code the data was analysed again, with a
marked change in results (Fig 5.16). The stoichiometry of Mal changes upon stimulation with
LPS. Unstimulated cells display a peak of approximately 10 Mal molecules per maxima (Fig.
5.16A), which bifurcates upon 5 minutes stimulation with 10 ng/ml LPS into two peaks of
approximately 6 and 12 Mal molecules per maxima with a peak present also of approximately
46 Mal molecules (Fig. 5.16B). The distribution of Mal molecules then contracts after 10
minutes LPS stimulation to approximately 10 Mal molecules per maxima (Fig. 5.16C),
similarly at 15 minutes post LPS stimulation, with a main peak of approximately 10 Mal
molecules per maxima and retention of much larger stoichiometry observed around 46 Mal
molecules (Fig. 5.16D). The histograms outlining Mal stoichiometries were overlaid in order
to better compare the stoichiometry observed in each condition against the stoichiometry
observed without stimulation (Fig. 5.17A, B and C). The empirical cumulative distribution
function (eCDF) can also be used to compare the distribution of Mal stoichiometry between
different conditions (Fig. 5.17D). A similar distribution of Mal stoichiometry is observed in
unstimulated, 10 minutes post LPS stimulation and 15 minutes post LPS stimulation Mal+
iBMDMs whilst the distribution of Mal after 5 minutes stimulation with LPS is significantly
different.
122 Investigating the stoichiometry of Mal/TIRAP using single molecule imaging
Fig. 5.16 Stoichiometry results using a mixed Gaussian distribution model to determine the
monomer value. The cells analysed were A) unstimulated for 15 minutes, or stimulated with
10 ng/ml LPS for B) 5, C) 10 or D) 15 minutes. A) 18, B) 13, C) 19 and D) 17 cells were
analysed per condition.
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Fig. 5.17 Overlay of Mal stoichiometry results using a mixed gaussian distribution model to
determine the monomer value. Histograms with data from unstimulated cells (Control) with
cells stimulated with 10 ng/lm LPS for A) 5 minutes, B) 5 and 10 minutes or C) 5, 10 and 15
minutes. D) Empirical cumulative distribution function of unstimulated cells (control) and
cells stimulated wiht 10 ng/ml LPS for 5, 10 or 15 minutes.
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The Kolmogorov Smirnov statistic can be used to determine whether two distributions
are distinct from one another or from the same distribution (Table 5.4). Analysis with this
new code resulted in all of the stimulated distributions being calculated as different when
compared to the unstimulated distribution.
Table 5.4 Kolmogorov Smirnov test of Mal stoichiometry upon stimulation with or without
LPS
Test data sets Different distribution P value
Control vs. 5 min Yes 4.689e-08
Control vs. 10 min Yes 4.4105e-05
Control vs. 15 min Yes 6.5530e-08
The data analysed thus far has been of all cells pooled within each condition. Single cells
from the unstimulated data set were analysed to determine whether every cell exhibited the
same stoichiometry profile. I attempted to use the monomer value obtained within each cell,
however, due to smaller datasets to determine the Gaussian mixed distribution model this
was not possible. Due to the decrease in data when analysing cells individually, I propose
that analysing data from all cells combined provides a more robust analysis.
5.2.4 Using R to determine the monomer step size intensity value
Although MATLAB is well equipped for image processing, manipulation of parameters
within its mixed Gaussian distribution model function (fitgmdist) is limiting. The programme
R, however, is renowned for its statistical modelling power. Furthermore, the package
“mixtools” has been previously used to determine mixed Gaussian distribution models used
to determine the monomer value for stoichiometry calculations [243]. Sophie Ip wrote a
script to use the mixtools package in R to fit step size data with Gaussian distribution models
and use the BIC value to determine which model was best. The BIC was used instead of
the AIC as it more heavily penalises the number of parameters used in a model. In order
to test this method I ran the script analysing the control, unstimulated dataset. A Gaussian
distribution model containing 4 Gaussian distributions was determined to be the best model
as it had the lowest BIC value of the models that converged within 1000 iterations (Fig.
5.18A). Similar to when using MATLAB to determine the monomer value, the value of the
Gaussian with the lowest mean was used as the monomer value. When plotting the mean
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values of the Gaussians found within each of the models, it became apparent that with higher
numbers of Gaussians, over-fitting starts to occur; the mean value of the first Gaussian picks
up noise whilst the mean of the second Gaussian starts to converge with what has been
determined as the monomer value (Fig. 5.19). This can also be demonstrated by looking at
the heights of the Gaussian peak (Fig. 5.18B compared to Fig. 5.18C).
The monomer value when determined using R is 1.1087 compared to the monomer value
determined using MATLAB, 1.6897. The monomer value determined using R for each
condition is outlined in Table 5.5. The number of Gaussians within the models that had the
lowest BIC varied with each condition, although the monomer values determined were very
similar (Table 5.5).
Table 5.5 The monomer value for each condition determined using R
Condition Number of Gaussians in Model Monomer Value
Unstimulated 15 minutes 4 1.1087
10 ng/ml LPS 5 minutes 4 1.1276
10 ng/ml LPS 10 minutes 5 1.1032
10 ng/ml LPS 15 minutes 7 1.0311
These monomer values were applied to the photobleaching data sets, the histograms
produced are presented in Figure 5.20. As the monomer values determined using R are lower
in value than those determined using MATLAB, the stoichiometry of each maxima containing
Mal shifted to an increased value as a result (Fig. 5.20). Instead, a peak is observed at roughly
15 Mal molecules per maxima under control conditions, which bifurcates into approximately
10 and 20 Mal molecules per maxima after 5 minutes stimulation with 10 ng/ml LPS. This
stoichiometry again reverts back to around 15 Mal molecules per maxima after 10 minutes
stimulation with 10 ng/ml LPS with a similar profile after 15 minutes stimulation with 10
ng/ml LPS, although possibly closer to 20 Mal molecules per maxima than 15 (Fig. 5.20).
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Fig. 5.18 Using the mixtools package in R to determine monomer step size in the unstimulated
control dataset. A) The BIC values for each distribution model with a different number of
Gaussians present was plotted. Black circles represent models that converged within 1000
iterations, whilst red circles represent models that did not. B) A histogram of photobleaching
step sizes plotted with the model containing 4 Gaussian distributions plotted (black) as well
as the individuals Gaussian distributions (colour). C) A histogram of photobleaching step
sizes plotted with the model containing 9 Gaussian distributions plotted (black) as well as
the individual Gaussian distributions (colour).
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Fig. 5.19 The Mean value of Gaussians within Gaussian distribution Models. The package
’mixtools’ in R was used to determine the mixed distribution of Gaussians within the control
unstimulated step size data set. The mean value of the first Gaussian within the model
containing 4 Gaussians (red) was determined to be the monomer value within the data set.
The red dotted line corresponds to this value.
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Fig. 5.20 Stoichiometry results using the mixtools package in R to determine the monomer
value. The cells analysed were A) unstimulated for 15 minutes, or stimulated with 10 ng/ml
LPS for B) 5, C) 10 or D) 15 minutes. A) 18, B) 13, C) 19 and D) 17 cells were analysed per
condition.
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In order to make comparison of stoichiometries observed under LPS stimulated conditions
compared to unstimulated conditions more clear, the histograms produced were overlaid
(Fig. 5.21). Interestingly, whilst the eCDF of stoichiometries present after 15 minutes
stimulation with 10 ng/ml LPS was to the left of the control eCDF when using MATLAB to
determine the monomer value, it shifted to the right of the control eCDF when using R to
determine the monomer value (Fig 5.21D), suggesting the presence of complexes with larger
stoichiometries than observed under control conditions (Fig. 5.21C).
It is important to note that the distributions observed are not as a consequence of the
attempt to determine the number of molecules present in each maxima. The changes in
distribution over time are true, as observed by measuring the total intensity drop of each
maxima without dividing by a calculated monomer value (Fig. 5.22). The eCDFs produced
for maxima from unstimulated cells and those stimulated with 10 ng/ml LPS for 10 or 15
minutes display greater overlay than when determining complex stoichiometry using this
analysis (Fig. 5.22E). The distribution of maxima intensity after 5 minutes stimulation with
10 ng/ml LPS is still observably different and displays a similar distribution profile (Fig.
5.22B&E).
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Fig. 5.21 Overlay of Stoichiometry results using the mixtools package in R to determine the
monomer value. Histograms with data from unstimulated cells (Control) with cells stimulated
with 10 ng/ml LPS for A) 5 minutes, B) 10 minutes or C) 15 minutes. D) Empirical cumulative
distribution function of unstimulated cells (control) and cells stimulated with 10 ng/ml LPS
for 5, 10 or 15 minutes.
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Fig. 5.22 The intensity drop profiles of Mal maxima. The cells analysed were A) unstimulated
for 15 minutes, or stimulated with 10 ng/ml LPS for B) 5, C) 10 or D) 15 minutes. A) 18,
B) 13, C) 19 and D) 17 cells were analysed per condition. The intensity drop profiles were
calculated by subtracting background intensity from the maximum intensity of each maxima.
E) Empirical cumulative distribution functions of unstimulated cells (Control) and cells
stimulated with 10 ng/ml LPS for 5, 10 or 15 minutes.
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5.2.5 Combining the step counting photobleach code with the monomer
determining photobleach code
The main point of uncertainty within the new code designed to determine stoichiometry is
that of determining the monomer value, the value of a single fluorophore photobleaching. As
of yet, there has been no quality control measure to determine whether the steps detected by
the step change function are accurate steps within the native intensity trajectory or whether
they are poorly fitted. The code produced by Dr. Weimann does contain such a quality control
step; a trajectory is kept for analysis based on the R2 value of the fit between the change
point finder trace with the Chung-Kennedy filtered intensity trajectory. I reasoned that the
real issue with why the code written by Dr. Weimann was unable to analyse my data was
actually due to the particle tracker function, not the step detection or step counting functions
themselves. Given that Anna Lippert has created a separate code within image J to determine
the position of maxima (SpotFin.ij that stores the coordinates of all of the maxima detected
within an image), I reasoned that I could combine the output of this function with the code
written by Dr. Weimann to Chung-Kennedy filter the traces, fit those traces to find steps
and then use these values to determine the monomer value. I could use only the step sizes
that correlate to trajectories that show a good fit with the step change trace to determine the
monomer value, increasing the confidence that the step sizes being used for further analysis
are true steps. The pipeline for the new analysis is outlined in Figure 5.23. This version of
the code shall be referred to as the “combined code”. This method was able to analyse all
2500 frames within each cell image stack. I chose a preliminary LM threshold value of 50
for analysis, as visually it appeared to produce change point finder traces that fit the filtered
trajectories.
This method produces bar charts outlining the percentage of cells discarded and kept
for further analysis (Fig. 5.24). The kept trajectories were then analysed by counting the
photobleaching steps present within the trace to determine the stoichiometry of Mal at these
analysed maxima (Fig. 5.25). The resulting bar charts for each condition are shown. As
demonstrated in Figure 5.24, a high percentage of traces were still rejected based on their R2
value, the fit between the filtered trajectory and the change point finder trace. I hypothesised
that this was due to the large initial drop in intensity associated with traces starting with
higher intensity values. Also, consistently approximately 13% of trajectories displayed
positive steps within the trace and were therefore not used for counting photobleaching steps.
Approximately 33-46% of trajectories were kept for further analysis.
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Fig. 5.23 Pipeline for determining the stoichiometry of proteins by using photobleaching
step size from Chung-Kennedy filtered trajectories with a good fit to the identified change
point finder trace to determine monomer intensity value.
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Fig. 5.24 Bar charts depicting the percentage of trajectories discarded and kept for analysis.
Trajectories in data sets from A) unstimulated cells or cells stimulated with 10 ng/ml LPS
for B) 5, C) 10 or D) 15 minutes, were discarded based on having no step (no step), an R2
fit value below 0.95 (R2) or a positive step (pos step). Otherwise the trajectories were kept
(kept) for further analysis.
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Fig. 5.25 Bar charts depicting the percentage of trajectories with 1 to 12 photobleaching
steps present. Trajectories that fit the criteria to be kept in data sets from A) unstimulated
cells or cells stimulated with 10 ng/ml LPS for B) 5, C) 10 or D) 15 minutes were analysed.
The number of photobleaching steps present within each trajectory were counted.
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In order to test my hypothesis that trajectories were being rejected based on their R2 value
due to the large initial drop in intensity associated with traces starting with higher intensity
values, I analysed the intensity drops present in traces with a good R2 value (Good) versus
all traces (All). Interestingly, traces with a good R2 value displayed a similar intensity profile
as all of the traces combined, suggesting that a large initial intensity drop not being fitted by
the step change function was not the reason for the lower R2 values (Fig. 5.26). This remains
true even when increasing the LM Threshold value (Fig. 5.26).
When the traces with a good fit were analysed for the number of photobleaching steps
within each trajectory, maxima with as many as 10 Mal molecules were counted (Fig. 5.25).
In all of the tested conditions, the peak stoichiometry appears to be between 4 and 5 Mal
molecules per maxima. I do not believe, however, that the stoichiometries calculated here
are an accurate representation of the datasets as it is possible that the higher the number of
molecules present within a maxima, the more likely positive photobleaching steps will occur,
and thus the trajectory will not be used for further analysis. The Good traces depicted in
Figure 5.26 may also include traces that contain positive bleaching steps within them that
would not be analysed as the trajectories were only separated on the basis of the R2 value.
Secondly, it is possible that steps counted as a single photobleaching event may still contain
more than one photobleaching event. I combined using only the traces with a good R2 value
for determining the monomer value needed for whole population analysis.
In order to correctly determine the monomer value, the LM threshold used to analyse
the data must be the best threshold for the data set to accurately determine photobleaching
steps. To determine which is the best LM threshold value to use, I ran the analysis using
the control data set increasing the LM threshold value each time. I then analysed the effect
this had on the determined monomer value. The monomer value was determined by fitting
Gaussian distribution models using both MATLAB and R. The results are outlined in Table
5.6. The number of steps available for analysis decreased when using only trajectories
with a good R2 value compared to when using all traces. The number of steps decreased
further when the LM threshold value was increased, as the threshold size of a step to be
fitted increased. Interestingly, when using MATLAB to ascertain the monomer value, the
value obtained using Good trajectories was very close across the higher LM threshold values
of 300, 400 and 500 with the value obtained using all traces. This was replicated when
analysing good trajectories R to ascertain monomer value, which determined very similar
values to that of the MATLAB function. Interestingly, when using lower LM threshold values
(50, 100 or 200) in combination with all trajectories lower monomer values were determined
than when only trajectories with a good fit were used. The much lower values determined
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Fig. 5.26 A comparison of intensity drops in all trajectories versus trajectories with an R2
value of 0.95 or more when applying different LM thresholds. The control data set was
analysed using a number of different LM threshold values. The above histograms depict the
intensity drops present in the dataset of all trajectories (All) and of the trajectories with an
R2 value of 0.95 or more (Good) when using different LM threshold values.
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using all trajectories could be due to improper fitting of smaller step sizes toward the end
of the intensity trajectories. Determining the correct LM threshold to use for analysis can
be difficult. Too low a LM threshold would detect false positive steps, whilst too high a
threshold would bias towards only detecting steps with a large enough intensity drop. If false
positive steps were being inaccurately fitted to the intensity trajectories, their inclusion in
all trajectories would skew the monomer step size to a smaller step size; a step size actually
determined by false positive noise. This was observed when analysing histograms of the step
sizes for Good traces versus all traces (Fig. 5.27A).
There is a common step size peak across all of the threshold values (Fig. 5.27D&E).
When the LM Threshold was 300 or above, this common peak was the Gaussian peak with
the lowest mean value (Fig. 5.27B&C). Therefore, lower LM threshold values may result
in false positive steps of smaller size skewing the monomer value to an inaccurate smaller
value as analysis using the lower LM threshold of 50 results in a small peak before the main
peak observed across all of the LM thresholds analysed (Fig. 5.27A). This phenomenon
occurs when also using an LM threshold value of 100 or 200. When the second, taller
peak is analysed, the mean value is closer to that of the first peak when using higher LM
threshold values (Table 5.7). Given the summarised data, I propose that the best method for
determining the monomer value for analysis of stoichiometry is by Chung-Kennedy filtering
trajectories, determining which trajectories have a good fit with the change point finder trace
and using only those traces for determining the monomer value. In addition, I propose that
the Gaussian distribution model function in R is more amenable for this analysis than that
in MATLAB due to its flexibility in changing parameters. Furthermore, comparison of step
size data using multiple different thresholds needs to be conducted to determine the true
monomer step size distribution.
Table 5.7 The mean value of the second Gaussian peak obtained when using only traces with
a good R2 value and all traces in R
Threshold Good traces 2nd peak mean value All traces 2nd peak mean value
50 1.2215 1.2085
100 1.2686 1.2792
200 1.3174 1.3220
300 1.3887 1.3561
400 4.5151 1.3856
500 4.4663 2.8607
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Fig. 5.27 Histograms of step sizes in all trajectories versus trajectories with an R2 value
of 0.95 or more when applying different LM threshold values. The control data set was
analysed using a number of different LM threshold values. The above histograms depict the
step sizes present in the dataset of all trajectories (All) or only the trajectories with an R2
value of 0.95 or more (Good) when using the LM threshold values A) 50, B) 300 or C) 500.
D) and E) depict histograms of step sizes from Good traces from data sets analysed using the
LM threshold values 50, 300 or 500. The histograms depict D) actual freuquency of step
sizes or E) the normalised frequency of step sizes.
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I analysed the data sets once more using only traces with a good R2 value and using an
LM threshold value of 300, as this LM threshold value removes detection of false positive
steps. The monomer values obtained were then applied to all of the filtered trajectories that
had had their individual backgrounds (determined by averaging over the last 100 frames)
subtracted from their maximum intensity value. As the trajectories have been filtered, the
maximum intensity value should produce less error for stoichiometry overestimation than
when using unfiltered trajectories, as the noise present within the trajectories has been
reduced. I decided to use individual trajectory backgrounds for simplicity for first testing this
new code. The histograms of Mal stoichiometry produced using this method are in Figure
5.28. Due to time constraints use of the other methods of determining background values
discussed previously have not been implemented in this new analysis pipeline. The results
obtained were very similar to that from the first analysis with the new code, as expected given
that the underlying distribution does not change, only the monomer value is being refined.
A peak of approximately 10 Mal molecules per maxima was observed when cells were
unstimulated, which bifurcated to approximately 8 and 16 Mal molecules per maxima after 5
minutes stimulation with 10 ng/ml LPS and returned to approximately 10 Mal molecules
per maxima after 10 and 15 minutes stimulation with 10 ng/ml LPS. The monomer values
obtained for each condition are outlined in Table 5.8.
Table 5.8 The monomer value for each condition determined using only trajectories with a
good R2 value in R
Condition Number of Gaussians in Model Monomer Value
Unstimulated 15 minutes 4 1.331550
10 ng/ml LPS 5 minutes 4 1.304534
10 ng/ml LPS 10 minutes 5 1.271511
10 ng/ml LPS 15 minutes 5 1.322734
Furthermore, when analysing the Kolmogorov Smirnov statistic (to determine whether
two distributions are distinct from one another or from the same distribution) this new
pipeline revealed that only the dataset from Mal+ iBMDMs stimulated with 10 ng/ml LPS for
5 minutes was of a different distribution compared to the control dataset. Both datasets from
Mal+ iBMDMs stimulated with 10 ng/ml LPS for 10 minutes and 15 minutes were calculated
as being from the same distribution as the control unstimulated dataset (Table 5.9).
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Fig. 5.28 Overlay of Stoichiometry results using only trajectories with an R2 value of 0.95
or more fitted to a mixed gaussian distribution model in R to determine the monomer value.
Histograms with data from unstimulated cells (Control) with cells stimulated with 10 ng/ml
LPS for A) 5 minutes, B) 10 minutes or C) 15 minutes. D) Empirical cumulative distribution
function of unstimulated cells (control) and cells stimulated with 10 ng/ml LPS for 5, 10 or
15 minutes.
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Table 5.9 Kolmogorov Smirnov test of Mal stoichiometry upon stimulation with or without
LPS
Test data sets Different distribution P value
Control vs. 5 min Yes 5.1702e-04
Control vs. 10 min No 0.0592
Control vs. 15 min No 0.0685
In fact, when the total intensity drops from the different distributions were analysed
using this statistic, the same result was produced (Table 5.10), indicating that the manipula-
tion of the data to determine the stoichiometry represents the raw, original intensity data.
Table 5.10 Kolmogorov Smirnov test of Mal total intensity drop upon stimulation with or
without LPS
Test data sets Different distribution P value
Control vs. 5 min Yes 1.5016e-04
Control vs. 10 min No 0.7913
Control vs. 15 min No 0.9660
However, there is dispute as to whether monomer fluorescent intensity can be described as
Gaussian. Due to the stochastic nature of fluorophore photon emission that follows a Poisson
distribution and due to noise generated with equipment it has been suggested that monomer
intensity actually follows a Lognormal distribution [249]. Here the Gaussian distribution has
been used because it has previously been used for similar analysis of stoichiometry [243]. I
decided, therefore, to apply a Lognormal distribution to the combined code good step sizes –
step sizes known to represent true photobleaching events (Fig. 5.29).
Visually alone, this preliminary Lognormal distribution fit does not appear to be a good
fit for the step size data. While this analysis alone is not sufficient to dismiss the possibility
of a Lognormal distribution for fluorescent intensities, this line of investigation was not taken
further due to time constraints. A possible extension of this analysis would be to determine
whether there are multiple Lognormal distributions within the dataset.
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Fig. 5.29 Determining the monomer step size using a Lognormal distribution. The step size
data of good traces determined using the combined code was fitted with either A), B) a mixed
Gaussian distribution model in A), R or B) MATLAB or C) the step size data was fitted with
a Lognormal distribution in MATLAB.
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5.2.6 Validating the accuracy of the stoichiometry analysis code
Having created this new combined analysis pipeline, the next step was to validate its ability
to accurately determine the number of molecules per maxima within a dataset. A number of
different approaches were undertaken to determine the accuracy of the analysis.
Firstly, I attempted to determine whether the code could accurately determine protein
complexes of known stoichiometry. In order to do this I transduced Mal-/- iBMDMs with
pHR:CD28HALO or pHR:CD86HALO, a known dimer and monomer respectively. I used
Mal-/- iBMDMs to ensure that the fluorophores being imaged were within the same cellular
background as in my experimental MalHALO expressing data set. Transduction of Mal-/-
iBMDMs to express both CD28HALO and CD86HALO was of limited success, even when
using Neat lentivirus solution to do so (Fig. 5.30). However, given the very modest increase
in median fluorescence intensity (Table 5.11 and Table 5.12) I imaged Mal-/- iBMDMs
transduced with neat lentivirus solution containing pHR:CD28HALO or pHR:CD86HALO
using TIRF microscopy to determine whether the halo-tagged proteins could be visualised.
Some Mal-/- iBMDM were successfully transduced. However, upon fixation the transduced
iBMDMs looked unhealthy and I was unable to achieve complete fixation of fluorophores for
image analysis even when fixing the transduced iBMDMs for longer periods of time. Of the
fluorophores that did remain in a fixed position, I visualised their fluorescence intensity traces
using imageJ (Fig. 5.31). As predicted, there were more than one or two fluorophores present
per maxima. This is because TIRF microscopy is diffraction limited, if two fluorophores
are within 200 nm distance they will be resolved as a single fluorescent spot. Therefore, it
is possible that more than one or two proteins are clustered within the same area of plasma
membrane. This also holds true for the analysis of Mal stoichiometry. Rather than looking at
single complexes per se, it is possible that instead, clusters of Mal were being observed. Due
to the observed clustering, this method will not be suitable for validating the code as the size
of these clusters is not well defined.
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Fig. 5.30 Expression levels of CD28HALO and CD86HALO in transduced Mal-/- iBMDMs
assessed by flow cytometry. Mal-/- iBMDMs were transduced with or without Neat or diluted
(1/2, 1/4, 1/8 or 1/16) lentivirus containing A) pHR:CD28HALO or B) pHR:CD86HALO or
with a 1/10 dilution of lentivirus containing pHR:MalHALO as a positive control and stained
using 100 nM R110-HALO dye. Non-transduced and transduced Mal-/- iBMDMs were
assessed for HALO expression using flow cytometry.
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Fig. 5.31 Representative photobleaching trajectories of maxima present in Mal-/- iBMDMs
transduced with pHR:CD28HALO or pHR:CD86HALO. Intensity trajectories were created
from photobleaching data at positions of fluorescent maxima within TIRF images using
imageJ. The photobleaching profile of a maxima from Mal-/- iBMDMs transduced with A)
pHR:CD28HALO or B) pHR:CD86HALO.
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Table 5.11 Mal-/- iBMDMs transduced with pHR:CD28HALO flow cytometry statistics
Sample % R110 positive Median fluorescence intensity
Non-transduced 5.52 308
Non-transduced stained 6.41 309
Transduced 1/16 6.17 311
Transduced 1/8 5.88 310
Transduced 1/4 5.79 312
Transduced 1/2 5.73 311
Transduced Neat 5.68 312.5
Transduced pHR:MalHALO 1/10 21.14 445
Table 5.12 Mal-/- iBMDMs transduced with pHR:CD86HALO flow cytometry statistics
Sample % R110 positive Median fluorescence intensity
Non-transduced 4.51 318
Non-transduced stained 4.97 323
Transduced 1/16 4.65 325
Transduced 1/8 4.50 326
Transduced 1/4 4.57 326
Transduced 1/2 5.56 328
Transduced Neat 6.68 333.5
Transduced pHR:MalHALO 1/10 19.81 464
A second avenue for assessing the accuracy of the combined code to determine the
correct stoichiometry of maxima within an image is by running simulations. Simulations
of photobleaching traces will be analysed to assess the accuracy with which the code
determines how many fluorophores are present within maxima compared to the known
number programmed. This work is being conducted in collaboration with Sophie Ip but is
too preliminary to report here. However, the premise of the simulations is that information
such as fluorophore photobleaching rates, noise within the traces for a single fluorophore
and whether this noise increases upon increased number of fluorophores is extracted from
the dataset to be analysed, and used to create simulated data of photobleaching events with
defined number of fluorophores per maxima. This simulated data will be analysed using the
combined code described above. The number of fluorophores per maxima detected by the
combined code will be compared to the number of fluorophores programmed to appear.
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5.2.7 Investigating the stoichiometry of Mal mutants
Having determined that the stoichiometry of WT Mal changes over time upon stimulation with
LPS I decided to investigate whether the mutations R121A, P125H and F193A would affect
this stoichiometry. The pEF6v5histopo plasmids encoding WT, mutant R121A, P125H and
F193A Mal were kindly provided by Professor Bostjan Kobe (The University of Queensland,
Australia). These versions of Mal were subcloned into the pHR:HALO vector and sequenced
(Fig 5.32).
Fig. 5.32 The amino acid sequences of Mal variants in the pHR:HALO vector. Amino acid
sequences of Mal used for the analysis of WT stoichiometry (original), WT, mutants R121A,
P125H and F193A, provided by Professor Bostjan Kobe, cloned into the pHR:HALO vector.
Amino acid differences to the original Mal variant are red.
The Mal variants provided were a different isoform of Mal compared to the Mal analysed
thus far and contained the S55N polymorphism. Given these differences, the ability of the
new WT Mal isoform and Mal mutants to signal was tested by a transient transfection assay
in HEK293 cells as described previously (Fig. 5.33). A dose response curve was initially
produced (Fig. 5.33A&B). The WT and mutant F193A were able to induce NF-κB activation
in a dose dependent manner (Fig. 5.33A) whilst the mutants R121A and P125H were unable
to induce NF-κB activation (Fig. 5.33B). These results were confirmed, transfecting 10 or
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50 ng per well (Fig. 5.33C). The WT isoform had a greater ability to activate NF-κB when
the same amount of plasmid was transfected compared to the original Mal isoform used
for determining Mal stoichiometry. The mutant F193A was able to activate NF-κB to the
same extent as the WT Mal, and both R121A and P125H resulted in a significant increase in
NF-κB activation compared to TLR-4 transfected HEK293 cells, although this activation
was minimal compared to that of WT Mal (Fig. 5.33C).
Having established that the Mal variants subcloned into pHR:HALO were able to induce
signalling in the context of HEK293 cells, transduction of Mal-/- iBMDMs with lentivirus
containing pHR:MalHALO was optimized as described previously. No transduction of the
MalHALO variants was observed by flow cytometry after staining with R110-HALO dye; not
even when neat virus was used for transduction (Fig 5.34). Due to time constraints and as
the different Mal variants were unable to be expressed this work was not taken further.
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Fig. 5.33 MalHALO mutants differ in their ability to activate NF-κB. HEK293 cells
were transiently transfected with constituents for TLR-4 signalling (pCDNA3:hTLR-4,
pEFIRES:hMD-2, pCDNA3:hCD14 and pNF-κB-luc (an NF-κB inducible Firefly luciferase
reporter) and phRG-TK (a constitutively active Renilla luciferase reporter)) or increasing
amounts of original, WT, R121A, P125H or F193A pHR:MalHALO A) and B) (1, 2.5, 5, 10,
25 or 50 ng per well) or C) (10 or 50 ng per well) and pNF-κB-luc and phRG-TK. After
48 hours the cells were lysed and the NF-κB luciferase activation was measured using a
microplate reader. Data is repesented as normalised luminescence calculated by dividing
Firefly luciferase counts by those obtained for Renilla luciferase. Each data point represents
one well. Data from one experiment (A and B) or pooled from three experiments (C) with
triplicate wells for each condition. Data represents mean ± SD. P-value calculated using
one-way ANOVA, **** = p < 0.0001, ** = 0.001 < p < 0.01.
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Fig. 5.34 Expression levels of MalHALO in Mal+ iBMDMs assessed by flow cytometry. Mal-/-
iBMDMs were transduced with or without neat virus containing Original Mal, or WT, R121A,
P125H, or F193A cloned into the pHRHALO vector. The Mal-/- and Mal+ iBMDMs were
stained using 100 nM R110-HALO dye and assessed for MalHALO expression using flow
cytometry.
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5.2.8 Investigating the stoichiometry of MyD88
The advantage of the stoichiometry analysis described above is that it can be used to analyse
the stoichiometry of any protein present at the plasma membrane. Mal recruits MyD88 to
the TLR-4 signalling complex. I decided, therefore, to investigate whether I could detect
changes in the stoichiometry of MyD88 at the plasma membrane upon stimulation with
LPS. Work has been conducted using the pHR:MyD88GFP construct, kindly provided by
Dr. Brett Verstak (Department of Biochemistry, University of Cambridge). I utilised the
viral transduction experimental cell model currently used by members of the laboratory to
visualise fluorescently labelled MyD88. Transduction of MyD88-/- iBMDMs with lentivirus
containing pHR:MyD88GFP has previously been shown to reconstitute MyD88-/- iBMDMs
signalling in response to LPS. Briefly, HEK293T cells were transfected with a DNA mix
containing 0.5 µg p8.91 plasmid, 0.5 µg pMDG plasmid (plasmids encoding proteins for
lentivirus production) and 0.5 µg pHR:MyD88GFP (the construct of interest). After 72 hours
culture, supernatant containing lentivirus was aspirated from the transfected HEK293T cells,
clarified, diluted (Neat, 1/2, 1/4, 1/8, 1/16, 1/32 or 1/64) and used to transduce MyD88-/-
iBMDMs. After 24 hours incubation, the lentivirus was removed and replaced with fresh
media. The transduced MyD88-/- iBMDMs were ready for stimulation assays 7 days post
transduction. Flow cytometry was used to assess which viral dilution was appropriate for
transduction (Fig. 5.35). Transduction of MyD88-/- iBMDMs with increasing concentrations
of lentivirus increased the number of MyD88-/- iBMDMs expressing of MyD88GFP and also
increased the expression level within the successfully transduced iBMDMs (as demonstrated
by an increase in median fluorescence intensity value) in a dose-dependent manner (Fig. 5.35
& Table 5.13). Due to time constraints this work was taken no further.
Table 5.13 MyD88-/- iBMDMs transduced with MyD88GFP flow cytometry statistics
Sample % GFP positive Median fluorescence intensity
Non-transduced 5.29 184
Transduced 1/64 10.24 197
Transduced 1/32 14.19 206
Transduced 1/16 20.97 225
Transduced 1/8 34.26 308
Transduced 1/4 47.11 472
Transduced 1/2 62.37 723
Transduced Neat 74.08 949
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Fig. 5.35 Expression levels of MyD88GFP in transduced MyD88-/- iBMDMs assessed by flow
cytometry. MyD88-/- iBMDMs were transduced with or without Neat or diluted (1/2, 1/4, 1/8,
1/16, 1/32 or 1/64) pHR:MyD88GFP containing lentivirus. Non-transduced and transduced
MyD88-/- iBMDMs were assessed for MyD88GFP expression using flow cytometry.
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5.3 Discussion
I have developed a protein stoichiometry analysis code that is user friendly and able to analyse
a large number of frames within an image stack, necessary for photobleaching analysis of
proteins within larger complexes. The code includes a number of changeable parameters
such as the threshold for detection of maxima, the threshold for step detection and the method
used to obtain background levels. This analysis code can be applied to any TIRF microscopy
dataset investigating the stoichiometry of proteins close to the coverslip/sample interface.
Mal is the first adaptor protein recruited to a TLR-4 signalling complex upon stimula-
tion with LPS [10, 11, 151, 152]. TLR-4 plays a central role in immunity and has been
implicated in a number of diseases including infection [144], autoimmunity [116, 117, 94],
cardiovascular disease [148, 149] and cancer [150]. A comprehensive knowledge of the
signalling complexes that form upon stimulation of TLR-4 with different ligands including
the stoichiometry of these complexes is of vital importance for design of targeted therapeutics.
I have applied this newly developed code to determine the stoichiometry of Mal at the plasma
membrane and determine whether the stoichiometry changes over time upon stimulation with
LPS. In order to do this I have developed a lentiviral transduction experimental cell model to
visualise fluorescently labelled Mal. A halotag was genetically attached to the C-terminus
of Mal. The halotag covalently bound the R110-HALO dye enabling a one-to-one ratio of
protein to fluorophore, an absolute requirement for stoichiometry analysis.
Computer analysis of the photobleaching trajectories obtained provides a comparatively
quick method for unbiased photobleaching step detection and step size measurements. Ini-
tially I analysed the obtained Mal photobleaching datasets using a counting code written
by Dr. Weimann [244]. This code was unable to analyse the number of frames needed to
ensure that the photobleaching events of MalHALO were well delineated in order for optimal
detection and ensure that all of the fluorophores were fully photobleached. The combinatorics
produced whilst tracking maxima within the particle detection function was too complex.
In collaboration with Anna Lippert and Sophie Ip I produced a new code to determine the
stoichiometry of Mal. This new code measured the intensity step size of each photobleaching
event to determine a monomer value, the value of a single fluorophore photobleaching. The
total intensity drop present at each fluorescent maxima was divided by this monomer value to
obtain the distribution of Mal complex stoichiometries within the datasets. A caveat of this
method was the lack of a quality control step to ensure that the step sizes used to determine
the monomer value were accurate. As such, I developed a new code - a combination of the
two previous codes. In this new code trajectories were Chung-Kennedy filtered (as in the
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counting code) and the step sizes within trajectories found to have a good fit with the applied
change point finder trace were analysed to determine the monomer value.
There are a number of differences when comparing the analysis methods described above.
Firstly, a major difference between the newly developed code and the counting code is the
method to determine stoichiometry – determining a monomer value to apply to all maxima
versus counting the number of photobleaching steps present at each maxima. Counting the
number of steps present within photobleaching trajectories may appear more effective as the
number of photobleaching events relates to the number of fluorophores present within each
maxima. There are, however, a number of caveats to this method. Firstly, the change point
finder trace applied to each trajectory must be accurately fitted to determine real steps. In
order to determine this is the case, the goodness of fit between the intensity trajectory and
the change point finder trace is determined by analysing the R2 value; an R2 value above
0.95 indicates a statistically significant fit to the data. This process can result in a large
proportion of trajectories being rejected and not analysed further, particularly as trajectories
displaying positive photobleaching steps are also rejected from further analysis. A large
population of fluorescent maxima, therefore, are not being analysed and the resulting complex
stoichiometries determined may not be representative of the entire population. Another
confounding factor is the possibility of multiple fluorophores photobleaching within a single
photobleaching step; the probability of this occurring increases with increasing numbers
of fluorophores present within a single maxima. A single photobleaching event would be
counted as one molecule and the resulting stoichiometry would be an underestimation of the
true stoichiometry. The halotag used for this project can react with a number of different
fluorophores attached to a reactive linker. Staining samples with multiple fluorophores could
reduce the likelihood of more than one fluorophore photobleaching at the same moment
in time. By analysing fluorophores in different channels the stoichiometry of the maxima
being analysed per channel would be effectively reduced. Alternatively, a monomer value
for a single fluorophore photobleaching can be obtained by fitting all step sizes obtained
from trajectories with a good fit to the change point finder trace with a mixed Gaussian
distribution model. The presence of multiple photobleaching events occurring within one
step is not an issue in this scenario as the intensity drop produced would be larger and would
be incorporated into the mixed Gaussian distribution model as part of a Gaussian other than
that corresponding to the monomer Gaussian distribution. Using the monomer value method
to determine stoichiometry enables all fluorescent maxima to be analysed; no data is lost.
The main point of difficulty with using a monomer value to determine complex stoi-
chiometry is determining the monomer value itself. Previous studies have been conducted
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using the intensity value obtained through analysing single fluorophore fluorescence inten-
sity profiles and then applying these values to the experimental dataset [240–242]. This
method, however, does not account for differences in fluorophore environment between the
monomer reference dataset and the experimental dataset. For example, the distance from
the sample/coverslip interface would affect the intensity value measured. The environmental
context of the fluorophore could also affect the intensity value measured. For example,
nearby molecules could result in quenching of fluorescence. In the analysis method presented
here, the monomer value is obtained from within the experimental dataset, avoiding these
confounding factors. For example, it is possible that addition of LPS could somehow affect
the fluorescent intensity of the R110 fluorophore. Determining the monomer value from
within the experimental dataset ensures a more accurate stoichiometry is obtained. This
current code iteration assumes that fluorophore fluorescence displays a Gaussian distribution.
It is possible, however, that this is not the case [249]. It has been proposed that fluorescent
intensity follows a Lognormal distribution. The step sizes determined within this dataset
appear to fit a mixed Gaussian distribution rather than a single Lognormal distribution, unlike
that determined by Mutch et al. [249]. Mutch et al., however, do not present photobleaching
data that resolutely determines that the fluorescent maxima they take to be their singly
labelled population are indeed true monomers and display a single photobleaching step.
The pipeline for the new code analysis was based on that of Chen et al. [243]. A key
difference between the analysis pipeline used by Chen et al. and the methods described
here is the determination of change points within the trajectories. Chen et al. considered
two different methods. Using the t-test or BIC to determine the position of steps within
trajectories. Both of these methods required no parameter input by the user and assumed that
the data was a step function hidden under Gaussian white noise. Firstly the variance of this
noise was calculated. For the t-test based method, the trajectory analysed was split into every
possible combination of two sections, and the difference of the means was calculated. If
there was a significant difference of the mean compared to the normal distribution expected
then the two sections were determined to be separate plateaus, and thus a step was present
there. This process was then repeated again on the two newly defined plateaus and so on until
no more plateaus were determined. Only a single most significant difference of the mean
was considered significant during each round of fitting. They also applied this method whilst
considering that variance would change throughout the trajectory, using the same method
described above but comparing for differences in variance, not in the means. Once all of
the sections had been discovered that differed in variance the same method of step detection
described above was carried out taking into account the changes in variance determined. The
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other method described was using the BIC value to determine the position of steps, a method
first described by Kalafut & Visscher [250]. This method modelled the whole trajectory
containing one step, with all possible positions of that step considered. The model with the
best BIC value for step position was determined. This model was then compared to a model
of the trajectory containing no steps. If the model with a step had a better BIC value than
the model for no steps, the position of the step was indexed and the process was repeated to
find a second step. All models possible containing the first indexed step and a second step
were compared. The model with the lowest BIC value was chosen and compared against
the model of the trajectory containing one step. If the model with two steps had a better
BIC value than the model with one step then the second step position was indexed and the
process continued until the situation where a model with n+1 steps no longer had a better BIC
value than a model with n steps. Chen et al. also implemented this method taking variance
into account. Photon counts are best measured as a Poisson distribution; the assumption of
white noise and the fluorescent signal being defined as Gaussian was justified due to noise
within the signal created by fluctuating background intensities and fluorophore blinking as
well as due to noise from the camera. The method determining step sizes using the t-test
accounting for differences in variance was considered best when analysed to use simulated
photobleaching data. This was due to its increased precision for identifying correct steps,
displaying a reduced identification of false positive steps [243]. Although the accuracy of
step positions were measured, accuracy of the plateaus on either side of the steps to the raw
intensity trajectory data was not measured. Thus, for analysis dependent on accuracy of step
size, it is possible that although the positions of steps were accurately determined, the step
heights defined were not as accurate as possible.
In comparison to these methods, the change point finder function used here was based on
the algorithm determined by Boudjellaba et al. [248] and Watkins & Yang [247] [244]. This
method contains user-defined parameters, that of LM threshold – the threshold above which a
step is determined significant and of window size, the smallest window of trajectory used for
analysis [244]. This method first analysed the whole trajectory and used the log-likelihood
ratio to determine a position in the trace with the most significant ratio. If, at this position,
the LM ratio determined was larger than the user-defined LM threshold the position was
considered a step. The trajectory was then scanned from the start of the trajectory until this
defined step to determine the position of a step within this window until the window size for
analysis was too small. Then the code analysed between defined steps to determine whether
there were any steps in-between which had a significant LM ratio value [244]. This method
does not assume that noise fits a Gaussian distribution, but instead applies the assumption that
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detection of photons within a period of time is governed by Poisson probability distribution.
Furthermore, trajectories were then analysed for the goodness of fit between the change point
finder trace and the filtered intensity trajectories [244]. Therefore, only trajectories with a
statistically significant good fit were further analysed to determine the monomer step size
intensity drop, improving accuracy.
A key element to this method was determining the correct LM threshold value in order
for the change point finder function to correctly determine the position of photobleaching
steps within an intensity trajectory. It is possible to use the R2 value to determine which
LM threshold value results in the best fitting change point finder traces. Decreasing the LM
threshold value, however, increases the likelihood of false positive steps being assigned to
the intensity trajectory of a sufficiently small size within the range of fluorophore noise that
they may not result in a low R2 value. This thesis describes a method for determining the
optimal threshold value to use for this analysis pipeline. Firstly, the intensity trajectories
need to be analysed using a range of LM threshold values. The higher the LM threshold
value, the more trajectories that are discarded based on the R2 value. The trajectories with
an R2 value of 0.95 or more are then analysed further by measuring the size of the step
intensity drops. Interestingly, the trajectories that fit this criteria displayed a similar total
intensity drop profile as that of all trajectories, contrary to my hypothesis that maxima with
higher intensities were likely to be discarded based on R2 value. Once the step sizes have
been determined, a Gaussian distribution model then needs to be applied to the datasets to
determine the monomer value. Histograms of the step sizes determined using each threshold
should be overlaid to determine whether there are common Gaussian peaks associated with
each threshold. I found that there was indeed a common peak associated with all of the
thresholds analysed, and that after a LM threshold of 300, this peak corresponded with
the first peak within the Gaussian distributions determined. Over all thresholds this peak
was also the most frequent. I propose, therefore, that the lower threshold values resulted in
false positive steps of smaller size being detected, thus skewing the monomer value to an
inaccurate smaller value. As such, a comparison of multiple thresholds on the step sizes they
produce rather than the number of trajectories kept or discarded based on R2 value provides
a better measure for determination of which threshold is optimal for analysis.
As described above, the monomer value needs to be determined within a step size data set
containing step sizes of increased intensity due to more than one fluorophore photobleaching
at the same time. Application of a mixed Gaussian distribution model can determine the
monomer value by applying differing numbers of Gaussian distributions to the data set. The
model providing the best fit to the step size dataset can be determined and the value of the
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Gaussian distribution with the lowest mean value is determined to be the monomer value. The
fitgmdist function in MATLAB was first used to determine the monomer value. The ability
to change parameters for fitting models within this function was limited. The ‘mixtools’
package in R, previously used for this purpose by Chen et al. [243] was applied to analyse
the step size dataset. Sophie Ip wrote a script in R that fitted the step size datasets with a
number of models containing differing numbers of Gaussian distributions. Primarily the
model was determined using the AIC value; the lower the value the better fit between the
model and the data. Use of the AIC value was replaced by the BIC value, as this value more
heavily penalises the number of parameters used within a model.
Once the monomer value had been determined, the next step was to apply it to the maxima
intensity values. In order to do this the total intensity drop present at each maxima needed to
be determined. This was calculated by subtracting the background value from the maximum
intensity value. Determining both of these values is important for an accurate calculation of
complex stoichiometry. The initial intensity value provided within the first image has been
used as the maximum intensity value for similar studies [243]. Use of the first intensity value
provides an unbiased approach and this value usually correspond to the highest intensity
value present within the trajectory. The frame-to-frame variations at the beginning of a
trajectory, however, are too large to rely on a single value. Also, as demonstrated within this
chapter, it is possible that the blinking behaviour of fluorophores results in the true maximum
intensity occurring within the trajectory. In order to capture all true maximum fluorescent
values the maximum fluorescent value from within the trace was used. An issue with using
the maximum value is that it will result in an overestimation of stoichiometry. Fluorescence
fits to a Gaussian distribution, there is noise around a mean; the intensity oscillates above and
below a mean intensity value. Using the maximum value will not, therefore, capture the true
mean value of fluorescence. In order to combat this issue, trajectories were Chung-Kennedy
filtered in the combined code, a combination of code written by Laura Weimann [244] and
the code developed in this chapter. This process reduces the noise found within a trajectory.
Using the maximum value in a Chung-Kennedy filtered trace should decrease stoichiometry
overestimation. The highest value of the change point finder trace was not used as trajectories
without a good fit between the change point finder trace and the intensity trajectory would
need to be excluded from the analysis.
Determining the value of background fluorescence is also critical for accurate stoichiom-
etry analysis. A number of methods to determine this value have been pursued in this
thesis. These include using the average fluorescent intensity of the last 100 frames of each
trajectory, using an average of the average fluorescent intensity of the last 100 frames across
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all trajectories, and using a defined area present within the image that does not contain
fluorescent molecules. The blinking behaviour of fluorophores can also result in incomplete
photobleaching at the end of the intensity trajectory. In order to overcome this, using an
average of the lowest 100 fluorescence intensity values within a trajectory was considered.
This would, however, result in a too low intensity value, not capturing the mean background
intensity value. Use of a 20x20 pixel square from each of the four corners of an image was
therefore used to determine the background value. Use of background within the image rather
than trajectories negates the potential for incomplete photobleaching whilst providing an
unbiased method to determine background fluorescence. This method was not implemented
into the combined code pipeline due to time restraints and is part of my ongoing work. Using
the lowest value of the change point finder trace was also considered although this method
would rely on the trace fitting the intensity trajectory well; therefore some trajectories may
have needed to be discarded.
Now that a functioning code has been produced the next step is to determine the accuracy
of this code. Simulation studies in collaboration with Sophie Ip are about to be undertaken to
analyse how well the code can analyse datasets of varying quality and datasets containing
various fluorophore stoichiometries. Attempts to analyse proteins of known stoichiometry
in the Mal-/- iBMDM background was unsuccessful. Another approach would be to label
DNA molecules with a known number of fluorophores [251] and analyse whether the code
correctly determines the number present.
Another important consideration when conducting this type of analysis is that of labelling
efficiency. Labelling efficiency can be determined by dividing the molar concentration of
the fluorophore by the molar concentration of the molecule of interest [208]. This method,
however, only works in in vitro systems where the molar concentration of each can be
measured. Coincidence detection of antibody labelled protein and halotag or snaptag dye
has also been proposed as a measure for labelling efficiency [209]. Latty et al. used CD86,
a monomeric protein, with a halotag or snaptag attached and measured the coincidence
between stained CD86HALO or CD86SNAP with fluorescently labelled α-CD86 antibody.
This method, however, has a number of caveats. Firstly, labelling efficiency of α-CD86
antibodies themselves with Alexafluor fluorophores was measured to give a mean labelling
efficiency, whether more than one fluorescently labelled antibody was present within a
diffraction limited maxima was not assessed. Secondly the labelled antibody was used
at a concentration of 100 µg/ml to ensure saturation and monovalent binding; this high
concentration, however, could also lead to off-target binding. Thirdly the on-off binding
rate/labelling efficiency of the antibody itself was not considered. Furthermore, it is possible
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that more than one CD86 molecule was present within the diffraction limited maxima. My
work has shown that it is possible to have more than one CD86 molecule present in a
diffraction limited maxima in Mal-/- iBMDMs. Diffraction limited maxima represent a 200
nm wide area within the plasma membrane. Although CD86 is monomeric it is possible that
they are present at the plasma membrane within 200 nm proximity. This may not be the case
in HEK293T cells; Latty et al., however, did not assess this in their analysis. Should a stained
CD86HALO/CD86SNAP molecule coincide with a labelled α-CD86 antibody, therefore, it is
unclear whether a single antibody is labelling a single CD86 molecule, rendering it difficult
to estimate the labelling efficiency of the halotag or snaptag. Another factor to consider when
analysing labelling efficiency is that fluorescent proteins may not fluoresce within living
cells either due to misfolding or incomplete “maturation” into functional fluorescent proteins
within a cell [252]. Some authors have addressed issues with labelling efficiency through the
statement that stoichiometry detected determined the minimal stoichiometry of a complex
[237]. Chen et al. also circumvented this issue by determining the “lower limit” of complex
size when using fluorescently tagged proteins [243].
Once the labelling efficiency has been estimated, the observed stoichiometry can be
corrected. The question of Mal labelling efficiency has yet to be addressed. A proposed
method was by using fluorescently labelled antibodies that recognise Mal and determining
whether the above data can be replicated. Antibodies, however, have on-off binding rates that
would need to be accounted for. Also, it is possible that the binding epitope may be disrupted
upon stimulation with LPS. Another issue would be determining the labelling efficiency of
the antibody itself.
Development of a lentiviral transduction experimental cell model to visualise fluorescently
labelled Mal enabled the stoichiometry of Mal within this context to be elucidated. There
is, however, room for improvement within this model. Lentiviral transduction is a widely
used method for introducing genetic constructs to be expressed in cell models. Lentiviral
transduction, however, has its caveats. Firstly, transduction efficiency can be an issue. Ideally
all cells within a transduced population would have the same expression levels of the gene
of choice, but this is rarely the case; lentiviral transduction results in a mixed population of
cells with respect to their expression levels and not every cell is transduced either. In the
method described here, I have used a dilution (1/10 for Mal) of the lentiviral supernatant
produced each time that the experiment has been conducted; the exact amount of lentivirus
used was not quantified. Quantification of lentivirus may improve consistency between
experiments of cell transduction levels. Sorting successfully transduced cells using flow
cytometry so that only cells expressing appropriate levels of MalHALO are stimulated and
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imaged has also been considered. Flow cytometry based sorting, however, would have to
be conducted on the day of cell stimulation and imaging and may affect cellular behaviour.
The staining assay would need to be optimised accordingly but this is being considered
for future application of this work. In my analysis, only successfully transduced iBMDMs
with expression levels that enabled individual fluorescent spots to be detected were imaged
and used for analysis. Cells expressing high levels of MalHALO were unsuitable for this
analysis; the effects of overexpression were potentially negated by cell selection for imaging.
It is difficult to determine what the physiological expression level of Mal actually is within
iBMDMs due to the lack of useful antibody reagents and the issues with labelling efficiency.
Lentiviral insertion of genetic constructs may also affect expression of other endogenous
proteins, as the insertion is not directed. A mixed population of transduced iBMDMs was
analysed; each successful transduction insertion event may have occurred at different places
within the genomes of different cells, affecting cellular function. In order to negate these
issues, I have prepared reagents to apply two different methods of MalHALO expression for
image analysis. I have modified a fosmid (a large stable vector) to contain MalHALO under the
control of endogenous Mal promoters, as described in chapter 6. This fosmid can be inserted
into Mal-/- mESCs using the piggyBAC transposase system. The successfully modified
mESCs can then be differentiated into macrophages, which behave in a similar manner
to BMDMs [253], and undergo the same experimental stimulation assays and imaging as
described above. This would ensure that endogenous levels of Mal are being analysed for
their stoichiometric dynamics. Another avenue is to use CRISPR to endogenously tag Mal
with the halotag within the genome of WT mESCs. I have designed plasmids and gRNAs for
this purpose as described in chapter 6.
Attempts to determine the structure of the Mal TIR domain have been made using crys-
tallography [232, 234], NMR [170] and cryo-electron microscopy [233]. Crystal structures
revealed dimeric Mal TIR domains, monomeric Mal TIR was used for NMR and filaments
of Mal TIR were analysed using cryo-electron microscopy. The stoichiometry of full-length
Mal within the context of a living cell is unknown. The work presented in this chapter
describes the first investigation into the stoichiometry of Mal within the context of a living
cell. Within a living cell all of the cellular machinery is present to enable full-length Mal
to form complexes. Mal undergoes a number of post-translational modifications that may
be important for its physiological stoichiometry that would not necessarily be recapitulated
in vitro. Analysing the stoichiometry of Mal within the context of a living cell also allows
unique investigation into the dynamics of Mal stoichiometry over time upon stimulation with
LPS. Here I have used TIRF microscopy to analyse MalHALO expressing Mal-/- iBMDMs that
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have been stimulated with LPS and fixed at different time points post stimulation. Diffraction-
limited fluorescent maxima were analysed – it is important to consider that fluorophores
within approximately 200 nm will be visualised as a single maxima. Therefore, this analysis
may be defined as the stoichiometry of Mal clustering rather than the stoichiometry of Mal at
a single signalling TLR-4 complex. In order to determine the ratio of Mal to TLR-4, TLR-4
molecules would also need to be labelled. We currently do not have Tlr-4-/- Mal-/- iBMDMs
that would be required for this investigation. I have, however, been able to demonstrate that
the stoichiometry of Mal within approximately 200 nm regions of the plasma membrane
do in fact change over time with stimulation of LPS. The first code able to fully analyse
the data (new code) determined a birfucation after 5 minutes stimulation with 10 ng/ml
LPS to stoichiometry of 6 and 12 Mal molecules. This was incredibly interesting as it
nicely mirrored the stoichiometry of MyD88 within the crystal structure of the myddosome
indicating a possible 1:1 ratio of Mal to MyD88 [45]. Six MyD88 molecules are present
within the myddosome; the observed Mal stoichiometry could indicate maxima containing
1 or 2 separate TLR-4 signalling complexes present respectively. It is also possible that
the maxima displaying 12 Mal molecules could represent the aggregation of two TLR-4
signalling complexes into a single signalling platform. Another scenario is that a single
TLR-4 signalling complex is able to form myddosomes of higher stoichiometry, or that the
ratio of Mal to MyD88 within a signalling complex is not 1:1. As promising as this result
was, I decided to improve the new code by making it more robust. This led to the creation
of the combined code – a code that utilised the Chung-Kennedy filtering method of the
first counting code [244] and the monomer determining strategy of the new code. Using
this new code Mal molecules bifurcated to structures of roughly 8 and 16 after 5 minutes
stimulation with 10 ng/ml LPS. This result is more robust due to the quality control measures
implemented into the combined code – only trajectories with a good R2 value when compared
to the change point finder trace are used for determining the monomer value. The choice
of threshold was more robust also through analysing the size of the steps generated when
using multiple different thresholds. The values 8 and 16 indicate that signalling complexes
may be constructed out of Mal dimers interacting at the same TLR-4 signalling complex.
Until the stoichiometry of TLR-4 is determined at these maxima the stoichiometry of Mal
at TLR-4 signalling complexes is unknown. It has been proposed that the formation of
larger oligomeric platforms, termed “signalosomes”, may provide a threshold for TLR signal
transduction [254]. Endogenous TRAF6 forms patches at the plasma membrane upon stimu-
lation with LPS [255, 254]. It is possible that TRAF6 bound to multiple activated TLR-4
complexes form these patches creating a network of activated receptors all interlinked [254].
5.3 Discussion 165
This level of interconnectivity has also been proposed to occur at the level of myddosome
formation. Mal dimers bound to different TLR-4 TIR domains may facilitate the formation
of myddosomes between multiple active TLR-4 signalling complexes, providing a bridge
between multiple activated complexes [256]. These proposed processes could account for
the increased stoichiometry of Mal observed upon stimulation with LPS. In such a scenario,
the lines between a single activated complex and that of clustering becomes blurred, as it is
possible that the network created between individual complexes comprises the actual active
signalling complex, once a threshold of activation has been reached.
The change in stoichiometry from approximately 10 Mal molecules during unstimulated
conditions to the bifurcation described and then return back to 10 Mal molecules per maxima
suggests active complex formation upon induction of TLR-4 signalling. Mal is not present at
the plasma membrane in pre-formed signalling complexes, although it is likely that Mal is
dimeric at the plasma membrane on the basis of structural studies of the Mal TIR domain.
Active production of PI(4,5)P2 upon CD14 binding LPS [39] may account for this change
in Mal distribution. Mal may move from defined lipid rafts within the plasma membrane to
areas of greater PI(4,5)P2 concentration, allowing its movement to activated TLR-4 signalling
complexes. Application of PALM may provide an answer to whether the maxima observed
represent clusters of Mal within a 200 nm radius or a single active signalling complex. As
Mal is attached to a halotag, a different fluorophore dye can easily be applied for this analysis.
Unfortunately the importance of defined residues within the TIR domain of Mal was
unable to be analysed within this experimental model. The mutants R121A, P125H and
F193A were cloned into the pHR:HALO vector used for these experiments. I demonstrated
that F193A was able to induced NF-κB activation in an overexpression HEK293 assay, whilst
R121A and P125H were unable to. This nicely corroborates data previously determined
that mutants R121A and P125H, but not F193A, disrupted MyD88 clustering in HEK293
cells [233]. Unfortunately I was unable to transduce Mal-/- iBMDMs to allow stoichiometry
determination by TIRF microscopy.
A benefit of the analysis method described above is that it can be applied to any photo-
bleaching data obtained using TIRF microscopy. Any protein present at the plasma membrane
of a living cell can be analysed by this method. I decided to apply this method to investigate
the stoichiometry of MyD88 and formation of the myddosome upon stimulation with LPS. I
was able to successfully transduce MyD88-/- iBMDMs with pHR:MyD88GFP. Investigating
the stoichiometry of MyD88 upon stimulation with LPS is part of my ongoing work.
Having developed the appropriate code to analyse data obtained, experiments need to
be repeated again using the same experimental set up. The time points 5 and 10 minutes
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need to be analysed without LPS stimulation to conclusively determine that the change in
stoichiometry is a consequence of LPS stimulation and not the length of time a cell has had
to settle on the coverslip for imaging. Also, lower concentrations of LPS should be used
to determine whether this delays complex stoichiometry formation. Unfortunately during
this work the TIRF microscope used underwent a number of modifications, such as the
changing of CCD cameras. The data sets presented are comprised of a representative control
dataset imaged using a 20 mW laser, an exposure of 35 ms, 70 ms or 100 ms over 700
frames. The camera was then changed. This new camera was used to collect the data set
presented here using the new code and the combined code. The dataset comprised of 2500
frames, using exposure of 35 ms and a 0.4 neutral density filter. Unfortunately before repeats
could be obtained the camera was changed once again. Obtaining biological repeats of Mal
stoichiometry experiments is part of my ongoing work.
Chapter 6
Creation of Reagents
6.1 Introduction
6.1.1 CRISPR technology
The Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated
(Cas) loci is a defensive mechanism within the genome of bacteria; CRISPR-Cas provides
acquired resistance against viruses [257]. CRISPR loci are composed of non-contiguous
repeats separated by spacers of variable sequence and length and are often situated next to
Cas genes. Using Streptococcus thermophilus it was demonstrated that sensitivity to viruses
correlated with the spacer content within the CRISPR1 locus. When challenged with a virus,
bacteria incorporate new spacers encoding some of the viral genome at the leader end of
CRISPR loci. Cas5 was suggested to be critical for protection, possibly through nuclease
activity [257]. It was subsequently discovered that this system could be used to cleave
DNA through use of a guide CRISPR RNA (crRNA) in cooperation with the Cas9 enzyme
found in Streptococcus pyogenes [258]. The crRNA base pairs with a transactivating RNA
(tracrRNA); this complex then binds to Cas9 which cleaves DNA strands complementary
to the crRNA next to a protospacer adjacent motif. This process results in a double strand
break in the DNA. The crRNA and tracrRNA can be combined into a single RNA chimera
(guide RNA; gRNA), which can also induce DNA strand cleavage [258]. The Cas9 nuclease
of S.pyogenes type II CRISPR system has been modified so that it can perform this function
within eukaryotic cells [259, 260], opening up a world of genomic editing possibilities. A
number of modifications to improve Cas9 specificity and technologies to improve gRNA
design have also been developed [261].
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Of particular interest is the use of CRISPR-Cas9 in genetic screens [262, 263] and as
a method to incorporate tags into the genome [264]. Two different pathways can repair
DNA double strand breaks in mammalian cells; non-homologous end joining (NHEJ; an
often imprecise repair mechanism resulting in insertions and deletions) or homology-directed
repair (HDR) if a homology template is available. The former pathway is of use when
conducting loss-of-function genetic screens to determine which genes are necessary for a
certain function as minor insertions and deletions often disrupt gene function, whilst the latter
pathway is useful for tagging endogenous genomic loci with tags provided on a template.
NHEJ, however, can also be utilised for tagging endogenous loci [264].
6.1.2 Genetic recombineering
Another method for tagging genes is by recombination-mediated genetic engineering (re-
combineering). Recombineering allows genetic modification of sequences within bacterial
artificial chromosomes (BACs) or fosmids without the need for restriction digestion or DNA
ligation. This is particularly useful when trying to modify large stretches of DNA where
restriction digestion sites absent from the sequence of interest may be limiting. BACs and
fosmids, large stable vectors, can be modified within E.coli using lambda (λ ) Red-mediated
homologous recombination [265]. Within the λ Red system, three genes make recombi-
neering possible: exo, that encodes an exonuclease to generate 3’ DNA overhangs, bet, that
encodes a protein that binds to these overhangs and enables homologous recombination
with complementary DNA, and gam, that encodes an inhibitor of the endogenous E.coli
exonuclease inhibitor RecBCD protecting the linear DNA sequence to be recombined. These
three genes are present on a prophage under the control of prophage promoter pL in SW102
E.coli. This promoter is regulated by the temperature-sensitive repressor cI857. This ensures
that the genes necessary for recombineering are not active at 32°C, but are expressed when
E.coli are incubated at 42°C, enabling recombineering to occur [266].
Once a Bac/fosmid has been successfully modified, the piggyBAC transposon system
(identified in the cabbage looper moth) can be used for its insertion into genomic DNA in the
cell of interest [267]. Inverted terminal repeats on either side of the DNA to be inserted into
the genome are recognised by the piggyBAC transposase. Co-transfection of the modified
BAC/fosmid with a helper plasmid encoding the transposase results in the insertion of DNA
of interest into a TTAA site within the host genome in a region enriched with A’s and T’s.
This process results in duplication of the TTAA site. Insertion occurs in transcription units
within the genome. Using this method up to 14kb of DNA can be stably integrated into the
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genome as a single copy that can then be expressed. Inverse PCR can be used to identify the
integration site within the genome, enabling prediction of any insertional effects [267].
This chapter describes the generation of an NF-κB reporter THP-1/Cas9 cell line for use
in genetic screens. This chapter also includes the modification of a fosmid encoding Mal to
express MalHALO under control of the endogenous Mal promoters for use in single molecule
imaging assays.
6.2 Results
6.2.1 Generation of an NF-κB THP-1/Cas9 reporter cell line
In order to conduct a CRISPR screen to determine the components necessary for signalling
downstream of protein activation of TLR-4 I created an NF-κB THP-1/Cas9 reporter cell line.
THP-1 cells expressing Cas9 were kindly provided by Genentech and are hereon referred
to as simply THP-1. Firstly, the THP-1 cells were tested for their ability to respond to LPS
stimulation to determine whether they could be used for TLR-4 signalling assays. THP-1
cells were stimulated with or without LPS (1, 5, 10 or 1000 ng/ml) for 2 or 6 hours. 1000
ng/ml LPS was used as a positive control; a concentration that has been used previously
in the literature to stimulate THP-1 cells and has activated the TLR-4 signalling pathway
[167, 171]. Cellular cytotoxicity and TNF-α production was then measured (Fig. 6.1). In
order to sort cells based on their NF-κB reporter sensitivity it was critical to determine a
concentration of LPS stimulation that would induce NF-κB activation without inducing cell
death.
When THP-1 cells were stimulated for 2 hours, only 1000 ng/ml LPS induced significant
cell death (Fig. 6.1A) and TNF-α production (Fig. 6.1C). However, upon 6 hours stimulation,
10 ng/ml LPS was able to induce significant production of TNF-α (Fig. 6.1D) without
inducing statistically significant cell death (Fig. 6.1B). Therefore, stimulation with 10
ng/ml LPS for 6 hours was chosen for conditions to test NF-κB reporter responsiveness in
transduced THP-1 cell lines and for stimulation conditions to sort positive populations.
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Fig. 6.1 THP-1/Cas9 validation tests to determine conditions for NF-κB reporter THP-
1/Cas9 stimulation. THP-1/Cas9 cells were stimulated with or without LPS (1, 5, 10 or 1000
ng/ml) for A), C) 2 or B), D) 6 hours. A), B) Percent cytotoxicity was measured using the
Promega non-radioactive cytotoxicity assay. C), D) The amount of TNF-α present within the
supernatant was determined by Meso Scale Diagnostics human TNF-α ELISA. Data from a
representative experiment. P-value calculated using one-way ANOVA, **** = p < 0.0001, **
= 0.001 < p < 0.01, * = 0.01 < p <0.05.
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Having determined the conditions necessary to test a THP-1 reporter cell line, THP-1
cells were transduced with lentivirus containing an NF-κB reporter composed of 6 NF-
κB promoter response elements followed by either a blue or red fluorescent protein con-
struct (BFP or RFP). The reporter also contained a puromycin resistance cassette to allow
for positive selection. Positively transduced THP-1 cells were selected by culture with
1 µg/ml blasticidin in the culture medium. The responsiveness of these generated cell
lines (THP-1:BFP and THP-1:RFP respectively) was tested by stimulation with or with-
out 10 ng/ml LPS for 6 and 24 hours (Fig. 6.2). Stimulation of THP-1 with or with-
out 10 ng/ml LPS was used to determine background fluorescence present within the
DAPI and DsRED channels (Fig. 6.2 C and D respectively). The fluorescent intensity
of the cells upon stimulation was analysed using flow cytometry (Fig. 6.2). The percent-
age of BFP and RFP positive cells is outlined in Table 6.1 and Table 6.2 respectively.
Table 6.1 BFP positive cells after LPS stimulation
Cell line LPS (10 ng/ml) Stimulation time (hours) BFP positive cells (%)
THP-1 - 6 0.95
THP-1 + 6 1.79
THP-1 - 24 1.61
THP-1 + 24 9.7
THP-1:BFP - 6 13.8
THP-1:BFP + 6 85.5
THP-1:BFP - 24 13.24
THP-1:BFP + 24 92.31
Table 6.2 RFP positive cells after LPS stimulation
Cell line LPS (10 ng/ml) Stimulation time (hours) RFP positive cells (%)
THP-1 - 6 1.27
THP-1 + 6 2.04
THP-1 - 24 1.65
THP-1 + 24 5.92
THP-1:RFP - 6 3.68
THP-1:RFP + 6 53.01
THP-1:RFP - 24 4.43
THP-1:RFP + 24 74.04
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Fig. 6.2 NF-κB Reporter THP-1/Cas9 LPS stimulation. WT THP-1/Cas9 (THP-1) cells
or THP-1/Cas9 cells transduced with and NF-κB BFP (THP-1:BFP) or RFP (THP-1:RFP)
reporter were stimulated with 0 or 10 ng/ml LPS for 6 or 24 hours. The presence of BFP or
RFP positive cells was then analysd by flow cytometry, A) THP-1:BFP and C) THP-1 were
gated for BFP expression and B) THP-1:RFP and D) THP-1 were gated for RFP expression.
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THP-1 cells displayed a minor increase in fluorescent intensity in both the DAPI and
DsRed fluorescent channels upon stimulation with 10 ng/ml LPS which increased with
time (Table 6.1, Table 6.2 and Fig. 6.2 C and D). THP-1:BFP cells displayed background
fluorescence in unstimulated conditions (13.8% after 6 hours and 13.24% after 24 hours),
although the percentage of BFP positive cells did increase with LPS stimulation after both 6
hours (85.5%) and more so after 24 hours stimulation (92.31%) (Fig. 6.2A).
THP-1:RFP cells displayed less background fluorescence in unstimulated conditions
(3.68% after 6 hours and 4.43% after 24 hours) than THP-1:BFP cells. The percentage of
RFP positive cells also increased with LPS stimulation after both 6 hours (53.01%) and more
so after 24 hours stimulation (74.01%), albeit to a lesser extent than THP-1:BFP cells (Fig.
6.2B).
In order to conduct a CRISPR screen with high confidence the background fluorescence
of cells present in unstimulated conditions needs to be minimal. I therefore sorted the THP-
1:BFP cells without stimulation with background fluorescence present in THP-1 cells to try
and segregate a population of THP-1:BFP with minimal background fluorescence that could
be used for a CRISPR screen (Fig. 6.3A). The sorted population (Fig. 6.3A) was analysed
by flow cytometry after 6 days of culture to determine whether background fluorescence
of the sorted population remained the same or had increased back to the values observed
prior to sorting (Fig. 6.3B). Unfortunately the background fluorescence of the THP-1:BFP
population had returned to that of the unsorted population (18.1% vs. 15.25% previously,
compared to THP-1 0.35% vs. 3.68% previously). As the background fluorescence of the
THP-1:BFP cells was not reduced investigations using this cell line was not continued.
The THP-1:RFP cells displayed much lower background fluorescence than the THP-
1:BFP cells, and the percentage of RFP positive cells increased with LPS stimulation. There-
fore, I decided to stimulate the THP-1:RFP cells with 10 ng/ml LPS for 6 hours, as little cell
death is observed (Fig. 6.1B) and sort for populations of cells expressing low, medium and
high RFP fluorescence (Fig. 6.4). Approximately 8% of the parent population was collected
for each fluorescent intensity population. Due to time constraints this work was taken no
further.
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Fig. 6.3 NF-κB BFP Reporter THP-1/Cas9 cell sort. WT THP-1/Cas9 (THP-1) cells or THP-
1/Cas9 cells transduced with an NF-κB BFP reporter (THP-1:BFP) were assessed for the
presence of BFP positive cells by flow cytometry. A) The parent population of THP-1:BFP
and THP-1 cells were sorted and B) tested 6 days later for BFP positive cells.
Fig. 6.4 NF-κB RFP Reporter THP-1/Cas9 cell sort. WT THP-1/Cas9 (THP-1) cells or
THP-1/Cas9 cells transduced with an NF-κB RFP reporter (THP-1:RFP) were stimulated
with or without 10 ng/ml LPS for 6 hours and assessed for the presence of RFP positive cells
by flow cytometry. RFP positive THP-1:RFP cells expressing low, medium or high levels of
RFP were sorted.
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6.2.2 Modification of a fosmid encoding Mal
At present, single molecule image analysis of Mal stoichiometry has been conducted using
lentivirally transduced Mal-/- iBMDMs. Lentivirus transduction can result in overexpression
of proteins within the target cell, which could have an effect on protein stoichiometry and
inflammatory state of the cell. A method for avoiding possible confounding factors would be
to use cells that have Mal endogenously tagged within their genome or under the control of
the endogenous promoter. I decided to focus on two main methods outlined in Figure 6.5;
using homologous recombination with a fosmid and by directly tagging Mal using CRISPR.
Fosmids can be modified by recombineering and inserted into mammalian cell genomes
using the piggyBac transposase system. Therefore I modified a fosmid containing Mal to
genetically tag the C-terminus of Mal with halotag for insertion into the genome within Mal-/-
mouse embryonic stem cells (mESCs). The reconstituted mESCs can then be differentiated
into macrophages and the stoichiometry of Mal can be determined using TIRF microscopy
and photobleaching analysis. A schematic of the fosmid modification steps by recombineer-
ing is outlined in Figure 6.6.
Fig. 6.5 A schematic of endogenous protein tagging strategies.
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Fig. 6.6 Schematic of fosmid modification. A) The unmodified fosmid, B) removal of exon
1 of Foxred1 and Srpr by addition of piggyBac homology arms (PBHA) and an ampicillin
resistance cassette (Amp), C) insertion of piggyBac inverted terminal repeats (ITR) and a
hygromycin resistance cassette (Hygro) and D) insertion of the halotag to the C-terminus of
Mal and inclusion of a neomycin resistance cassette (Neo) between exon 6 and 7 of Mal.
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The fosmid WI1-508K24 was chosen for modification and was electroporated into
SW102 cells for modification by recombineering. This fosmid also contained the genes
FAD dependent oxidoreductase domain (Foxred) 1 and Signal recognition particle receptor
subunit α (Srpr) (Fig. 6.6A). Foxred 1 is linked to mitochondrial complex 1 deficiency
whilst Srpr is an ER membrane protein, a member of the GTP binding SRP family. In order
to reduce confounding factors due to potentially increased expression of these two genes
upon insertion into the genome, exon 1 of Foxred 1 and the whole Srpr gene was deleted by
insertion of an ampicillin resistance cassette flanked by piggyBac homology arms (Fig. 6.6B).
The Ampicillin resistance cassette was then replaced with the piggyBac inverted terminal
repeats flanking a hygromycin resistance cassette (Fig. 6.6C). Finally, halotag was added
C-terminally to Mal whilst also inserting the neomycin cassette between exon 6 and 7 of Mal
to enable selection of positively reconstituted mESCs (Fig. 6.6D). After every modification
event the fosmid was checked for correct insertion by restriction digest. This modified fosmid
is now ready to be used for electroporation of mESCs. Due to time constraints this work was
not taken further.
CRISPR can also be used to directly genetically tag endogenous genes within the genome.
The homology plasmid containing a section of exon 7 and halotag has been designed and
gRNA guides have been designed that are ready for use in mESCs.
6.3 Discussion
New technology and techniques are continually being developed enabling new experiments
to be conducted and previous methods to be improved upon. The advent of CRISPR-Cas9
technology revolutionised the modern field of genetic engineering enabling more specific
and malleable systems to carry out genetic modifications. As such, it is important to apply
advancing techniques to experimental procedures currently in use to ensure that the best
possible experimental system is being used to answer hypotheses.
I have developed an NF-κB RFP reporter THP-1/Cas9 cell line. This cell line will be of
great use for conducting CRISPR screens to determine the components needed for protein
ligands to signal via TLR-4. This reporter cell line can be easily used for this purpose as
RFP expression can be visualised using flow cytometry, and the populations of interest can
be sorted to determine which genes were disrupted to produce the phenotype. I sorted three
differently expressing pools of NF-κB RFP reporter THP-1/Cas9 cells; high, medium and
low expressing cells. These three pools should provide a range of sensitivity. For example,
using the high expressing cells it will possibly be easier to pull out populations of cells that
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have lost RFP expression due to gene disruption, corresponding to positive regulation, whilst
using low expressing cells it may be easier to pull out populations of cells that have gained
RFP expression due to gene disruption, corresponding with disruption of negative regulatory
proteins. The middle expressing population should hopefully provide a window to cover
both of these scenarios. Due to time limitations it has yet to be verified that the populations
sorted still behave in the same way, as the THP-1:BFP cells sorted that were negative for
BFP regained background fluorescence after 6 days culture. Currently the transduced cells
have been pooled, trying to capture cells with a similar fluorescent profile. This method was
chosen due to time limitations. Single cell cloning may provide more robust populations
with similar expression levels, and prevent confounding results such as different cells having
the reporter located in different regions of their genomes.
Another main avenue of interest is determining protein stoichiometry of signalling
complexes over time in response to stimulation. Currently, I have utilised Mal-/- iBMDMs
that have been lentivirally transduced to express MalHALO for this purpose. However,
lentiviral transduction has a number of caveats. Expression levels in cells vary upon lentiviral
transduction, either by some cells being transduced by more than one lentivirus particle or by
insertion of MalHALO in a more readily transcribed area of the genome. Furthermore, the
transduction efficiency when using the viral concentration necessary for optimal imaging
can be low. It is also possible that the MalHALO construct may be inserted into a part of the
genome that disrupts the function of surrounding genes. Furthermore, the MalHALO construct
currently being used is not under the control of the endogenous Mal promoter, therefore
ensuring expression levels are similar to that of physiological conditions is challenging. Given
these challenges associated with lentiviral transduction, I have produced a modified fosmid,
containing MalHALO with the endogenous Mal promoters present that can be inserted into
the genome of mESCs using the piggyBac transposase system. This system will ensure that
expression of Mal should be similar to that of endogenous levels of Mal. The reconstituted
Mal-/- mESCs will then be differentiated into macrophages for stimulation and imaging.
However, this method still has the caveat of undirected insertion into the genome (albeit at
TTAA sites). Therefore, I have also designed the homology plasmids and gRNAs necessary
to insert the halotag to the C-terminus of Mal within the genome of WT mESCs using
CRISPR/Cas9 technology.
Chapter 7
Discussion
TLR-4 plays a central role in immunity and as a consequence must be tightly regulated;
TLR-4 mediated signalling is critical for combating infections but excessive TLR-4 activation
can lead to sepsis or drive other pathological processes such as autoimmune diseases and
cancer. For example, TLR-4 is crucial for the control of Gram-negative bacterial infections
through recognition of LPS such as for control of Salmonella infection in mice [144, 145].
Excessive TLR-4 signalling in response to LPS, however, can also lead to endotoxic shock
whereas mice with defective TLR-4 signalling are protected from endotoxic shock [21, 146].
TLR-4 signalling has also been implicated in the pathology of a number of autoimmune
diseases including Scleroderma [116] and Rheumatoid arthritis [117, 94] and in cancer and
cardiovascular disease [148–150]. Given the involvement of TLR-4 with respect to many
different types of pathology, knowledge of how it’s signalling is governed by different ligands
and how it functions in different cell types is of critical importance for effective therapeutic
targeting and disease symptom amelioration.
The aim of this PhD was firstly, to determine whether different protein fragments within
ECM proteins activate TLR-4 signalling. Secondly to develop methods for producing
endotoxin-free fragments which could be used for TLR-4 activation experiments. The final
aim of this PhD was to develop an analysis pipeline for determining the stoichiometry of
proteins at the plasma membrane in order to investigate changes in the stoichiometry of the
TLR-4 signalling complex upon ligand stimulation.
The TLR-4 signalling pathway has been extensively investigated but there is much
that remains uncertain. In particular, TLR-4 signalling in response to DAMPs has come
under recent investigation. Domains within the ECM proteins FN and tenascin-C have been
shown to activate TLR-4 signalling. Both of these proteins play crucial roles in normal
physiology. FN is a major component of the ECM and is required for ECM deposition and
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retention of type I and III collagen [97–99]. FN is also required for embryogenesis [100],
maintenance of tissue integrity and wound healing [101]. Unlike FN, tenascin-C is minimally
expressed in adults, although it’s expression is induced by pathological stress [225], but is
present during embryogenesis [128]. Different isoforms of tenascin-C may confer different
roles, promoting either cellular attachment or migration [138]. Although both of these
ECM proteins play crucial roles during normal physiology they have also been implicated
as having deleterious effects in autoimmune conditions. For example, FNIII1c induces
inflammatory gene expression in dermal fibroblasts [120, 124] and has been implicated in
cytokine expression within a lung tumour environment [216]. FNIII13-14 has been implicated
in RA [121]. FNIIIEDA has also been implicated in RA [117, 119], scleroderma [116]
and allergen induced airway hyper-responsiveness and fibrosis [126]. The FBG domain
of tenascin-C has also been implicated in RA [94] and systemic sclerosis [140]. The FN
fragments mentioned above and the tenascin-C FBG domain have been shown to activate
TLR-4 signalling and that this signalling plays a role in the aforementioned pathologies.
However, the exact mechanism underlying these signalling events is unclear. In this thesis I
have confirmed that FNIII1c, FNIII13-14, FNIII9-E, FNIII9-E-14 and FNIIIEDA and the tenascin-
C FBG domain do induce TLR-4 activation using a transient transfection HEK293 assay
and preliminary studies using iBMDMs and G9 cells. I have also shown that mutant FBG
domains with an ablated TLR-4 binding site in loop 5 (Mut3) and a truncated C-terminal
tail (Mut5) or mutated residues in loop 7 (Mut7) are still able to activate NF-κB using a
transient transfection HEK293 system, albeit to a lower extent than WT FBG, suggesting
that sites other than the binding site located in loop 5 within the FBG domain are responsible
for TLR-4 activation. I have laid the groundwork for future studies into their mechanism of
action such as by exploring the effects that they have on NF-κB translocation events and
on stoichiometry of the TLR-4 signalling complex. I have also laid the groundwork for
producing FN fragments using HEK293T cells. A Gaussia luciferase signal peptide sequence
ensures that the FN fragments are secreted into the supernatant. Due to time limitations,
however, I was not able to pursue this further.
The signalling response of TLR-4 depends on both the activating ligand and the cellular
context within which the signalling event is taking place. It is possible that depending on
both of these contexts different co-receptors may be recruited. Different co-receptors may
direct preference for ligands to signal via different arms of the TLR-4 pathway or may induce
a novel signalling cascade that interacts with the classical TLR-4 signalling pathways. For
example, FBG is only able to induce IL-6 production in synovial fibroblasts whilst LPS
is able to induce both IL-6 and IL-8 [94]. Different co-receptors may alter transcription
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factor availability for gene expression. FNIII1c is unable to induce proMMP-9 expression in
THP-1 cells whilst FNIIIEDA is able to [83]. It is possible that FNIII1c induces a different
cellular expression output compared to FNIIIEDA. Cell type also plays a role in the ability
of FNIII1c to induce cytokine expression. FNIII1c induces production of IL-8 in human
dermal fibroblasts via TLR-4 [124], but induces IL-8 expression in human lung fibroblasts
via TLR-2 [216]. It is possible that different co-receptors present on these different cell
types may determine which signalling pathway FNIII1c activates. The work in this thesis
describes the generation of an NF-κB reporter cell line based on a THP-1/Cas-9 background
for use in a CRISPR screen to allow full delineation of the co-receptors and proteins involved
in signalling induced by the aforementioned DAMPs. Ideally, stimulation studies of all of
the DAMPs on a range of different cell types need to be assessed to gain clarity on how
signalling induced by these different fragments differs in the response generated by each
fragment and how the response differs across different cell types. Creation of a Cas-9/NF-κB
reporter mouse would enable extraction of multiple different cell types from the same genetic
background. This system would enable a comprehensive analysis of cell-type specific protein
requirements for signalling. Of interest would also be to create a Cas-9/IRF reporter for
a more comprehensive analysis of signalling components required for TRIF activation of
TLR-4 in response to an array of different ligands.
Improved knowledge of the specific signalling components necessary for TLR-4 sig-
nalling downstream of a number of different ligands enables the creation of targeted ther-
apeutics. In an ideal scenario, deleterious TLR-4 signalling pathways could be targeted
whilst leaving the crucial infection detection pathway intact. Should it be determined that
TLR-4 signalling downstream of different DAMPs requires unique subsets of proteins it will
be possible to target these proteins specifically whilst retaining the bodies ability to detect
bacterial infection. This targeted development of therapeutics could have wide-reaching
effects over a number of pathologies, vastly improving the lives of patients.
Given the importance of TLR-4 signalling in a range of diseases, a comprehensive
knowledge on the signalling complexes formed in response to different ligands is critical. It
is possible that different ligands induce different stoichiometry of proteins within the TLR-4
signalling complex. Should this be the case it may be possible to design therapeutics that
target specific protein interaction interfaces that would abolish pathological TLR-4 signalling
causing disease whilst leaving the ability to detect infection in tact. X-ray crystallography and
electron microscopy provide vital insights into the nature of protein interactions and potential
signalling complex structure. Signalling within living cells, however, is a dynamic process
involving complex formation, phosphorylation and degradation events ultimately resulting in
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transcription factor translocation. Within in vitro systems, all of the components necessary for
physiological complex formation may not be present. This thesis describes the development
of an experimental cell model to visualise Mal at the plasma membrane and an accompanying
analysis pipeline to ascertain the stoichiometry of proteins within a signalling complex at
the plasma membrane from photobleaching datasets produced using TIRF microscopy. This
method determines protein stoichiometry by measuring the size of each photobleaching event,
fitting these step sizes to a Gaussian distribution model to calculate the monomer value and
using the monomer value to determine the number of proteins within fluorescent maxima.
Using this approach it is possible to detect changes in stoichiometry of proteins within a
living cell over a period of time. The ability to analyse stoichiometry within living cells
ensures that all of the cellular machinery that may impact upon this stoichiometry is present.
Furthermore, it provides an insight into the dynamic nature of signalling complexes present
within cells and the time scales within which signalling events occur. I have demonstrated
that the stoichiometry of Mal changes at the plasma membrane upon stimulation with
LPS. The stoichiometry of Mal detected was of even numbers, suggesting that the dimers
determined using X-ray crystallography methods [232, 234] may be present within the
signalling complexes. Although the production of large Mal complex sizes were detected
after 5 minutes stimulation with 10 ng/ml LPS, the formation of filaments described by Ve
et al. [233] is unlikely. It is possible that multiple active signalling complexes are present
within 200 nm at the plasma membrane resulting in the large number of Mal molecules
detected at a maxima. In order to further advance this work experimental repeats need to be
conducted. Experiments using different ligands should be conducted to assess whether the
stoichiometry of Mal observed upon stimulation with LPS demonstrates a general clustering
mechanism of Mal in response to ligands or whether the stoichiometry induced is specific to
the specific ligand or receptor. This method can potentially be used to analyse stoichiometry
of any plasma membrane protein so could be applied to analysis of both TLR-4 and MyD88
stoichiometry upon stimulation. Moreover, this approach also allows the probing of protein
interfaces involved in complex formation through analysis of proteins containing mutations
and the effects these may have on stoichiometry in resting cells and upon stimulation. This
method can also be used for assessment of the mechanism of action of therapeutic drugs
targeted at proximal membrane signalling components. The methodology and analysis
pipeline described within this thesis provides a powerful tool for investigating the dynamic
nature of signalling complexes in response to different ligands and how therapeutics may
interfere with this process.
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A current issue with the experimental model used in this thesis is that it requires lentiviral
transduction of a tagged construct of the protein of interest into iBMDMs. In this thesis I
have described the modification of a fosmid containing Mal that can be used for insertion
using the piggyback transposase system into Mal-/- mESCs. This system will allow MalHALO
to be expressed using the endogenous promoters to enable physiological levels of Mal
expression to be achieved for stimulation and imaging assays. CRISPR can also be used to
endogenously tag Mal within WT mESCs for this purpose. Creation of a transgenic mouse
expressing tagged proteins of the TLR-4 signalling pathway would allow analysis of complex
stoichiometries formed in many different cell types in response to different ligands, helping
gain insight into cellular differences in TLR-4 signalling transduction. It may also be the
case that certain therapeutics can be targeted to interfere with TLR-4 signalling in a specific
cell type only. Tagged protein expression in a transgenic mouse would allow a complete
analysis on the effect of therapeutics on a vast array of cell types, providing confirmation for
specificity and sensitivity.
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Table A.1 Primers used to clone FN fragments into pCDNA3
Gene Forward/Reverse Sequence
FNIII1c F CCCCGGATCCATGGGAGTCAAAGTTCTGTTTGC
CCTGATCTGTCGCTGTGGCCGAGGCCACAAAA
ATGCACCACAGCCATCTCA
FNIII1c R CCCCGAATTCTTAAGGTGTGCTGGTGCTGGTGG
FNIII13-14 F CCCCGGATCCATGGGAGTCAAAGTTCTGTTTG
CCCTGATCTGCATCGCTGTGGCCGAGGCCAAA
AATGTCAGCCCACCAAGAAGG
FNIII13-14 R CCCCGAATTCTTATGTCTTTTTCCTTCCAATCAG
GGG
FNIII9-E F CCCCGGATCCATGGGAGTCAAAGTTCTGTTTG
FNIII9-E-14 CCCTGATCTGCATCGCTGTGGCCGAGGCCAAA
GGCCTGGATAGTCCGACC
FNIII9-E R CCCCGCGGCCGCTTATGTGGACTGGATTCCAAT
FNIII9-E-14 R CCCCGCGGCCGCTTATGTCTTTTTCCTTCCAAT
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Table A.2 Primers used to clone FN fragments into pHR-mGFP
Gene Forward/Reverse Sequence
FNIII1c F CCCCACGCGTATGGGAGTCAAAGTTCTGTTTGC
CCTGATCTGCATCGCTGTGGCCGAGGCCAAAA
ATGCACCACAGCCATCTCA
FNIII1c R CCCCGGATCCGCCCTGAAAATAAAGATTCTCAG
GTGTGCTGGTGCTGGTGG
FNIII13-14 F CCCCACGCGTATGGGAGTCAAAGTTCTGTTTGC
CCTGATCTGCATCGCTGTGGCCGAGGCCAAAA
ATGTCAGCCCACCAAGAAGG
FNIII13-14 R CCCCGGATCCGCCCTGAAAATAAAGATTCTCTG
TCTTTTTCCTTCCAATCAGGGG
FNIII9-E F CCCCACGCGTATGGGAGTCAAAGTTCTGTTTGC
FNIII9-E-14 ATAGTCCGACCCCTGATCTGCATCGCTGTGGCC
GAGGCCAAAGGCCTGG
FNIII9-E R CCCCGGATCCGCCCTGAAAATAAAGATTCTCTG
TGGACTGGATTCCAAT
FNIII9-E-14 R CCCCGGATCCGCCCTGAAAATAAAGATTCTCTG
TCTTTTTCCTTCCAAT
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Table A.3 Primers used to clone FN fragments into pGEX-6P-1
Gene Forward/Reverse Sequence
FNIII1c F CCCCGGATCCAATGCACCACAGCCATCTCA
FNIII1c R CCCCGCGGCCGCTTAAGGTGTGCTGGTGCTGG
TGG
FNIII13-14 F CCCCGGATCCAATGTCAGCCCACCAAGAAGG
FNIII13-14 R CCCCGCGGCCGCTTATGTCTTTTTCCTTCCAATC
AGGGG
FNIII9-E F CCCCGGATCCGGCCTGGATAGTCCGACC
FNIII9-E-14
FNIII9-E R CCCCGCGGCCGCTTATGTGGACTGGATTCCAAT
FNIII9-E-14 R CCCCGCGGCCGCTTATGTCTTTTTCCTTCCAAT
Table A.4 Primers used to clone Mal variants into pHR-HALO
Gene Forward/Reverse Sequence
Mal F ACTACGCGTATGGCATCATCGACCTCCCT
Mal R ACTGGATCCCCACTGAGTGTCTGCAGATA
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Table B.1 Analysing Mal stoichiometry by counting photobleaching steps
Cell Initial No. of No. of Monomers Dimers Trimers
number threshold trajectories trajectories
detected discarded
1 7 213 166 26 20 1
2 9 101 77 12 12 0
3 11 186 164 8 11 3
4 10 141 119 6 15 1
5 7 48 44 4 0 0
6 17 68 58 6 4 0
7 15 118 100 4 12 2
8 13 75 65 3 2 5
9 17 121 107 6 7 1
10 7 242 215 7 12 8
11 7 104 90 3 7 4
12 12 69 62 1 5 1
13 16 99 91 4 4 0
Total 1585 1358
% Discarded trajectories 85.68
Table B.2 Analysing Mal stoichiometry by counting photobleaching steps - imaging using 35
ms exposure
Cell Initial No. of No. of Monomers Dimers Trimers
number threshold trajectories trajectories
detected discarded
1 13 74 68 1 4 0
2 9 105 101 1 3 0
3 7 24 23 1 0 0
4 10 81 68 4 9 0
5 15 84 79 4 1 0
6 9 131 118 6 5 2
7 16 97 93 1 0 3
8 7 30 25 0 5 0
9 7 56 52 1 3 0
10 18 47 41 1 5 0
Total 729 668
% Discarded trajectories 91.63
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Table B.3 Analysing Mal stoichiometry by counting photobleaching steps - imaging using 70
ms exposure
Cell Initial No. of No. of Monomers Dimers Trimers
number threshold trajectories trajectories
detected discarded
1 31 48 44 1 3 0
2 17 65 55 3 7 0
3 25 37 35 0 1 1
4 13 102 95 2 5 0
5 14 76 72 3 1 0
6 19 61 53 3 5 0
7 9 76 67 3 3 3
8 21 68 64 2 2 0
9 16 63 54 3 6 0
10 11 162 154 4 4 0
Total 758 693
% Discarded trajectories 91.42
Table B.4 Analysing Mal stoichiometry by counting photobleaching steps - imaging using
100 ms exposure
Cell Initial No. of No. of Monomers Dimers Trimers
number threshold trajectories trajectories
detected discarded
1 25 62 52 7 3 0
2 20 145 133 9 3 0
3 36 42 37 2 3 0
4 30 54 44 6 4 0
5 22 31 28 1 2 0
6 31 56 51 2 3 0
7 33 41 38 2 1 0
8 19 82 79 1 2 0
9 20 18 15 0 2 1
10 19 92 82 7 3 0
Total 758 693
% Discarded trajectories 91.42
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B.2 Photobleaching software
All of the MATLAB scripts and the image J script used in this thesis can be found on the
accompanying CD. The "counting code" written by Laura Weimann [244], the "new code",
written in collaboration with Anna Lippert and Sophie Ip, and the "combined code" (a
combination of the "counting code" and "new code") can be found in separate folders.
